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Tuberculosis (TB) remains a significant cause of morbidity and mortality in countries with 
high HIV prevalence, such as South Africa. This doctoral work aimed to describe the 
epidemiology of TB in a high HIV and TB prevalent community from 1997 to 2008, and 
to assess the effect of HIV and a highly active antiretroviral therapy (HAART) 
programme on the TB epidemic in this setting.  
 
The study community was a typical South African peri-urban township, with substantial 
burdens of both TB and HIV disease.  The community was geographically well-defined, 
and population data were available from repeated community censuses. The community 
clinic provided TB treatment for all resident TB patients, in accordance with the national 
TB control programme guidelines, based on the World Health Organization’s Directly 
Observed Therapy, Short-course programme. The HAART programme was 
implemented in 2003, and scaled-up in 2005. By 2008, 22% of the HIV-infected 
population was receiving HAART.   
 
Data were drawn from a number of sources, including population surveys, TB notification 
registers, and HIV and HAART databases.  Transmission to children was assessed 
using school-based cross-sectional tuberculin skin test surveys. The risk factors 
associated with TB transmission to children on residential plots were analyzed 
retrospectively, using adult and childhood TB cases extracted from the community TB 
notification register and the tuberculin survey results.  Molecular epidemiology and 
geographic informatio  systems were used to investigate TB transmission between 
adults, as well as the interaction between the HIV-associated and HIV-unassociated TB 
epidemics. The impact of the HIV epidemic, and of the HAART programme, on the 
burden of TB disease was assessed through analysis of TB incidence trends over time 
(as determined by notification rates) and a repeated cross-sectional community TB 
prevalence survey.  
 
This thesis reported a substantial rate of TB transmission in the study community, and 
that risk factors for transmission to children and adults differed. Children were at 
increased risk of acquiring TB infection and disease from adult source cases on their 
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transmission. In contrast, adult to adult TB transmission did not occur primarily on 
residential plots. While the adult HIV-associated and HIV-unassociated TB epidemics 
were inter-related, HIV-infected TB patients contributed proportionally less to the adult 
transmission of TB than HIV-uninfected counterparts. Further, HIV infection was not 
associated with an increased risk of acquiring TB infection among adolescents. As a 
result, the impact of HAART on TB transmission appeared to be relatively small.  
 
The HIV epidemic was responsible for a significant proportion of the burden of TB 
disease in the study community. Consequently, it was in TB disease that the greatest 
benefit of a HAART programme was noted, with a significant reduction in TB notification 
and TB prevalence rates. While the reduction in both TB notifications and prevalence 
was reported overall, it was predominantly noted in the HIV-infected population.  
 
In conclusion, in a high TB and HIV disease setting, the HIV epidemic contributed 
significantly to the burden of TB disease, but was responsible for proportionally less TB 
transmission compared to HIV-uninfected patients. A high coverage HAART programme 
was associated with a reduction in the overall burden of community TB disease. 
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Tuberculosis Infection: Latent infection of an asymptomatic individual with 
Mycobacterium tuberculosis. Individuals with latent infection are not infectious. 
 
Annual Risk of TB Infection (ARTI): The probability that a susceptible individual will 
become infected with Mycobacterium tuberculosis during a one year period1.  ARTI is an 
averaged measure of risk of TB infection over the lifetime of the study participants1;2. 
 
Force of Infection: The proportion of susceptible individuals that have become infected 
with Mycobacterium tuberculosis in a specified period. Force of infection provides a 
recent estimate of infection incidence, and can be estimated over a range of age groups. 
 
Tuberculosis Disease: Active tuberculosis illness is characterised by actively multiplying 
Mycobacterium tuberculosis, resulting in clinical symptoms and/or the ability to recognize 
Mycobacterium tuberculosis in the patient’s sputum or other involved organ. 
 
Incidence of tuberculosis disease: The number of new cases of active tuberculosis 
disease occurring in a specified period of time3. Incident tuberculosis encompasses 
recognised (notified) and unrecognised tuberculosis disease, as well as TB patients who 
die before diagnosis. 
 
Prevalence of tuberculosis disease: The proportion of a population with active 
tuberculosis disease, both treated (diagnosed) and untreated (undiagnosed), at a given 
point in time. 
 
Highly Active Antiretroviral Therapy (HAART): Combination triple drug therapy used to 
treat patients infected with HIV. HAART is the current UNAIDS recommendation for the 






























1.1  BACKGROUND 
 
1.1.1  Epidemiology of Tuberculosis and HIV Epidemics 
Tuberculosis (TB), cause by the bacterium Mycobacterium tuberculosis, is an ancient 
disease, with evidence of the pathogen dating back to ancient Egypt4 and pre-Columbian 
Peru5.  And yet, far from controlling or eliminating this disease, it remains a major cause 
of morbidity and mortality worldwide6-9.  A third of the world’s population is estimated to 
be infected with Mycobacterium tuberculosis (Mtb)10, and the World Health Organization 
(WHO) reported a global TB disease prevalence of 11.1 million cases in 200811. Of the 
9.4 million incident TB disease cases in 200811, 15% were also HIV-infected. In the 
same year, TB-associated mortality accounted for approximately 1.3 million deaths 
among HIV-uninfected TB patients, with an overall mortality rate of 28 deaths/100,000 in 
HIV-infected and uninfected individuals11.   
 
HIV, in contrast, is one of the newest diseases known to man but has spread across the 
world with alarming efficiency. Globally, 33.3 million people are estimated to be living 
with HIV12, with 2.7 million new infections occurring in 200813. An estimated two million 
AIDS-related deaths occurred in the same year13. HIV-infected patients have a 
substantially increased risk of developing TB disease compared to HIV-uninfected 
individuals14-16 and as a result the advent of the HIV epidemic is considered one of the 
primary factors responsible for the dramatic escalations noted in the TB epidemic in the 
past two decades9;17-20.  It has been postulated that without the impact of the HIV 
epidemic, TB epidemics would be “in decline almost everywhere”21 
 
Antiretroviral therapy (ART), specifically highly active antiretroviral therapy (HAART), 
substantially reduces the morbidity and mortality associated with HIV-infection22-25 and 
UNAIDS recommends initiating ART in HIV-infected patients with CD4 count <350 cell/µl 
or WHO stage 3 or 4 disease. There has been a global call for the scale-up of ART 
availability, and through programmes such as the “3 by 5” initiative26, the President’s 
                                                           











Emergency Plan for AIDS Relief (PEPFAR)27 and the Global Fund28, there has been 
substantial progress in patients’ access to ART29 over recent years. By the end of 2009, 
it was estimated that, in low and middle income countries, 36% of HIV-infected patients 
who meet the UNAIDS treatment guidelines were receiving HAART12. 
 
TB and HIV in Sub-Saharan Africa 
Africa is hardest hit by both the TB and the HIV epidemics. The African region has the 
highest per capita TB incidence, prevalence and mortality rates in the world11, and 
poverty, a poor health infrastructure and increasing urbanization30-32 are further 
challenges for TB control. WHO estimated there to be 3.8 million prevalent TB cases in 
Africa, with 2.8 million new cases occurring in 2008. The TB-associated mortality in the 
African region was 48/100,000 in 2008. Of the global incident TB cases, 78% of those 
co-infected with HIV occurred in Africa11.  
 
Two thirds of all HIV-infected people live in sub-Saharan Africa. In 2008, 1.9 million new 
HIV infections and 1.4 million HIV-related deaths were estimated for the region13. On a 
more positive note, sub-Saharan Africa boasts the largest scale-up of HAART access 
over the past five years, with 44% coverage being achieved by 200829. However, TB 
remains the most common opportunistic infection17;33;34 and the most common cause of 
death in people infected with HIV in Africa, including those receiving antiretroviral 
therapy35;36.  
 
TB and HIV in South Africa  
With over a quarter of the global burden of TB/HIV29, South Africa bears the brunt of 
these two epidemics. The country is undergoing rapid urbanization37;38, with immigrants 
to the cities concentrating in poor and crowded peri-urban slums where both HIV 
prevalence and TB incidence rates are high39.  By 2008, the HIV epidemic in South 
African adults aged 15 to 49 years had grown to an estimated prevalence of 16.9%13 
(Figure 1.1).   
 
Over this same period, the incidence rates of TB in South Africa have increased more 
than 3-fold, with an estimated TB rate of 960/100,000 in 2008 (Figure 1.1). Of these 
more than 476,000 incident cases, 71% were thought to be co-infected with HIV7;11.  











2007 and the treatment success rate was 74%11. TB prevalence in South Africa was 



















































































TB Incidence HIV prevalence (15 to 49 year olds)
 
Figure 1.1: TB incidence rates7 and HIV prevalence40 in South Africa, from 1990 to 2007 
 
According to the 2008 UNIADS report, 5% of HIV-infected patients in South Africa who 
meet the UNAIDS HAART treatment guidelines were receiving treatment in 2004, and 
this increased to 28% in 200740. However, only 39% of all notified TB patients in South 
Africa had a known HIV test result and only 35% of HIV-infected TB patients were 
receiving or started on HAART in 200740.  
 
Stop TB Partnership Targets 
The STOP TB Partnership is a collaboration comprising of the WHO, together with 
countries, donors and international organisations, whose aim is to eliminate TB as a 
public health problem. In keeping with the Millennium Development Goals (MDG), the 
Stop TB Partnership aims to reduce the 1990 per capita TB disease prevalence and TB 
mortality rates by 50% by the year 2015. By 2050, they aim to have reduced incidence of 
active TB to <1 case/million population/year7.    
 
The STOP TB Strategy for achieving these goals includes (1) the pursuit of high-quality 











addressing HIV-associated TB, multi-drug resistant (MDR) TB, and the needs of poor 
and vulnerable populations, as well as (3) contributing to primary care health system 
strengthening, (4) engaging all care providers, (5) empowering people with TB, and 
communities through partnership and (6) enabling and promoting research7.   
 
The technical elements of the DOTS strategy include early case detection of 
symptomatic patients through passive case-finding and utilizing sputum smear 
microscopy and, where appropriate and available, sputum culture. In addition, 
standardized short course chemotherapy regimens are recommended, with directly 
observed treatment during at least the intensive phase (first 2-3 months) of therapy. Key 
targets in the DOTS programme are the detection of 70% of all smear-positive TB cases 
and 85% treatment completion of detected cases7. 
 
Progress towards the Stop TB Partnership’s targets for TB prevalence, incidence and 
mortality has been encouraging on the global scale, with disease incidence rates 
appearing to have peaked in 2007, disease prevalence rates falling and mortality targets 
already achieved in four of the nine WHO epidemiological sub-regions. However, it is 
well documented that the WHO Stop TB strategies are inadequate for controlling TB in 
African countries with high HIV prevalence9;39;41;42 (Figure 1.2).  
 
While TB disease incidence appears to have stabilized in the African region, the 
estimated incidence rates remain over 350/100,000 in 200811. Of all the sub-regions, 
Africa is furthest from reaching case detection targets of new smear-positive TB cases, 
with only 39% of cases detected in 2008. It should, however, be noted that treatment 
success was achieved in 75% of those identified. The estimated 2008 TB prevalence 
and mortality rates remain substantially higher than those reported in 1990, and the 
latest WHO report acknowledged that achievement of the prevalence and mortality 
STOP TB targets “appears impossible in African countries”11.  
 
In 2005 the WHO Committee for Africa, declared the TB epidemic an Africa regional 
emergency 43, calling for “urgent and extra-ordinary actions” to assist in TB control.  
The STOP TB Partnership has proposed adjunctive strategies to address the ongoing 
difficulties in TB control in this setting, including the “Three I’s” strategy for reducing the 











therapy, and infection control44. However these strategies have not been widely 
implemented to date. Due to the reduction in TB risk in HIV-infected patients on 
HAART45;46, ART has also been proposed as an adjunctive strategy for controlling the 
TB epidemic in low and middle-income countries with generalised HIV epidemics, such 
as South Africa47. This strategy has been more extensively implemented, as discussed 
above. 
TS   




1.1.2 Natural History of TB 
Tuberculosis infection is caused by the bacterium Mycobacterium tuberculosis48. The 











             
Figure 1.3: The Natural History of Tuberculosis (adapted from C Horsburgh) 
 
TB Exposure and Infection 
An individual’s risk of exposure to Mtb is a function of the prevalence of infectious cases 
in their community, the duration of time the cases are infectious, and the number and 
nature of contacts the individual has with these cases49. The risk of infection following 
exposure for an individual who is not infected with TB (susceptible) is determined by a 
number of factors: the pathogen, the infectious patient, the susceptible individual and the 
environment49.  Individuals already infected with Mtb can become secondarily infected 
following repeat exposure50;51. 
 
Mtb  is primarily an airborne pathogen48;52;53, and as a result tuberculosis is 
predominantly spread by those patients with respiratory tract disease49 . TB patients with 
lung cavitation20;54 and sputum smear-positive TB are the most infectious cases54-59, with 
sputum smear-negative, culture-positive TB patients accounting for approximately 9-
18% of transmission55;57;60-62.  The tubercle bacilli are aerolised in droplet nuclei when the 
infected person talks or coughs63. Droplets of 1-3µm in size may remain suspended in 
the air indefinitely, and when inhaled are able to reach the alveoli of the lungs52.  
 
Environmental factors may substantially impact the risk of infection, through destroying 











outdoors or through ventilation, can dilute the concentration of infectious droplets, 
reducing the risk of inhaling infected droplets. Therefore a simple intervention such as 
opening windows in a house can significantly reduce an individual’s risk of 
infection49;60;64. In addition to the rapid dilution of droplets that occurs outdoors, the ultra-
violet (UV) rays of the sun are capable of killing suspended bacilli53;65. Therefore contact 
that occurs outside carries a lower risk of infection, compared to sharing a room with an 
infected person. Increased time and proximity of contact with an infectious person, such 
as in overcrowded conditions or intimate contacts, increases a susceptible individual’s 
risk of acquiring TB infection60;66;67. 
 
Once in the susceptible individuals’ alveoli Mtb may be eliminated by the host immune 
response or infection may be established. Of susceptible individuals exposed to Mtb, 
from zero to almost 100% may develop TB infection, depending on the conditions of 
exposure55;57;68. Infection may remain latent for months, years or for the individual’s 




For an individual infected with Mtb the risk of developing TB disease is, again, a function 
of a number of factors related to the infected individual, the infecting pathogen and the 
environment.  
 
TB disease is the result of progression of recent, exogenous TB infection or reactivation 
of previous, latent infection. The time period since becoming infected is a strong risk 
factor for developing disease71-73: patients with recent infection are 10 times more likely 
to progress to TB disease compared to those with chronic, latent infection49. It is 
estimated that for a child newly infected with TB at least half the risk for developing 
disease occurs in the first two to five years following infection1;57;60;72. 
 
The risk of progressing from TB infection to disease is largely dependent on the ability of 
the infected individual’s immune defenses to contain the TB infection49. HIV infection has 
been identified as the most significant risk factor in progression to TB disease14;15;49;74 
due to increasing immune deficiency75;76. Other medical conditions associated with the 











lymphoma81;82 and lung cancer82, and certain medications such as high dose 
corticosteroids83-85.  
 
There is evidence to suggest that the dose of bacilli may be a risk factor for TB disease: 
studies report that the risk of disease is greater if infection is caused by sputum smear-
positive disease compared to sputum smear-negative cases55-57. The virulence of the 
inhaled pathogen is another factor that may influence the risk of disease86;87.  In addition, 
there are environmental factors that also increase an individual’s risk of TB disease 
including smoking88;89, alcohol abuse73;90-92 and malnutrition73;93;94.  
 
1.1.3  Interaction between TB and HIV  
HIV infection has a major impact on the natural history of tuberculosis, and subsequently 
on TB epidemics in high prevalence areas. In TB endemic areas, such as South Africa, 
Mtb is the most common opportunistic infectious disease in HIV-infected patients17;18;34;95 
and is often the presenting opportunistic infectious diseas  that leads to the diagnosis of 
AIDS14;18. TB also occurs more frequently in HIV-infected patients at higher CD4 counts 
than other opportunistic infectious diseases34;75;96. 
 
TB Infection and HIV 
To date, there is little evidence to suggest that following exposure to TB, HIV-infected 
patients are at increased risk of developing TB infection. However, studies assessing 
this risk identify TB infection status using tests reliant on immune response, such as 
tuberculin skin tests (TST)14;97. False negative TST results in HIV-infected patients are 
common, due to anergic immune responses in advanced HIV disease98-101. Therefore TB 
infection in HIV co-infected patients may be underestimated in these studies. One 
molecular epidemiological study of a TB outbreak among co-inhabiting HIV-infected 
individuals in San Francisco suggested that HIV-infected patients may be at increased 
risk of acquiring HIV infection102, but evidence for this was not statistically substantiated.   
 
TB Disease and HIV 
In contrast, it is well documented that HIV-infected patients have a substantially 
increased risk of developing TB disease compared to HIV-uninfected individuals14-16: a 












The immune response to infection by Mtb is a complex cell-mediated response, in which 
the CD4 lymphocyte is the key effector and mediator103;104. Interleukin-driven expansion 
of CD4 lymphoctyes results in the T-cells secreting interferon γ, which in turn activates 
macrophages. Additional chemokines and cytokines assist with further recruitment and 
activation of monocytes105. The aggregation and differentiation of these activated 
macrophages and lymphocytes results in the formation of a granuloma106: the primary 
mechanism within which the immune system controls Mtb infection107. The granuloma 
contains potentially viable Mtb organisms104, and in this way latent infection is achieved. 
With the progression of HIV disease, the quantity and the functioning of CD4 T cells is 
adversely affected75;108;109, resulting in the compromise of both granuloma formation to 
new infections, as well as maintenance of established granuloma104;110.  
 
Consequently, HIV-infected patients have an increased risk of rapid progression to 
active TB following new infection14;102;111 and an extraordinarily high rate of re-activation 
of latent tuberculosis infection compared to HIV-uninfected individuals14;112. South 
African studies among HIV-infected patients have shown that from the time of HIV 
infection the risk for TB disease doubles16 and this risk continues to increase as the CD4 
cell count decreases45;75;113.  
 
Impact of HIV on TB epidemics 
The HIV-associated TB epidemic has changed the face of the generalized TB epidemic 
in high burden co-infection areas. As the risk of TB infection declined in developed 
countries, the incidence of adult TB disease shifted from young adults into the older age 
groups, occurring predominantly in males >45 and females >65 years of age114;115. In the 
1980’s there was evidence to suggest that TB infection rates were decreasing in 
developing countries116, and it was suggested that a similar shift in the distribution of TB 
disease was starting to emerge in these countries117. However, with the escalation of the 
HIV epidemic among the younger, sexually active population, the incidence of TB 
disease has concentrated in the 20-40 year old population group39;118. HIV-infected 
patients, particularly those with advanced HIV disease, are recognized to have atypical 
presentations of TB infection, including an increase in extra-pulmonary18;118-121 and 
disseminated TB18;120;121, and an increased likelihood of smear-negative pulmonary 











disease following TB treatment, whether through re-infection or reactivation of latent 
infection125-129. 
 
TB disease is the leading cause of death in HIV-infected patients in sub-Saharan 
Africa33;95;130;131. In autopsy studies of HIV-infected patients, TB disease was identified in 
40-51% of patients33;130;131. TB patients co-infected with HIV have a higher mortality than 
HIV-uninfected TB patients131-134 and mortality in HIV-infected patients with TB is two to 
three times higher than that of HIV-infected patients without TB disease15;112;135.  
Impact of TB on HIV 
Tuberculosis, in turn, has been shown to have an effect on the natural history of HIV 
infection. TB disease accelerates the progression of HIV-associated immune deficiency, 
as demonstrated by a significant drop in CD4 T cell counts in patients with active TB 
disease96;112. Furthermore, active TB disease enhances viral replication96;136-140, and 
studies have indicated that viral load may not return to baseline levels despite an 
apparently good response to TB treatment96;140-142.  As a r sult, HIV-infected TB patients 
have both an accelerated clinical course112;143, with more opportunistic infections 
compared to HIV-infected patients at similar CD4 cell counts who do not have a recent 
history of TB135;143,  and a significant reduction in survival rates112;135;144;145. 
 
1.1.4  Impact of HAART on Individual TB Risk 
Highly active antiretroviral therapy inhibits viral replication, which in turn is associated 
with the restoration of the immune system146-148. Studies have shown improvement in 
both the quantity and function of CD4 cells in patients on HAART. However, it must be 
noted that function of CD4 cells does not appear to be fully restored146;147, especially 
when HAART initiation occurs at advanced stages of HIV disease149;150. This not 
withstanding, as a result of immune recovery, HAART has been shown to reduce both 
morbidity and mortality associated with tuberculosis disease23;151;152 (Figure 1.4).   
 
While the risk of TB disease incidence is estimated to be 5-10% per annum in untreated 
HIV-infected cohorts14;153, HAART treatment cohort studies from sub-Saharan Africa 
have reported a reduction in incidence of active TB of 61-90%35;45;46;154-158. TB incidence 
rates are high in the first three months of antiretroviral treatment157;159-161, with rates of up 
to 22 cases/100 person-years reported in this period35. However, with increasing time on 











years by two to three years on treatment35;156;157;162, and rates as low as 1.01/100 person 
years reported at 5 years of HAART46 (Figure 1.5).  
 
 
Figure 1.4: Risk of TB disease on and off HAART, stratified by WHO clinical stage and 
















TB is the most common opportunistic infection occurring in the early months of HAART, 
both in developed and developing countries155;159;162;164;165. The high rates of TB in the 
early months of treatment may be due to risks associated with low baseline CD4 
counts45;46;152;165 and persisting immune deficiency in the early months of HAART146.  
However most patients respond with a rapid decline in viral load and associated 
increase in CD4 cells146;147, which may, in turn, result in the unmasking of previously 
subclinical disease. The rapid recovery and reactivation of the immune system can also 
result in dysregulation of antigen specific responses, leading to an exaggerated 
inflammatory response and presentation of TB disease in the first 3 months on 
HAART106;161;166-168.  
 
Low CD4 cell count (<100 cells/mm3), whether at baseline or at five years on treatment, 
was consistently found to be a key risk factor for developing TB disease on 
HAART35;45;46;152;154-156. 
 
Despite these substantial declines in TB risk on HAART, two to three years into HAART 
treatment patients still have a 2-10 times higher risk of TB disease compared to HIV-
uninfected individuals35;156;165;169.  Studies show that the reduction in TB risk is lowest in 
those that have a suboptimal immunological response to HAART, as determined by CD4 
cell count recovery35;46;170.  Because TB disease occurs across a wider range of CD4 cell 
counts than most other opportunistic infections, this persistently elevated risk of TB on 
HAART may also be due to incomplete functional recovery of the immune system on 
HAART35;146;147.  
 
In addition to reducing the risk of TB disease, HAART has been associated with 
decreased mortality in HIV-infected patients who develop TB171;172. This reduction in TB-
associated mortality associated with HAART may be as high as 52-60%157;173.  
 
1.1.5  Population Level Impact of HAART  
While the impact of HAART on TB risk for an HIV-infected cohort is well defined, the 













- Impact on HIV-associated TB Rates 
As discussed above, the HIV epidemic is driving the TB epidemic in countries with high 
HIV and TB burdens such as South Africa, where as many as 70% of TB cases are HIV 
co-infected7.  As the incidence of active TB disease in HIV-infected patients is 
substantially reduced on HAART, it can be argued that wide-scale HAART programmes 
should have a considerable, positive impact on TB epidemics. However, HIV-infected 
patients on HAART still have a substantially increased risk of TB disease compared to 
HIV-uninfected individuals, and the combination of prolonged survival and residual 
increased risk of TB disease will result in an increased number of highly susceptible 
individuals in the population. In addition, HAART is generally initiated relatively late in 
the HIV disease process, with the result that as many as 50% of these patients have a 
prior history of TB in the past two years and have therefore already contributed 
substantially to the population TB rates35;174.  Therefore even substantial population 
coverage with HAART may have a limited impact on TB incidence at a population-level.  
 
- Impact on TB Transmission 
In addition to the direct benefits of HAART with regards to the reduction of HIV-
associated TB rates, ART programmes may also have indirect benefits on TB 
epidemics, ie a possible reduction in TB transmission.  The impact of HAART 
programmes on TB transmission will be determined, in part, by the contribution of HIV-
associated TB to transmission in communities. As discussed previously, the 
infectiousness of a TB patient is a function of the bacillary load a patient expectorates 
and the time they remain infectious in the community.  
 
HIV-co-infected TB patients are considered to be less infectious than HIV-uninfected TB 
patients due to higher rates of extra-pulmonary TB18;118-121 and lower rates of smear-
positive18;118;122;123 and cavitatory122;124 pulmonary TB. These findings are consistent with 
lower bacillary load in HIV-infected patients compared to HIV-uninfected patients122. 
However, some studies have reported lower rates of transmission from HIV-infected 
patients175, even following adjustment for sputum smear status124;176;177. It has been 
suggested that this may be due to a decreased infectious period in the community as a 
result of faster progression to disease and therefore less time to diagnosis or death of 











time pre-diagnosis has also been reported with HIV co-infection due to poor symptom 
development179, and other studies have reported a higher risk of transmission from HIV-
infected index cases111;180. By and large, most studies report no difference in risk of 
transmission based on HIV status of index case181-186 including a meta-analysis of 11 
studies of household contacts of TB patients187.  
Overall, given the clinical characteristics of HIV-infected TB patients, it has been 
suggested that HIV-associated TB is responsible for approximately 7% of TB 
transmission in communities with high TB prevalence9, in which case a reduction in HIV-
associated TB transmission may not have a significant impact on overall TB 
transmission in such settings.   
 
Modeling in the Impact of HAART on TB Epidemics 
Empirical data addressing the impact of HAART on TB epidemics at population level are 
sparse and most evidence comes from mathematical modeling.  
 
A number of models have predicted limited impact of HAART on population TB 
epidemics. The model by Currie et al showed that providing HAART at the coverage 
levels targeted by WHO (3 million patients on HAART by 200526) would have limited 
impact on TB incidence and deaths, especially compared to a combined strategy of 
improving both case detection rates and cure rates188;189. In addition, this group reported 
that increasing TB case detection and cure rates would be more cost-effective strategies 
for TB control than the provision of HAART188.  
 
A model by Williams et al predicted that in countries with HAART eligibility criteria of 
CD4 count <200cell/µl, complete ART coverage and 100% compliance on HAART would 
only reduce TB incidence in HIV-infected patients by 22% over 20 years190.   
 
Similarly, a modeling paper on the TB epidemic in India reported that a HAART 
programme would not have a substantial impact on the population TB incidence, but, 
could lead to a 50% reduction in TB mortality, most notably among HIV infected 
patients191. 
 
A more recent modeling paper reported that, under the assumption of 100% of HIV-











programme would have a dramatic impact on the reduction of TB disease. However this 
paper did not report the impact of the slower, more practical implementation of a lower 
coverage HAART programme192. 
 
In summary, modeling exercises have conflicting results as to the impact of HAART on 
population-level TB epidemics, although generally HAART is predicted to have little 
impact on TB incidence in communities. However, it should be noted that the benefit 
predicted by mathematical models is dependent on the assumptions made and different 
parameters incorporated, such as the timing of HAART initiation, the coverage achieved 
by programmes and patient compliance.  In addition the benefits predicted for different 
control strategies will vary widely at different HIV prevalences, and therefore in different 
settings193.  
 
1.2 AIMS AND OBJECTIVES  
Although control of tuberculosis will undoubtedly require increased investments in health 
and social infrastructure194, a better understanding of HIV and TB interactions at the 
levels of transmission, infection, prevalence and incidence within the prevailing crowded 
social environment is also required in order to assess the impact of interventions such as 
HAART on the control of this dual burden at a community level.  
 
The aim of this thesis is to describe the interaction between the HIV-associated and HIV-
unassociated TB epidemics in a well-demarcated community with high HIV and TB rates 
and to assess the impact of a high coverage HAART programme as an intervention 
strategy on these epidemics. This thesis will describe the TB epidemics at key stages of 
TB pathogenesis (Figure 1.6) and to describe the impact of HIV and the HAART 
programme on the epidemics at these stages. The stages in the natural history of TB 
that will be described include (1) transmission of TB infection and the factors associated 
with transmission dynamics in children and adults, and (2) the burden of TB disease, 












Figure 1.6: A model of the interactions between the TB and HIV epidemics 
 
The specific objectives include: 
 
1) To determine the prevalence of TB infection and the force of TB infection in the 
study community. 
2) To determine the risk of TB transmission to children residing in close contact with 
adult TB cases, and to determine the importance of HIV-associated TB in this 
transmission. 
3) To describe the molecular epidemiology of TB in the study community, and to 
utilize molecular epidemiological techniques to investigate the extent of clustering 
of Mtb disease, to assess the impact of the HIV-associated TB epidemic on 
transmission, and to identify risk factors associated with adult to adult 
transmission.  
4) To describe the changes in TB disease incidence (as determined by TB 
notification rates) and outcomes in the overall community population and in the 
HIV-infected and HIV-uninfected subsets of the population. These changes will 
be assessed over time and following the scale-up of HAART access in the 
community. 
5) To determine the prevalence of microbiologically-confirmed pulmonary TB (PTB) 
disease in both the HIV-infected and HIV-uninfected subsets of the population 
and describe changes in the prevalence of PTB disease following the scale-up of 












1.3 STUDY COMMUNITY 
Site M is a peri-urban township typical of many such communities in Southern and South 
Africa today. Recently urbanized, overcrowded and largely consisting of informal 
dwellings with low socio-economic status, Site M is a community where both HIV and 
tuberculosis rates are high.  
 
In the 1980’s a few hundred, predominantly Xhosa-speaking individuals, hoping to find 
work, moved into the area where the study site currently stands. These informal dwellers 
were repeatedly forcibly removed. However, with the end of Apartheid in the early 
1990’s, a section of land was serviced for development, and a few thousand people 
settled in what was to become known as Site M. 
 
The community covers approximately 0.93km2 and an unusual feature of the township is 
its clear geographical demarcation and isolation from surrounding areas (Figure 1.7). 
This feature of the community has facilitated population-based research by enabling an 
accurate population denominator to be determined. In 1996 a South African national 
census was performed which included Site M, and more recently Desmond Tutu HIV 
Centre (DTHC) has carried out community censuses the every second year since 2002. 
These censuses have enabled the development of a population model for this 
community and a description of this population model is provided in Appendix A.  
 
Within the perimeter of the township, the community consists of a formal sector with 
demarcated individually numbers serviced plots and an informal sector of shacks sharing 
communal services. Approximately 5,239 houses (mostly informal structures) are built in 
the community, and in the formal sector there are between 1 and 22 dwellings on a plot 
(mean of 4 houses per plot). Overcrowding is therefore a significant problem in this 
township. 
 
The community has grown in population size from 5,518 residents in 1996 (based on a 
South African National census in that year), to 14,592 residents in 2008 (DTHC census).  
The original residents were predominantly Xhosa-speaking individuals from the Eastern 
Cape Province. However, over the past few years a growing proportion of foreign 











predominantly young population, with 62% of the residents between the ages of 20 and 
40 years (2008 DTHC census), as shown in Figure 1.8. 
 
Socio-economic status is poor2, with unemployment rates of 47-50% consistently 
reported in community surveys, an average monthly household income of <R2,000 and 
a high proportion of informal income generation such as hawking, home shops, 
collecting tins for recycling, etc (unpublished data from 2002, 2005 and 2008). 
 
 
Figure 1.7: Satellite map of Site M 
 
The community is served by a single primary health care clinic, which is nurse-driven 
and doctor-supported, with a part-time medical officer assisting with HIV and TB clinics. 
In 2005, the DTHC established a HAART clinic, with full-time doctors and primary health 
care nurses running this service.  A local referral hospital provides X-ray facilities and 
specialist referral services, including both outpatient and inpatient services. 
                                                           
2 Socioeconomic status of the community was assessed using the Cape Metropolitan council per-suburb 
composite index, which is based on household income, education level, unemployment status, welfare 
status and overcrowding status (http://www.environment.gov.za/enviro-info/sote/citysoe/cape/povrty). The 

































































Figure 1.8: Site M population by age categories: 1996, 2002 and 2008 
 
 
1.3.1  TB Control Programme and Epidemic in Study Community  
The community clinic provides TB management and treatment for all TB patients 
resident in the community. The TB programme follows the National TB Control 
programme guidelines195;196, which are based on WHO-recommended DOTS 
programme.  
 
The TB programme is based on passive case-finding, and is dependent on TB patients 
presenting to health care services for investigation and treatment. Sputum investigations 
form the mainstay of the diagnostic approach, together with chest X-rays and, in 
paediatric cases, tuberculin skin testing. TB patients are treated with standardized, 
rifampicin-based chemotherapy regimens. The sputum smear-positive TB case detection 
rates obtained by TB control programme in the study community fall short of the WHO 
targets of 70% (45% case detection rate in the community)197, although the programme 
did average 82% treatment completion rates from 1998 to 2005. 
 
We have previously reported on the escalating TB epidemic in this community:  
notification rates among adults have increased from 789/100,000 in 1996 to 
>1,400/100,000 in 2004, with the incidence of smear-positive TB among adults also 
increasing from 326/100,000 to 1,307/100,000 over the same period39;179. HIV-infected 












HIV testing has been routinely offered to all TB patients at the clinic since mid 2001.  
From 2002 to 2008, on average 89% of adult patients tested for HIV infection and, of 




















Tested for HIV HIV-infected
 
Figure 1.9: HIV testing uptake and HIV-infection prevalence among adult TB patients in 
study community from 1999 to 2008 
 
While TB management in the study site remained the responsibility of the government 
clinic, it is worth considering that some research activities may have had an impact on 
the TB control programme in this community. Of note, is the potential beneficial effect of 
active case-finding, as performed in two community-based, cross-sectional TB 
prevalence surveys (in 2005 and 2008), as well as the active TB disease screening in 
children who were determined to be tuberculin skin test (TST) positive in the school-
based TST surveys (Figure 1.10).   
 
1.3.2  HIV Epidemic in Study Community  
Based on the Actuarial Society of South Africa (ASSA) 2003 AIDS and Demographic 
model198 together with HIV prevalence surveys performed in the community in 2005179 
and 2008197, an HIV infection model was developed for this community (Appendix A).  It 
is estimated that in 1997 that the overall HIV prevalence in this community was 8%, by 











shows the growing HIV epidemic by age strata and year, from 1997 to 2008, based on 
the community model. For more information on the development of the HIV infection 
model, see Appendix A. 
 
Figure 1.10: Timeline for research studies in Site M 
 
In 2004, the DTHC obtained limited HAART funding for HIV-infected patients in Site M. 
In 2005 a collaboration between the DTHC, the NIH-funded CIPRA-SA project and 
provincial health authorities enabled the large scale implementation of a HAART 
programme in this community. The HAART programme used standard antiretroviral drug 
regimes, as outlined in the South African HAART treatment guidelines199. Prior to 
February 2005 and after February 2007 (following completion of the CIPRA-SA ART 
project enrolment), the South African National guidelines for treatment initiation were 
followed, with patients eligible for HAART at CD4 count <200cells/mm3 or WHO clinical 
stage 4 (which does not include TB disease)55. However, between February 2005 and 
January 2007, patients were eligible for HAART if they had a CD4+ count 
<350cells/mm3 or WHO clinical stage 3 or 4 illness  (including TB disease200)201.  
 
The numbers of patients accessing HAART increased from 11 patients (1% of HIV-
infected population) in 2003, to 308 patients (13% of HIV-infected population) in 2005. 
By 2008, 713 residents were receiving HAART in the study community (22% of HIV-
infected population). HAART coverage varied by CD4 strata in the HIV population. An 
unpublished model for the study site estimated that in 2008, 81% of the adult HIV-
infected population with CD4 count <200cells/mm3 were receiving HAART, and 46% of 
those with CD4 count <350cells/mm3 (personal communication L Johnson and K 











small proportion of patients do not fully restore their CD4 count152;202, and this is 
evidenced by the estimated 18% of patients on ART who have a CD4 count 
<200cells/mm3 (unpublished data). 
 
According to the WHO, 12% of HIV-infected patients in South Africa who met UNAIDS 
treatment guidelines were receiving ART in 2005203, and this increased to 56% in 
200912;29. Given that this coverage reflects the proportion of those “who need 
antiretroviral therapy”, the coverage in the study community of up 21% of the total HIV-
infected population, and a possible 81% of those in need, represents a high coverage 
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Figure 1.11: HIV infection by year and age 
 
1.3.3  Geographical Information System  
Every plot in Site M has been assigned a unique digital location on a Geographical 
Information System (GIS) database (based on aerial photographs, road plans and 
surveyor general plans from 1998 to 2007). Residents use this plot number as an 
address, and therefore each inhabitant of the community can be located on this system 
by identifying their home address. In addition, clinical and epidemiological data as well 
as molecular data (such TB genotyping data) can be linked to the geographical location 












1.4  ETHICAL CONSIDERATIONS  
All the studies described in this thesis were approved by the University of Cape Town’s 
Human Research Ethics Committee. Genotyping of Mtb specimens was performed at 
the University of Medicine and Dentistry of New Jersey (UMDNJ), and all studies 
involving genotyping were also approved by the Institutional Review Board of UMDNJ.  
Written informed consent/assent was obtained from participants in all cross-sectional 
survey studies performed. Written informed consent/assent was also obtained from TB 






















  Chapter 2 
 
Tuberculosis Infection:  
Prevalence and Force of Infection 
 
 
2.1  RATIONALE 
The first step in the natural history of tuberculosis (TB) is the establishment of TB 
infection in susceptible individuals. Throughout this thesis, TB infection refers to the 
latent infection of an asymptomatic individual with Mycobacterium tuberculosis (Mtb), 
and not to active TB disease. While the conventional risk factors for acquiring TB 
infection have been well documented, and are outlined in Chapter 1, it is not well 
understood how HIV-related TB epidemics have impacted transmission of TB infection in 
communities heavily affected by both diseases.  
 
An increasing proportion of non-infected individuals in a population is required in order to 
achieve control of a TB epidemic115 and therefore, in order to develop effective 
intervention strategies for TB control, it is important to understand the transmission 
dynamics of the epidemic in HIV and TB prevalent settings.  Under the assumption that 
children with TB infection have been infected in the recent past, assessing the 
prevalence of TB infection in children may provide insight into the amount of recent TB 
transmission in a community204.  
 
This chapter will address the first objective of this thesis, namely to determine the 
prevalence of TB infection and the force of TB infection in a community with high TB and 
HIV burdens as well as examining risk factors associated with the transmission of TB 
infection to children. Data from this chapter have been published in the first paper205 
listed in the preface on page xi.  
 
2.2   BACKGROUND 
2.2.1 The Tuberculin Skin Test 
In 1890 Koch prepared the original tuberculin material as, he thought, a cure for TB206. 
While therapeutic use of tuberculin was rapidly disproved, in 1907 the potential for 
tuberculin as a diagnostic tool was first realized207;208. The tuberculin skin test (TST) is, 













recently developed tools such as interferon-gamma release assay, TST remains the 
most commonly used tool for the diagnosis of latent TB infection.  
 
The test is based on the fact that within 6-12 weeks of infection with Mtb a cellular-
immune mediated delayed hypersensitivity reaction occurs to components of the 
mycobacterium210-212. The TST is performed by the injection of a standardized dose of 
PPD (purified protein derivative) intradermally on the volar surface of the individual’s 
forearm. Previously sensitized T-cells and macrophyges migrate to the skin site, where 
lymphokines are released. The ensuing vasodilation, oedema and recruitment of further 
inflammatory cells results in induration at the test site209;213. This induration (not 
erythema) is measured to determine the presence of infection. In an infected individual a 
reaction to the PPD is produced within 48-72 hours. 
 
The tuberculin skin test is routinely utilized in the National TB Control Programme to 
diagnose TB infection195;196 and is widely used as an epidemiological tool to measure the 
prevalence of TB infection in community settings. Advantages of this test include that it 
is relatively cheap, easy to administer and has an extremely low adverse event 
rate209;214;215.   
 
Limitations of TST 
However, there are a number of limitations associated with this tool216. Firstly, TST 
cannot differentiate between latent TB infection and active TB disease. Secondly, the 
sensitivity and specificity of the TST test are variable210.  TST sensitivity appears to 
remain relatively constant, at approximately 75-90% (at a 10mm reaction size cut-off for 
positivity) across countries and regions216-218. However, immune response to TST is age-
dependent, and tuberculin sensitivity is recognized to wane in TB infected patients over 
time213;219-221 . Sensitivity of TST is adversely affected by medical conditions that 
compromise the immune system, such as malnutrition, cancers (in particular 
lymphomas) and HIV100;101;216;221-223.  False-negative reactions may also be due to 
problems in storing the tuberculin209, in the technique of TST administration, or errors in 
reading the test result1;221;224, although these can be minimized with training225. 
Specificity, in turn, may be influenced by cross-reaction with environmental mycobacteria 
other than tubercule bacilli (MOTT bacilli)209;218;226;227, or with Bacillus Calmette-Guérin 











in different regions and countries, from virtually absent to substantial226;227;230, and is less 
marked in temperate or sub-tropical climates226. TST reactions as a result of MOTT 
bacilli infection tend to be of a smaller diameter231, and at a 10mm reaction size cut-off 
for positivity, specificity for TB infection can be as high as >95% in settings with low 
MOTT bacilli prevalence209. Cross-reaction with BCG wanes significantly with time since 
vaccination232.  Similar to issues of sensitivity, small reactions may be due to the 
technique of TST administration, trauma, or errors in reading the test, rather than TB 
infection1;221.  
 
While sensitivity and specificity are inherent characteristics of the tuberculin skin test, the 
positive predictive value of the test (ie the probability that someone with a positive TST 
result truly has TB infection233) is determined by the prevalence of TB infection233. 
Consequently, in high TB prevalence areas, such as South Africa, the positive predictive 
value of the test is greater than that in low prevalence areas210.  
 
2.2.2 The Interferon-Gamma Release Assay 
A more recently available test for the detection of TB infection is the interferon-gamma 
(IFN-gamma) release assay. This is a blood-based, ex vivo test that is based on the 
quantification of IFN-gamma released by effector T cells following stimulation with 
tuberculin234;235. Studies have shown that IFN-gamma release assays have greater 
specificity for latent TB infection compared to TST, particularly in BCG-vaccinated 
populations236. Other advantages of the IFN-gamma release assays include an objective 
determination of infection, which is not subject to reader variability, and the absence of 
activation or boosting of the immune response to TB-related antigens, providing an 
excellent tool for repeat testing of individuals for the detection of new TB infection.  As 
with TST, these assays are unable to distinguish between TB infection and disease237. 
The literature discussing this assay is only available from the late 1990’s and therefore 
TST was utilized in this study to enable comparison with a large body of both historical 
and more recent data. 
 
2.2.3 Calculating Incidence of TB Infection 
Despite the limitations described above, TST remains a useful tool to determine the 
prevalence of TB infection, which in turn can provide valuable information on the 












Incidence of TB infection is a measure of current transmission in a community. While 
repeated testing of a cohort of uninfected individuals over time is a conventional method 
for determining incidence of a disease, this methodology is both labour and time 
intensive, and is further complicated by the boosting of the immune response in 
immunology-based tests such as TST2;238. Therefore alternative approaches for 
calculating incidence from prevalence data have been developed.  I will discuss two 
methods, in particular, 1) the annual risk of TB infection (ARTI) and 2) the force of 
infection. 
 
Annual Risk of TB Infection 
Annual risk of TB infection has been defined as “the probability that an individual, who 
has not previously been infected with tubercle bacilli, will be infected during the ensuing 
period of one year”1.  ARTI is calculated from TB infection prevalence data, and 
comprehensive descriptions of the theoretical basis for the relationship between 
prevalence and ARTI are available in the literature1;239;240. 
 
ARTI is a cohort’s average risk of infection from the birth year of the cohort to the year of 
the survey, and therefore is a measure of the risk at a calendar time between these two 
time points2. ARTI incorporates all the factors that contribute to the transmission of TB 
over the specified time period: from the characteristics of the infectious case and 
susceptible individual, to infecting pathogen, environmental factors, the performance of 
the local TB control programme216. Repeated measurements of ARTI over time will 
provide information on overall trends in TB infection rates, but because of its “averaging” 
characteristics ARTI is not sensitive to short term changes216. 
 
In the pre-chemotherapy era Styblo described a fixed relationship between ARTI and 
smear-positive disease incidence241, although this theory has subsequently been 
criticized242. In addition, the availability of TB chemotherapy would have altered any 
relationship between ARTI and incidence49;216;242;243: TB treatment increases survival 
rates and reduces person-time of infectiousness in a community, thereby reducing 
infection risk216 and subsequently decreasing TB prevalence and incidence. However, it 
should be noted that these factors are all dependent on the performance of the TB 











between ARTI and TB incidence may again have been altered by the impact of the HIV 
epidemic on TB. This change is postulated based on the increase in both smear-positive 
and smear-negative TB cases in areas with high HIV prevalence, and the changes in the 
duration of infectiousness of HIV-infected TB cases216;244. The Styblo ratio of  ARTI to 
smear-positive disease incidence of 1% ARTI: 50 smear-positive cases/100,000241 is, for 
the most part, no longer used7.  
 
Force of Infection 
ARTI is an averaged measure of the risk of TB infection over the lifetime of the study 
participants1;2. The obvious limitation of this measure is that ARTI only provides an 
estimate of current transmission or incidence if calculated in very young participants. In 
comparison, force of infection provides a recent estimate of infection incidence across a 
wide range of ages. Force of infection is defined as the proportion of susceptible 
individuals that became infected in a specified period and can be calculated using 
changes in age-specific prevalence rates245-247.  
 
This approach is a relatively new concept that has been utilized to assess incidence in 
diseases in which incidence is difficult or costly to measure, such as glaucoma246 and 
more recently, HIV248;249. The mathematical techniques utilized are based on the 
principle that prevalence is a function of incidence and duration of illness or infectivity250. 
This principle holds true under the assumptions of stability of the population and 
therefore this approach requires minimal immigration into the community in the relevant 
age groups, as well as minimal emigration or removals through mortality. In addition this 
method is most appropriate in diseases that are irreversible. Among children and 
adolescents, TB infection itself is persistent and not fatal, unless it progresses to TB 
disease. 
 
2.2.4 Tuberculin Skin Test Surveys 
TST surveys have an important role in understanding the impact of changing risk factors, 
such as an HIV epidemic, or interventions, such as antiretroviral therapy (ART), on TB 
transmission251;252. Yet, there are few current data published on prevalence of TB 
infection, ARTI or force of infection, particularly in countries with high HIV prevalence253-












In a review of TB infection prevalence and ARTI trends in developing countries, studies 
ranging from 1949 to the mid 1980’s were assessed. In most countries, including many 
in the African region, ARTI trends were noted to be decreasing2. This review did not 
include South African data, but studies from South Africa have reported low256 and 
decreasing ARTIs in the pre-HIV era257;258.    
 
Since the advent of the HIV epidemic, the few studies that have attempted to assess the 
impact of the HIV epidemic on TB infection in children have reported mixed findings. 
One study from Tanzania reported a significant drop in ARTI in 6 to 14 year olds from 
1983 to 2003253 in the context of an increasing HIV epidemic (HIV prevalence of 7-
11%259). This trend was reported despite increasing TB notification rates, including 
increasing smear-positive TB notification rates253. Similarly, a study of Ugandan children 
reported a 2.9% drop in ARTI among 10 year old children, from 2.3% in 1970 to 1.2% in 
1987254, at a time of escalating HIV prevalence260. In contrast, research from Kenya 
reported an increased ARTI among young school children from 1986 to 1996 (0.6% to 
1.1%), associated with an increasing TB epidemic and high HIV prevalence255. 
Meanwhile the Republic of Djibouti, with a relatively low HIV prevalence of 2.9% in 
200213, reported a stable ARTI rate of 2.1-3% from 1994 to 2001261. While no trends in 
TB infection rates are available from Malawi, a study performed in 1994 reported an 
ARTI of 1%262.  
 
There are few recent, published tuberculin skin test data from southern African countries 
where HIV prevalence has reached staggering levels, but the few reports available 
indicate a substantial ARTI, of at least 2.5%, in these countries205;263;264. Studies have 
focused on TB infection in young children in high TB settings205;253;255;263,  and there are 
few data assessing ongoing TB infection in older children and adolescents in 
communities with high TB and HIV burdens265.  
 
To better understand the transmission of TB in communities with substantial TB and HIV 
prevalence, and the impact of HIV on transmission in this context, we performed a 
tuberculin skin test survey to determine the prevalence of TB infection and force of 












2.3   STUDY DESIGN 
The cross-sectional survey was performed in three stages, among children attending the 
local government primary and secondary schools in Site M. Children were eligible for 
participation if they were resident in the community and registered at the local schools.  
Children from grades 1 to 3 at the primary school were enrolled from October to 
November 2006 and children in grades 5 to 7 were enrolled from October to November 
2007.  Children from grades 8 to 12 at the secondary school were enrolled from August 
to October 2009. All three phases of the school surveys were performed on the primary 
school premises. Basic demographic information was collected on each participant. All 
participants were examined for the presence of a BCG scar, and participants received 
the TST regardless of BCG scar status.  
 
2.3.1 Tuberculin Skin Testing 
The World Health Organization (WHO)-recommended standard dose of 2TU of PPD 
RT23 with Tween 80 (Statens Seruminstitut, Copenhagen) was administered 
intradermally to the volar surface of the child’s left forearm by a trained nurse. The 
reaction size to the tuberculin was read by a trained assessor at a second visit 
performed 3 days following the inoculation. The presence or absence of a reaction was 
noted, and, where present, the size of the induration was measured along perpendicular 
axes using standard callipers.  
 
The secondary school children also provided an oral transudate specimen for HIV 
testing, using the Orasure® collection device and Vironostika Uni-Form II HIV-1 and 
HIV-2 plus 0 ELISA test (bioMérieux SA, Marcy l'Etoile, France). HIV results were 
anonymous but linked to TST results and all adolescents were encouraged to have 
voluntary counselling and testing at local facilities. HIV testing was not performed in the 
primary school surveys. 
 
All children with a TST reaction ≥10mm were recalled for investigation for active 
tuberculosis and children with signs or symptoms of active disease were referred to the 












2.3.2 Data Analysis 
Data were analyzed using STATA 10.0 (StataCorp, College Station, Texas). Analysis 
was performed in three parts: firstly on the primary school dataset, secondly on the 
secondary school dataset, excluding HIV-infected individuals, and thirdly on the 
secondary school dataset combined with the primary school dataset, excluding the HIV-
infected individuals from the secondary school survey. 
 
Primary and Secondary School Surveys 
TST results were calculated as the mean of the two diameters of the TST reaction, and a 
positive reaction was defined at 10mm cut-off, based on the guidelines for infection in 
clinical settings195;196;266. The study participants were divided into age quartiles, and TB 
infection prevalence and ARTI were calculated overall and for each age group. ARTI 
was calculated as 1- (1-prevalence)1/(mean age+0.5).  As the age in full years at participants’ 
last birthday was used, 0.5 was added to the mean age for the calculation of ARTI223. 
Bivariate analyses employed Student’s t- and Fisher’s exact tests, as appropriate; for 
comparison of TST results between different groups, Wilcoxon sum rank tests were 
used. Multiple logistic regression models were developed to examine factors associated 
with positive TST results.  Trends in ARTI by age groups were assessed using Cox-
Stuart test for trend267;268. 
 
Sensitivity analysis of TST positivity cut-off point 
As the 10mm cut-off for defining TST sensitivity is based on clinical criteria, rather than 
analytical epidemiologic criteria, we performed a sensitivity analysis on the primary 
school participant data, in which a TST positive reaction was determined as the mean 
reaction excluding all non-reactors223. This method is recommended in settings in which 
there is “a distinct separation between reactors and non-reactors”223, as was shown in 
our data. Association of TB prevalence with age, gender and BCG status was assessed, 
and ARTI calculated for this cut-off. Trends in ARTI by age groups were assessed using 
Cox-Stuart test for trend267;268. 
 
HIV Infection in Secondary School Participants  
Univariate and multivariate logistic regression models were developed to determine the 
demographic characteristics associated with HIV among the secondary school 











models, a TST reaction size of ≥5mm was used as a positive cut-off for TB infection in 
HIV-infected adolescents, in keeping with clinical guidelines195;196.  
 
Repeat TST Participants 
In 2009, 159 students who had participated in the 2007 survey also took part in the 
secondary school survey, resulting in repeat tuberculin testing of these participants. 
Bivariate analyses used Wilcoxon sum rank tests and Student’s t-, as appropriate for 
comparison of participant groups: participants with repeated TST compared to the 
participants in the combined surveys; participants who remained TST negative versus 
those who converted to a positive TST from 2007 to 2009. The McNemar test was used 
for matched comparison of 2007 and 2009 TST results. A change in TST reaction size 
was calculated by subtracting the 2007 reading from the 2009 reading for each 
participant. A multivariate regression model was developed to compare reaction sizes 
between the groups. A change in reaction size may be the result of random variability in 
administration or reading of the test238, or may result from reversion or the ”booster” 
effect of enhanced allergy238;269. In keeping with existing literature, we defined a true 
conversion to TST positivity between the two surveys as a change from a negative result 
(<10mm) on original TST to a positive result (≥10mm) on the second test, with an 
absolute reaction size increase of at least 6mm211;212;270.  In addition, the recent CDC 
guidelines define a conversion as an increase of TST reaction size of ≥10mm within a 
two year period, and this definition was also utilised271. 
 
Combined Primary and Secondary School Surveys 
In order to assess the effect of age on TB prevalence and force of infection, we 
investigated the possibility of combining the primary and secondary school surveys.  We 
compared the prevalence of TST positive results for the two sample populations in the 
overlapping age range of 14 to 16 years (Figure 2.1). The chi-squared test for 
comparison was not significant (survey 1 and 2: p=0.66; survey 2 and 3: p=0.46), nor 
was survey year a significant risk factor in multivariate logistic regression model for TST 
positivity. Therefore we combined the primary and secondary survey datasets.  HIV-
infected participants from 2009, as well as the second test in those participants who had 




































Primary school prevalence Primary school 95% Confidence interval
Secondary school prevalence Secondary school 95% Confidence interval  
 
Figure 2.1: TB prevalence in Primary and Secondary School surveys, by age 
 
The participants were divided into age quartiles, and prevalence and ARTI were 
calculated overall and for each age group. Smoothed prevalence of TB infection by age 
was calculated from predictive logistic regression models on the combined primary and 
secondary school dataset, excluding those who tested HIV-infected in the secondary 
school, and excluding the second test result in participants with a repeat test. Force of 
infection was defined as the proportion of susceptible individuals that became infected in 
a specified period, and was calculated as follows:  the probability of becoming infected at 
specific ages for the pool of individuals who remained uninfected = (prevalenceY1+1 - 
prevalenceY1) /(1-prevalence Y1)]*100.  Trends in ARTI and force of infection were 
assessed using Cox-Stuart test for trend267;268. 
 
For all analysis, 95% confidence intervals (CI) were based on the Poisson distribution 
and all statistical tests were 2-sided at alpha=0.05. 
 
2.4   STUDY FINDINGS 
2.4.1 Primary School Survey 
Of the 1060 children enrolled at the primary school, 1020 were eligible for study 











having dropped out of school during the course of the year (n=22). Consent was 
obtained from the parents of 837 children (82% of those eligible). The parents of 44 
children refused consent (4%) and 137 children had incorrect locator information in the 
school register (13%). We enrolled 832 children (99% of consented children). The 
outstanding five children were not enrolled due to persistent absenteeism. Tuberculin 
reaction was assessed in all children who were inoculated, except one who relocated 




Table 2.1 shows the demographic characteristics of the study sample. Ages ranged from 
5 to 17 years, with a mean age of 10.7 years (standard deviation [std dev]=2.7), and 
48% of the participants were female. The majority of the children did not have a BCG 
scar (74%); one child’s BCG scar status was unobservable due to burn scars on the 
upper arm, and he was thus excluded from analysis involving BCG scar status.   
 
 Table 2.1: Demographic characteristics of primary school participants 
*One participant’s BCG scar status was indeterminable due to burn scars 
 
TST Results 
TST reaction sizes ranged from 0 to 27.5mm (median=0mm; interquartile range [IQR]: 0-
16.5mm), and 506 (61%) participants had no reaction to the TST. The frequency 
distribution of reaction sizes for positive TST results is presented in Figure 2.2. There 
was no significant difference between the mean reactions of participants with BCG scars 
compared to those without scars (6.2 vs 7.0mm, respectively, p=0.28).  
AGE QUARTILES  
5 to 8 yrs 9 to 11 yrs 12 to 13 yrs 
 
14 to 17 yrs  TOTAL 
n=233 n=222 n=237 n=139 n=831 
 
n (%) n (%) n (%) n (%) n (%) 
Mean Age  7.3 years 9.9 years 12.5 years 14.6 years 10.7 years 
Gender    
  Male 115 (49%) 122 (55%) 110 (46%) 87 (63%) 434 (52%) 
  Female 118 (51%) 100 (45%) 127 (54%) 52 (37%) 397 (48%) 
BCG status    
















At the 10mm cut-off 311 participants (37%) had a positive TST result. TST positivity (as 
defined by the 10mm cut-off) was not associated with gender (p=0.97) or BCG status 
(p=0.39). In a logistic regression model predicting the relative odds of a positive TST 
result, age was positively associated with a positive TST result at the 10mm cut-off 
(adjusted odds ratio [OR] for a 1-year increase in age: 1.19, 95% confidence interval 
[CI]: 1.12 – 1.25; p<0.001).  
 
The total ARTI for this sample was 4.1%. The ARTI did not differ significantly across the 
age quartiles (p=0.50). Table 2.2 reports the TB prevalence and ARTI by age quartiles. 
 







positive Prevalence ARTI% 
5-8 yrs 7.8 233 61 26.2 3.8% 
9-11yrs 10.4 222 70 31.5 3.6% 
12-13yrs 13.0 237 107 45.1 4.5% 
14-17yrs 15.1 139 73 52.5 4.8% 
TOTAL 11.2 831 311 37.4 4.1% 
* The mean age reported here is the age used for the ARTI calculations, and is based on the 












Sensitivity Analysis of TST Positivity Cut-off Point 
The cut-off point for TST positivity determined by the mean of non-reactors was 17.4mm. 
At the 17.4mm cut-off 171 participants (21%) had a positive result. As with the 10mm 
cut-off, TST positivity at the 17.4 mm cut-off points was not associated with gender 
(p=0.69) or BCG status (p=0.08). In a logistic regression model predicting the relative 
odds of a positive TST result, age was positively associated with a positive TST result at 
both the 10mm cut-off (adjusted OR for a 1-year increase in age: 1.19, 95% CI: 1.12 – 
1.25; p<0.001), and at the 17.4mm cut-off (adjusted OR for a 1-year increase in age: 
1.19, 95% CI: 1.12 – 1.27).  
 
The total ARTI in the sensitivity analysis was 2.0% at 17.4mm cut-off. Table 2.3 reports 
the TB prevalence and ARTI by age quartiles for this analysis. The ARTI did not differ 
significantly across the age quartiles (p=0.50).  
 







positive  Prevalence  ARTI% 
5-8 yrs 7.8 233 25 10.7 1.4% 
9-11yrs 10.4 222 39 17.6 1.8% 
12-13yrs 13.0 237 71 30.0 2.7% 
14-17yrs 15.1 139 36 25.9 2.0% 
TOTAL 11.2 831 171 20.6 2.0% 
* The mean age reported here is the age used for the ARTI calculations, and is based on the 
mean age for the age category+0.5 years, as described in the methods section 
 
In conclusion, using a cut-off for TST positivity determined as the mean reaction 
excluding all non-reactors (17.4mm)223 did not substantively change the study findings 
when compared to the cut-off determined by clinical guidelines (10mm). 
 
 
2.4.2 Secondary School Survey 
Of the 959 children enrolled in the secondary school, 839 were eligible for study 
participation (87%). Ineligibility was due to residence outside of the community (n=80) 
and having dropped out of school (n=40). Consent/assent was obtained for 820 children 











and one child was not consented due to hospitalization for cancer over the study period. 
We enrolled all 820 consented learners. Four of the children enrolled declined 
participation in the TST component of the study, and four children declined HIV testing. 
Of the 816 children who underwent TST, 813 (99.6%) had TST test read within 72-96 
hours. No study-related adverse events were noted in the three children assessed 
outside the window period and these three participants were excluded from the analysis. 
 
Demographic Characteristics 
Table 2.4 shows the demographic characteristics of the secondary school study sample. 
Of the 813 participants who completed TST testing, 159 had received tuberculin skin 
testing in the 2007 survey in the community. These 159 participants were excluded from 
the main analysis and their results are presented in a sub-analysis. Of the remaining 654 
children in the secondary school survey, all but three of the participants underwent HIV 
testing. In total 34 of the remaining participants tested HIV-infected, and were excluded 
from the TB analysis (n=620). 
 
Among the 620 participants, ages ranged from 13 to 22 years, with a mean age of 17.5 
years (std dev: 1.9), and 41% of the participants were male. The majority of the children 
did not have a BCG scar (87%); one child’s BCG scar status was not recorded, and this 
participant was thus excluded from analysis involving BCG scar status.   
 
TST Results 
TST reaction sizes ranged from 0 to 30mm (median=11.5mm; IQR: 0-16.5mm), and 222 
(36%) participants had no reaction to the TST. The frequency distribution of reaction 
sizes >0mm are presented in Figure 2.3. There was no significant difference between 
the median reactions of participants with BCG scars compared to those without scars 













Figure 2.3: Frequency distribution of TST reactions (>0mm) in HIV-uninfected 
participants in secondary school survey 
 
 
At the 10mm cut-off, 334 participants (54%) had a positive TST result. There was no 
significant difference in the defined TB positivity by BCG scar status (p=0.99). In a 
multivariate logistic regression model predicting the relative odds of a positive TST 
result, age was positively associated with a positive TST result (adjusted OR for a 1-year 
increase in age: 1.10, 95% CI: 1.01 – 1.21; p=0.03), as was male gender (adjusted OR 
for female compared to male: 0.65, 95% CI: 0.47-0.90; p=0.01).  
 
The overall ARTI for this sample was 4.2% (95% CI: 3.8-4.7%). Table 2.5 reports TB 
prevalence and ARTI overall and by age quartiles. The ARTI did not differ significantly 












Table 2.4: Demographic characteristics of the secondary school sample 
First time TST participants ф Repeat TST participants фф 
HIV-uninfected HIV-infected Total 
HIV-
uninfected HIV-infected Total 
n=617 n=34 n=654 n=154 n=4 n=159 
 n (%) n (%) n (%) n (%) n (%) n (%) 
Age: mean (range) 17.5 (13-22) 18.4 (15-22) 17.5 (13-22) 15.4 (13-19) 15.3 (14-17) 15.4 (13-19) 
   13-16 yrs 176 (29) 5 (15) 183 (28) 133 (86) 3 (75) 136 (86) 
   17 yrs 148 (24) 4 (12) 152 (23) 13 (8) 1 (25) 15 (9) 
   18 yrs 112 (18) 9 (26) 121 (19) 6 (4) 0 (0) 6 (4) 
   19-22 yrs 181 (29) 16 (47) 198 (30) 2 (1) 0 (0) 2 (1) 
Gender: Male 255 (41) 9 (34) 266 (41) 81 (53) 2 (50) 84 (53) 
BCG Scar present 80 (13) 6 (18) 86*  (13) 32 (21) 0 (0) 32 (20) 
TST positive 331 (54) 11 (32) 345 (53) 90 (58) 1 (25) 91 (57) 
*n = 653: one participant’s BCG scar status was not recorded 
ф Three participants declined HIV testing 














Table 2.5: Secondary school TB prevalence and ARTI by age quartile for the 10mm cut-





Age* n (%) 
TST 
positive Prevalence  ARTI% (95% CI) 
13-16 yrs 15.8 178 (29) 85 47.8% 4.0% (3.2-5.0%) 
17 yrs 17.5 148 (24) 76 51.4% 4.0% (3.2-5.0%) 
18 yrs 18.5 112 (18) 58 51.8% 3.9% (2.9-5.0%) 
19-22 yrs 20.2 182 (29) 115 63.2% 4.8% (4.0-5.8%) 
TOTAL 18 620 334 53.9% 4.2% (3.8-4.7%) 
* The mean age reported here is the age used for the ARTI calculations, and is based on 
the mean age for the age category+0.5 years, as described in the methods section. 
 
 
Sub-analysis: HIV and TB infection 
Of the 820 participants enrolled in the 2009 secondary school survey, 816 (99.5%) 
consented to HIV testing. In total 40 (4.9%) participants tested HIV-infected. In a logistic 
regression model, HIV infection was associated with increasing age (OR: 1.3; 95% CI: 
1.1-1.6; p=0.001) and female gender (OR: 2.3; 95% CI: 1.1-4.7; p=0.03).   
 
Among the 809 participants who underwent both TST and HIV testing, 38 were HIV-
infected, four of whom had previous TST testing in 2007. The median TST reaction size 
among HIV-infected participants (n=34; excluding those with a repeat test) was smaller 
than that of HIV-uninfected participants (0 vs 11.5mm; p=0.08), and this difference was 
significant when adjusted for age and gender (p=0.04).  Using the revised cut-off of 
≥5mm, 15 (40%) HIV-infected participants were TST positive. In a multivariate logistic 
regression model adjusted for age and gender (Table 2.6), HIV infection was not 













Table 2.6: Risk factors associated with TST positivity in 809 secondary school learners 













OR (95% CI) 
Multivariate 
Analysis 
OR (95% CI) 
Age   1.09 (1.01-1.17) 1.09 (1.01-1.17) 
Gender   
  Male 132 (35) 215 (49) 1 1 
  Female 241 (65) 221 (51) 0.56 (0.42 – 0.75) 0.59 (0.44 – 0.78) 
HIV status   
  HIV-Uninfected 350 (94) 421 (97) 1 1 
  HIV-Infected 23 (6) 15 (3) 0.54 (0.28 – 1.06) 0.53 (0.27 – 1.05) 
 
 
Sub-analysis: Repeated TST testing 
In 2009, 159 students who had participated in the 2007 survey also took part in the 
secondary school survey.  The median age of these 159 participants was 15 years (IQR: 
15-16), which was marginally higher than the median age of the participants in the 
combined surveys (median 15 vs 14 years; p<0.001). Otherwise, the 159 participants did 
not differ statistically from the participants in the combined surveys combined in terms of 
gender (53% male vs 47% respectively; p=0.17), HIV status (2.5% vs 5.5% respectively; 
p=0.12) or BCG scar status (20% in both groups; p=0.99).  
 
TST results 
When assessing change in TST reaction size from 2007 to 2009, 55 (35%) of 
participants had no change in mean reaction size. Overall, 80 (50%) participants had an 
increase in reaction size, with a mean increase of 5.8mm.  Changes in reaction size are 
shown in Figure 2.4.  
 
Using a 10mm cut-off for positivity, in 2007, 76 (48%) of these participants had a positive 
TST result; in 2009, 91 (57%) tested TST positive.  Overall, 19 participants who were 
TST negative in 2007 tested positive in 2009 (23%; p=0.003), and four (5%) reverted to 

















































Figure 2.4: Changes in TST reaction size in participants tested in 2007 and 2009 
 
Table 2.7: Matched comparison of TST results in 2007 and 2009 
 
2007 
 TST Negative TST Positive TOTAL 
TST Negative 64 (40%) 4 (3%) 68 
2009 
TST Positive 19 (12%) 72 (45%) 91 
 TOTAL  83 76 159 
 
The 19 participants who converted to a positive TST result in 2009 did not differ 
statistically from the 64 that remained TST negative in terms of median age (15 years in 
both groups; p=0.89), gender (63% male vs 45% respectively; p=0.17) or BCG scar 
status (74% vs 80% respectively, p=0.58). Similarly there was no change between the 
four participants who reverted to a TST negative result in  2009 and those who remained 
TST negative in terms of age (p=0.81), gender (p=0.62) or BCG scar status (p=0.61).  
 
Using the definitions outlined above, 18 of the 19 convertors had an increase in reaction 
size of ≥10mm and were therefore considered true new infections with TB. These 18 
participants equate to an incidence of 22% over two years (95% CI: 13-32%), or an 













In 2009, the mean reaction size among participants with repeat tests was larger 
compared to those participants who tested for the first time (15 vs 11.5mm; p<0.001), 
and this finding persisted when adjusted for age and gender (p<0.001). Overall TB 
prevalence did not differ significantly between those that had a repeat TST test and 
those participants who were testing for the first time (58 vs 54%, p=0.29).  
 
2.4.3 Combined Primary and Secondary School Surveys 
TST results from the primary school children were combined with those of the 620 HIV-
uninfected secondary school children, excluding the second test in participants who had 
a repeat test in 2009, providing a sample of 1,451 participants.  
 
Demographic Characteristics 
Ages of the combined sample ranged from 5 to 22 years, with a mean age of 13.6 years 
(std dev: 4.1), and 52% of the participants were female. Overall 80% of the children did 
not have a BCG scar.  Demographic characteristics are reported in Table 2.8 
 
 Table 2.8: Demographic characteristics of the participants in the combined surveys 
*One BCG scar status unknown 
 
TST Results 
TST reaction sizes ranged from 0 to 30mm (median=0mm; IQR:0-16.5mm). Overall, 728 
(50%) of the participants had no reaction to the TST.  The frequency distribution of 
reaction sizes >0mm are presented in Figure 2.5. 
AGE QUARTILES  
5 to 9 yrs 10 to 14 yrs 15 to 17 yrs 
 
18 to 22 yrs  TOTAL 
n=325 n=488 n=344 n=294 n=1,451 
 
n (%) n (%) n (%) n (%) n (%) 
Mean Age 7.8 years 12.3 years 16.2 years 19.1 years 13.6 years 
Gender   
  Male 165 (51) 241 (49) 142 (41) 143 (49) 691 (48) 
  Female 160 (49) 249 (51) 202 (59) 151 (51) 760 (52) 
BCG status   



























Figure 2.5: Frequency distribution of TST reactions (>0mm) in combined primary and 
secondary school surveys 
 
At the 10mm cut-off, 645 participants (45%) had a positive TST result (Table 2.9). TB 
prevalence by age, and by age and gender are presented in Figures 2.6 and 2.7 
respectively. In a multivariate logistic regression model, a positive TST result was 
significantly associated with age (adjusted OR for a 1-year increase in age: 1.17, 95% 
CI: 1.10 – 1.25; p<0.001) and male gender (adjusted OR for female compared to male: 
0.74, 95% CI: 0.60-0.92; p=0.01). TST positivity was not associated with BCG scar 
status (p=0.40) or year of survey (p=0.23).  
 
Table 2.10 reports the smoothed prevalence of TB infection by age, as predicted by 
logistic regression model. Also reported in Table 2.10 are the ARTI and force of infection 
by age for this sample, calculated from the smoothed prevalence. The overall ARTI for 
this sample was 4.1% (95% CI: 3.8-4.4%). The ARTI did not differ significantly across 
age by years from 6 to 22 years of age (p=0.15), or from 6 to 14 years of age (p=1.00).  
 
The force of infection, as determined by the probability of becoming infected at a specific 













Table 2.9: TB prevalence and ARTI by age quartile and gender for the 10mm cut-off 
point for the three surveys combined (excluding HIV-infected and second tests in repeat 
TST participants) 
 
 Mean Age* n (%) 
TST 
positive Prevalence  ARTI% (95% CI) 
Age Category       
   5-9yrs 8.3 325 (22) 91 28.0% 3.9% (3.1-4.7%) 
   10-14yrs 12.8 488 (34) 207 42.4% 4.0% (3.2-5.0%) 
   15-17yrs 16.7 344 (24) 174 50.6% 3.9% (2.9-5.0%) 
    18-22yrs 19.6 294 (20) 173 58.8% 4.8% (4.0-5.8%) 
Gender      
    Male 13.8 691 (48) 330 47.8% 4.6% (4.1-5.1%) 
    Female 14.3 760 (52) 315 41.4% 3.7% (3.3-4.1%) 
TOTAL 14.1 1,451 645 44.5% 4.1% (3.8-4.4%) 
* The mean age reported here is the age used for the ARTI calculations, and is based on 


























Prevalence of TB infection 95% confidence interval  













Figure 2.7: Prevalence of TB infection in combined survey by age and gender 
 





(95% CI) ARTI** 
Force of 
infection  ф 
5 1 0.22 (0.17 - 0.27) 4.85   
6 36 0.24 (0.19 - 0.29) 4.47 2.93 
7 84 0.26 (0.22 - 0.30) 4.21 3.15 
8 112 0.28 (0.24 - 0.32) 4.06 3.39 
9 92 0.31 (0.27 - 0.34) 3.96 3.81 
10 71 0.33 (0.29 - 0.36) 3.91 3.96 
11 59 0.35 (0.32 - 0.39) 3.89 4.28 
12 107 0.38 (0.35 - 0.41) 3.91 4.47 
13 135 0.41 (0.38 - 0.43) 3.93 5.03 
14 116 0.43 (0.41 - 0.46) 3.97 5.11 
15 84 0.46 (0.44 - 0.49) 4.04 5.58 
16 106 0.49 (0.46 - 0.52) 4.10 5.70 
17 154 0.52 (0.48 - 0.55) 4.18 6.05 
18 112 0.54 (0.51 - 0.58) 4.27 6.44 
19 101 0.57 (0.53 - 0.61) 4.36 6.63 
20 46 0.60 (0.55 - 0.64) 4.45 7.11 
21 21 0.62 (0.58 - 0.67) 4.55 7.37 
22 14 0.65 (0.60 - 0.70) 4.66 7.34 
* Predictive logistic regression model: logit{P(Age)} = -1.82+0.111 age. 
** The ARTI calculations are based on the mean age for the age category+0.5 years, as 
described in the methods section. 













2.5   DISCUSSION 
A key finding of this study was the staggering ARTI and force of infection rates identified 
among children and adolescents in this community. These findings are in keeping with 
the substantial burden of TB disease prevalence179 and notifications39 in Site M, and are 
consistent with the prevalence of latent TB infection of 67 – 88% reported among young 
HIV-uninfected adult controls from similar communities in Cape Town265;272;273.  
 
2.5.1  Interpreting the ARTI 
The ARTI of 4.1% observed in this study was markedly higher than those documented 
both in sub-Saharan Africa prior to the HIV epidemic (1.5-2.5% in late 1980’s) and in 
many other sub-Saharan countries which are heavily affected by HIV (0.68-2% reported 
in other countries). If ARTI provides a measure of the risk of infection from birth to time 
of study, this survey covers the annual risk from 1987 through to 2009, a period of 
escalating HIV and TB epidemics in Site M39.  
 
We found that the ARTI remained constant across the age range of 5-22 years, despite 
children being exposed to a rapidly increasing TB epidemic. Unfortunately, the difficulty 
in separating the effect of age and calendar year in ARTI complicates the interpretation 
of ARTI across age groups. Figure 2.8 illustrates three hypothetical conditions under 
which an ARTI of 4.1% could be obtained for this community. 
 
The consistency of ARTI across age groups may seem to imply that the risk of TB 
infection has remained constant over the entire calendar period (Figure 2.8a). Given the 
relatively constant rates of TB notification among HIV-uninfected patients over this time 
period (Chapter 5), as well as the possibility that HIV-associated TB cases may be less 
infectious124;176;177, it is possible that the annual risk of infection has indeed remained 
constant in this community. This theory is further supported by the stable TB notification 
rates in children over this time period (Chapter 5). A constant ARTI may reflect that 
younger children are not proportionately affected by the HIV-associated TB epidemic 
since their predominant social contacts are young peers, parents and teachers.  
However social interactions of adolescents may more closely reflect those of adults in 













It could be argued that, despite the consistency across age groups, the ARTI may in fact 
be increasing in this community274;275 (Figure 2.8b). There is evidence to suggest that, as 
in other African countries with functional Directly Observed Therapy, Short-course 
(DOTS) programmes2, the risk of infection in South Africa may have been decreasing in 
the years preceding the HIV epidemics258, with reports of 0.5-1.4% ARTI in South Africa 
in the 1970’s256;258. It is possible that the HIV epidemic led to a reversal of this trend, and 
an increase in the risk of TB infection.  We have reported a significant increase in 
pulmonary TB (PTB), including smear-positive PTB, among adults in this community, 
associated with the HIV epidemic (Chapter 5). This may support the argument of an 
increasing ARTI over time, especially in light of a recent study that reported increasing 
ARTI from 1998 to 2005 in another South African community, albeit a community with 
low HIV prevalence264. It should be noted the same study also reported a stable ARTI in 
a second, low HIV prevalent South African community, over the same time period264.  
Conversely, if the community experienced an HIV-associated increased risk of TB 
infection, then it stands to reason that the introduction of the high coverage antiretroviral 
therapy programme may have led to a decline in TB infection risk, as the HAART 
programme has been associated with a decline in TB notifications, including smear-
positive TB, as well as a decline in TB prevalence (Chapters 5 and 6). However these 
changes would have occurred over a relatively short period in this community and may, 
therefore, be obscured by the “averaging” nature of the ARTI measure (Figure 2.8c).  
 
As ARTI is an average measure of risk across all the years from birth to time of testing, it 
may not be possible to separate variations in risk with age from changes in risk trends 
within calendar years in a single cross-sectional analysis1;274;275. Subsequent 
mathematical modeling has shown that in a single survey even with constant ARTI 
across age groups, the risk of TB infection could in fact be increasing, decreasing, or 













Figure 2.8: Hypothetical scenarios of risk of TB infection, resulting in the observed ARTI 
in Site M 
 
Because ARTI is an averaged measure of the participants’ life-time risk of infection, this 
measure most accurately reflects recent transmission risk in younger children. As such, 
the ARTI of 4.5-4.9% in children aged 5 to 6 years most likely provides a reasonably 
accurate estimate of risk of infection in these children over the past 5 years. When 
assessed with the low force of infection in children aged 5 to 10 years of age, it appears 
that the risk of transmission is high in very young children (<5 years), decreases as they 
enter early school years, and increases again as they approach adolescence.    
 
Site M was established in 1994, and consequently many of the older children may have 
spent some time in other communities. Therefore this measure reflects the annual risk 
over a period of up to 20 years, as well as the risk encountered in different communities 
in which participants may have resided over that time. As a result the ARTI across the 












population.  However, the ARTI does provide insight into transmission in South Africa 
generally, suggesting considerable TB infection rates over the past 20 years. 
Irrespective of the direction of the trend in risk of infection, an ARTI of 4% means that 
the national TB control programme is falling short of the goal of reducing the proportion 
of infected individuals necessary to achieve control of the TB epidemic115. 
 
2.5.2 Interpreting the Force of Infection 
A more accurate measure of recent transmission is required in order to understand the 
current transmission dynamics in the study setting. The force of infection measure is not 
subject to the “averaging” nature of ARTI and provides just such a gauge of recent 
transmission.   
 
In this study, we demonstrated a high force of infection that was positively associated 
with increasing age. These findings are consistent with those suggested by 
mathematical modeling265. The advance of this study on the mathematical paper was 
that of greater numbers of older adolescent participants recruited from the same 
community, and the ability to show that the force of infection continues to increase up to 
approximately 20 years of age, at which age force of infection may plateau.  
 
Force of infection is a function of the probability of an effective encounter with an 
infectious TB case, and as such is the product of infectious TB disease prevalence and 
social mixing patterns. The correlation noted between force of infection and age may be 
due to increasing social mixing patterns, resulting from changing social interactions 
associated with age. In this community TB infection in primary school children was 
associated with the presence of an adult TB case on their residential plot (Chapter 3)182, 
while TB transmission between adults was due to interactions off the residential plots 
(Chapter 4)265.  Molecular epidemiological data from elsewhere have also confirmed that 
young children are significantly more likely to acquire TB infection from a household 
contact compared to adolescents276. Data from Europe show that the number of social 
contacts peak in adolescence277, suggesting that the likelihood of contact with infectious 
persons may also peak at this time. The social interactions, and therefore risk of TB 
infection, of mid-teens may more closely resemble that of adults rather than younger 
children in the community.  Social mixing data show that people tend to be in contact 












suggested that index TB cases may preferentially transmit TB to people who are of a 
similar age278. Given that older patients are more likely to be sputum smear-positive 
compared to young children, these social interactions may, in part, explain the 
increasing force of infection noted in adolescents. 
 
We have also shown a changing risk of TB infection by gender. In the primary school 
surveys, gender was not a risk factor for TB infection, but in the secondary school survey 
male gender was associated with increased TB infection. In other words, as males get 
older, their risk of TB infection out-strips that of females of similar age, and this is 
consistent with other reports in the literature1;212. Hypothetically, this increased risk may 
be due to a combination of increased biological susceptibility, differing immunological 
responses, or differences in socialization patterns of male compared to female 
adolescents. Further studies into the changing and diversifying socialization patterns by 
age and gender in this setting are needed.  
 
Force of infection and HIV 
While the HIV-associated TB epidemic undoubtedly contributes to the force of infection 
in this community, it is unlikely to be driving force of infection to a greater degree than 
the HIV-unassociated TB epidemic. The m st significant risk factor for TB transmission 
is the sputum bacillary burden of the index case55-58. Up to 70% of TB patients in this 
community are co-infected with HIV, and HIV-infected TB patients have lower rates of 
smear-positive TB, compared to HIV-uninfected TB patients18;118 (in this community 47% 
vs 67% smear-positive respectively). There is also evidence to suggest that HIV-
associated smear-positive TB cases may be less infectious than their HIV-uninfected 
counterparts124;176;177 (although it should be noted that there is also evidence suggesting 
no difference in infectivity between HIV-infected and HIV-uninfected smear-positive TB 
cases181-186). In addition, HIV-infected patients may contribute a shorter infectious period 
in the community due to rapid progression to TB disease and increased mortality124;178. It 
has been estimated that HIV-associated TB may be responsible for as little 7% of TB 
transmission9 and is therefore unlikely to contribute significantly to the force of infection.  
 
However, while the HIV epidemic may not be the primary driver of the force of infection, 
it is certainly adding fuel to the raging TB epidemic. The high force of infection in this 












by the time of school entry at 6 years of age, approximately 25% of children are latently 
infected with TB and the majority of adolescent are infected before the onset of sexual 
debut205;279. The prevalence of latent TB infection among young HIV-uninfected adults is 
as high as 64-88%265;272;273. Given the high HIV prevalence among adults in Site M179;197 
and the considerable increased risk of progression to TB disease in HIV-infected 
individuals, both from reactivation of latent infection and following recent infection14;102, 
these findings could explain the substantial incidence of TB disease in this setting.   
 
In order to reduce the force of infection, we need to decrease the effective contact 
between infectious cases and susceptible individuals. This could be achieved by 
decreasing the prevalence of infectious cases and the duration of infectiousness in the 
community, as well as by changing the conditions of social contact. Chapter 6 reports 
that a high coverage HAART programme reduces TB prevalence among HIV-infected 
participants, due to both improved immune function and the active TB case-finding 
among patients initiating HAART197. Extending active case-finding (ACF) to HIV-
uninfected residents may substantially reduce the burden of infectious cases in the 
population as well280. ACF together with efficient initiation of TB treatment would also 
serve to decrease the infectious period of cases in the community. Social programmes 
that impact the environment in which individuals interact, such as improved housing with 
decreased crowding and improved ventilation, may also lead to a reduction in the 
incidence of TB infection.   
 
2.5.3 Interpreting the Repeat TST Testing Results 
The substantial incidence rate of TB infection in the subset of participants tested two 
years apart confirmed the current high force of infection, more than two-fold higher than 
the ARTI.  The incident rate in this subset was greater even than that suggested by the 
force of infection calculations, and this is likely due to the small sample size (and 
therefore wide confidence intervals, which included the force of infection measure) as 
well as the boosting of the immune response noted with repeated TSTs238;281-285. 
 
Boosting is an increase in TST reaction size resulting from increased sensitization of the 
immune system to the tuberculin2;238. Skin sensitivity to the tuberculin may wane with 
age213;220, resulting in a false-negative TST reaction on initial testing, and therefore 












response due to immunity recall in an individual who previously tested TST negative209. 
However, the boosting phenomenon does complicate the ability to distinguish between a 
boosted positive response and a true conversion due to new infection2.  
 
Boosting is associated with increasing age238;281;282;284;286. While the boosting effect may 
be more common in older patients, it has been recognised in young children269;283;285;286, 
although studies suggest it may not be as marked in children under 20 years of 
age238;269. 
  
The booster phenomenon is less frequent >60 days after the first negative TST 
result211;238;269, but has been reported at low rates of  3-4% in adult studies up to 1 to 1.5 
years following the first tuberculin test209;238;269,287.  
 
Boosting raises a key limitation of the tuberculin test: TST is dependent on 
immunological response. As a result, repeated testing to determine incident cases is 
difficult to interpret due to the ”booster” effect of enhanced allergy238;269 and this is 
highlighted by the fact that participants with a repeat test in 2009 had larger median TST 
reaction sizes compared to first-time participants. Similarly, immune suppression can 
limit the sensitivity of this test, resulting in anergic responses to TST, such as have been 
noted in HIV-infected patients98-101, and this is underscored by the smaller median TST 
reaction sizes in HIV-infected participants compared to HIV-uninfected participants.   
 
2.5.4 HIV and TB Infection 
The lack of association between HIV and TB infection is another key finding of this 
study. Adolescents infected with HIV did not appear to be at higher risk for acquiring 
primary TB infection. This is in keeping with findings reported from lower HIV and TB 
prevalent settings14;97, and is consistent with studies that suggest that the establishment 
of TB infection is mechanistic, as opposed to immune-based288. Despite the use of a 
revised TST cut-off of 5mm in HIV-infected participants, this finding should be 
interpreted with caution for a couple of reasons. Firstly, the lack of statistical significance 
is border line, and a larger sample size may provide greater power to detect an 
association between TB infection and HIV. Secondly, as mentioned above, the 
interpretation of TST results is difficult when immune function may be compromised. No 












of transmission identified. If adolescents were recently infected, then it could be 
expected that CD4 counts were relatively normal, thus accounting for the lack of 
association between TB and HIV infection. In this scenario the findings among the 
adolescents may not be generalisable to the broader HIV population. However, if a 
substantial number of the HIV-infected adolescents had acquired their infection through 
vertical transmission289, then their CD4 counts may be sub-optimal, impairing the 
participants’ response to the TST.  A larger study which includes CD4 count testing, or 
utilizes a non-immune based test for TB infection is required in order to determine the 
risk of infection in HIV-infected individuals versus HIV-uninfected individuals.  
 
This limitation notwithstanding, adolescents are at increased risk of progression to TB 
disease in the first two years following TB infection72, and the high TB infection rates in 
this community place adolescents at substantial risk of TB disease.   
 
HIV infection was associated with female gender in this study and this is characteristic of 
the HIV epidemic among adolescents and young adults in sub-Saharan13 and South 
African290 settings. 
 
2.5.5 Strengths and Weaknesses 
These data are based on a sample of school-attending children from a single community 
and therefore they may not be generalisable to other regions. However, our findings 
have been confirmed by the subsequent reports of similar TB infection and ARTI rates in 
other South African communities263;264. This study had a very low refusal rate (<4%), and 
as such volunteerism is unlikely to have biased our results. However, it should be noted 
that the school-attending children may not be representative of all the children in the 
community, in particular with regards to risk of HIV infection291;292.  
 
In this study, only 1% of TST results were between 0 and 5mm, and therefore there is 
little evidence of the cross-reaction with environmental mycobacterium. This is in 
keeping with the findings of other studies in similar settings205;263. Given the high 
prevalence of TB in this community, the positive predictive value of the TST is likely to 













The size of reaction used to define TST positivity is the topic of much discussion in the 
literature269;293-296, with a number of methods for determining the most epidemiologically 
appropriate cut-off suggested99;216;223. Epidemiologically-based methods include the 
mirror method or mixture analysis, and the most appropriate analytic method depends 
on the environmental context of the specific survey223. Due to the low rate of 
environmental mycobacterium cross-reaction noted in our study, we used the mean 
reaction excluding all non-reactors223 method for determining the TST positivity cut-off in 
our sensitivity analyses in the primary school sample. These sensitivity analyses 
confirmed the main study findings, and this consistency of findings across these 
methodologies was also reported in another South African study263. Therefore we used 
the conventional, clinical cut-off of ≥10mm to define TB infection for the main analyses, 
and this is in keeping with other reported studies263;283.   
 
Despite the South African policy since 1960 to vaccinate all infants with the BCG 
vaccine297, only 20% of the children in this study had an observable BCG scar.  However 
BCG scarring following vaccination may be variable285;298, and the absence of the scar  
does not necessary denote lack of immunity293. We found no difference in the distribution 
of TST results between those children with or without BCG scars, and we therefore 
included all children in the analysis. The lack of correlation between the presence of a 
BCG scar and tuberculin reaction has been shown in other studies293;298;299, as has a 
waning of BCG-related reaction to TST with increasing time since 
vaccination229;232;293;298;300. However the lack of association between BCG scar status and 
TST result may imply that there is no immunological benefit of infant vaccination in the 
adolescent age group.   
 
HIV testing was not performed for the primary school children in this survey as this may 
have adversely affected parental willingness to consent to their child’s participation. 
Primary school study participants were born between 1990 and 2001, when the reported 
HIV prevalence at antenatal clinics ranged from 0.7 to 24%301. This was prior to the 
introduction of the prevention-of-mother-to-child-transmission programme. With a 
transmission rate of approximately 30%, we estimate that 0.2% of the older participants 
and up to 7% of the younger children may have been infected with HIV perinatally. 
However considering the high early mortality rate among infected children302, it is 












infected. This reasoning is supported by the 1% HIV prevalence found in 13 to 15 year 
olds in the secondary school survey. This is a low prevalence is unlikely to have had a 
large impact on the TB results. We were also able to exclude HIV-infected children from 
the TB analysis in the secondary school, thereby reducing the potential bias resulting 




These data report an already considerable prevalence of TB infection, a staggering ARTI 
and a substantial force of infection among children and adolescents in a high HIV and 
TB prevalent setting. ARTI is high among very young children, followed by a force of 
infection that is lower among children aged 5 to 10 years, and subsequently escalating in 
adolescents. This association of force of infection, which provides a measure of recent 
transmission, with increasing age is most likely due to changing social mixing patterns 
among adolescents, which may result in increased contact with infectious TB cases.  



























Transmission of Tuberculosis to Children:  
Risk factors for TB Infection and Disease 
 
 
3.1  RATIONALE 
Chapter 2 demonstrated the high rate of tuberculosis (TB) infection in children resident 
in Site M. The next step was to determine the risk factors associated with transmission 
of TB to children in the community, and to determine the role of the HIV co-epidemic in 
the risk of transmission.  
 
Adult TB disease comprises a combination of recent infections and reactivation of latent 
TB, and therefore represents both recent and historic TB exposure.  Childhood infection 
is acquired predominantly from adults (as child to child transmission is uncommon) and 
represents acquisition of TB some time from birth to chronological age303. Once infected, 
young children have a greater risk for progression to active disease compared to 
adults69;304. Therefore infection and disease in young children are the result of recent TB 
transmission, predominantly from adults to children204. 
 
This chapter will address the second objective of this thesis, namely to determine the 
risk of TB transmission to children residing in close contact with adult TB cases, and to 
determine the importance of adult HIV-associated TB in this transmission. Data from this 
chapter have been published in the second paper182 listed in the preface on page xi.  
 
3.2    BACKGROUND 
3.2.1 Burden of Paediatric TB Disease 
While the World Health Organization (WHO) estimates sputum-positive TB rates for 
children <15 years of age to be in the range of 29/100,000 in South Africa305, these data 
grossly underestimate the total paediatric TB burden. Firstly, the difficulty in obtaining 
sputum specimens from young children results in a low proportion of confirmed smear-
positive paediatric TB cases306;307. Secondly, childhood TB disease occurs most 
frequently in children <2 years, resulting in a numerator of disease for this small age 















Studies from the 1980’s and early 1990’s estimated that childhood TB accounted for 15-
22% of TB cases in developing countries117;308, and 7% of TB mortality117. More recently, 
analysis of TB notification data from two South African communities showed TB disease 
rates of over 400/100,000 in children <15 years of age205;309 and >3,500/100,000 in 
children <6 years of age310. In these communities, paediatric TB may account for as 
much as 39% of community case load310.  
 
TB disease is a significant cause of mortality in children, especially in developing 
countries. The WHO estimated that 450,000 children died from TB in 19998. More recent 
studies of mortality in developing countries have shown TB to be an important 
respiratory cause of death311, especially among HIV-infected children312. 
 
3.2.2 Risk Factors for TB Transmission to Children  
As prolonged time and proximity of contact with an infectious person increases a 
susceptible individual’s risk of acquiring TB infection60;66;67, it is not surprising that the risk 
of infection and disease for children has long been associated with household exposure 
to TB disease, in both developed and developing countries54;57;313-316. More recently, 
investigators have attempted to confirm this risk using molecular epidemiological 
studies. While insufficient statistical power, due to the low yield of sputum specimens 
and therefore genotyping data, has hampered this endeavour317;318, the findings of at 
least one such molecular epidemiological study has confirmed the risk of household 
transmission to children276.  
 
In keeping with the general principles of TB transmission, household exposure to smear-
positive disease carries the highest risk of transmission57;59;61;319;320, although smear-
negative disease in the household has also been associated with transmission to 
children62. Similarly, the risk of transmission is associated with intimacy of contact with 
the adult index case56;57;61;313;321, as well as duration of contact313;321;322. Some studies 
have reported that index cases with close familial relationships are more likely to infect 
children in the household322, in particular female index cases54;319, presumably as a 













Other risk factors for TB infection and disease in young children include poor nutritional 
status319;323-325, and living in crowded households59;310;323;325;326. 
 
3.2.3 Studies of Household Transmission to Children in Sub-Saharan Africa 
Studies performed in sub-Saharan Africa have consistently reported increased risk of 
infection and disease in children exposed to infectious TB cases in the household.  
 
Sub-Saharan Africa 
In the 1960’s, before the HIV epidemic, data analyzed from 9 African countries, including 
Swaziland and Lesotho (then called Basutoland), confirmed a higher prevalence of TB 
infection in children living in households with an infectious TB case, compared to 
children living in other households316. Two Kenyan studies also performed in the 1960’s 
reported TB infection rates of 41-60% in children <15 years of age who were household 
contacts of sputum positive TB cases54;327, and these infection rates were considerably 
higher than the background infection rates54. The children also had a substantially higher 
prevalence of disease compared to the general population54. 
 
More recently, studies performed in the past two decades, subsequent to the advent of 
the HIV epidemic, have consistently reported high prevalence of TB infection and 
disease in children who are household contacts of infectious adult TB cases. TB 
infection rates ranged from 35%-54% in children up to 15 years of age184;185;313, and TB 
infection rates in contacts ≤5 years old were substantially higher than those in the 
background community (27% vs 10% respectively)319. The rate of TB disease varied 
from 1.7-23% in household contacts ≤5 years of age319;326;328 and 6% in all household 
contacts326, considerably higher than background TB rates in these countries7.  
 
South Africa  
South African-based studies in the 1980’s showed a background infection rate of 13% in 
the general child population256;329, while children who were household contacts of 
confirmed TB cases had an infection rate as high as 30%329, and a TB disease 
prevalence of up to 11%308.  
 
In a recent study in a community with high tuberculosis rates and relatively low HIV 












adult TB had TB disease and a conservative estimate of an additional 14% had TB 
infection323. 
 
Most studies in relatively low to moderate HIV prevalence settings (adult prevalence 
<10%330-332) have reported that the HIV status of the adult source case did not impact on 
transmission to children184;185;313, but in at least one study performed in a high HIV 
prevalence setting (HIV prevalence >10%333) HIV-infected status of the adult case was 
associated with less evidence of TB transmission175. 
 
3.2.4 Current Interventions to Reduce Childhood TB   
It is clear that transmission of TB to children in the household remains a significant 
problem. Childhood TB infection not only results in childhood TB disease, with a 
substantial burden of morbidity and mortality, but also serves as a reservoir for future 
adult TB disease.  Therefore, the WHO has recommended screening of children in close 
contact with adult pulmonary TB (PTB) cases, in particular sputum smear-positive cases, 
and the initiation of chemoprophylaxis or chemotherapy in these children as 
appropriate334. Although these guidelines have been incorporated into the national TB 
control programmes of many developing countries, due to limited resources328 the 
tracing, screening and management of child contacts is often poorly 
implemented319;335;336.   
 
Given the high rates of TB infection among children in Site M and the paucity of data on 
transmission to children in high TB and HIV prevalent settings, we performed a 
retrospective study to examine the risk of TB transmission to children residing on 
residential plots with adult TB cases in Site M, and to explore the importance of HIV-
associated TB in this transmission.   
 
3.3   STUDY DESIGN 
Adult TB notification data from Site M together with Geographic Information System 
(GIS) software were used to correlate the relationships between TB exposure, infection 
and disease in children with exposure to adult HIV-infected and HIV-uninfected TB 
disease on residential plots over time.  The temporal association between adult cases 













3.3.1 Childhood TB Infection 
TB infection data were obtained from primary school tuberculin skin test (TST) surveys 
performed in the community in 2006 and 2007, and described in Chapter 2205. Childhood 
TB infection was defined as an induration ≥10mm in response to two units of purified 
protein derivative (PPD) administered intradermally.   
 
3.3.2 Childhood and Adult TB Disease  
Childhood TB disease cases in the study community from 1997 to 2007 were extracted 
from the community TB register – this is the time period from which TB notification data 
are available for the study community, until the tuberculin surveys were performed.  All 
adult TB cases notified by the community TB clinic between 1997 and 2007 were cross-
referenced with both childhood TB cases and TST results from the school surveys. 
Children diagnosed with childhood TB disease during the study period were excluded 
from the TST database for this analysis.  Adult TB cases were defined as patients ≥15 
years and children were <15 years of age. 
 
Site M consists of a formal sector with demarcated, and individually numbered, serviced 
plots and an informal sector of shacks sharing communal services. In the formal sector, 
residents use the assigned plot number as their address. However, in the informal 
sectors no official addresses are available and, due to the hazards of fire and flooding, 
shack numbers may be “recycled” for different abodes.  Therefore, to ensure reliability of 
matched data, this analysis was restricted to residents in the formal sector 
(approximately 78% of the community, based on community census data). Demographic 
and clinical data including age, gender, TB clinical details and HIV status were collected 
from the TB register and clinic records.  
 
3.3.3 Data Analysis 
Data were analyzed using STATA 10.0 (StataCorp, College Station, Texas).  
Bivariate analyses employed Student’s t-, Wilcoxon sum rank and chi2 tests, as 
appropriate. Rates of notified child disease were calculated using denominators derived 
from the population model described in Chapter 1 and Appendix A.  
 
Childhood Infection: Children with positive TST results were compared to children with 












Multiple logistic regression models were developed to determine characteristics of adult 
TB cases that were associated with positive TST results. In the analysis of the primary 
school TST data, age of the child was the only factor significantly associated with a 
positive TST205 (Chapter 2), and therefore logistic regression models assessing factors 
associated with TST positivity included age of the child. Models were also adjusted for 
clustering effect on plots.  Adult TB case characteristics were included as binary 
exposures (any exposure to a TB case with a particular characteristic) and as counts of 
exposures to a TB case with a particular characteristic, per child. Children who were 
included in the childhood disease analysis were excluded from the childhood infection 
analysis.   
 
Childhood Disease: The characteristics of adult TB cases occurring on residential plots 
on which childhood TB disease cases were diagnosed were assessed. The time 
difference between adult and child cases was calculated as year of childhood TB case 
diagnosis minus year of adult TB case diagnosis.  Analysis of childhood TB cases 
initially included all adult TB exposures on the same residential plot, followed by an 
analysis of the adult TB exposure with the closest temporal link to each childhood TB 
case.  All statistical tests are 2-sided at α=0.05.   
 
Exposure was defined as a child living on the same residential plot as an adult 
diagnosed with active TB disease. This measure of exposure did not take into 
consideration the duration of contact with the adult case.  
An exposure rate, defined as the average number of exposure to adult TB disease per 
year, was determined for childhood TB disease, infection and non-infection. This 
measure was calculated by dividing the percentage of children exposed to adult disease 
by the median age of the group of interest. 
  
ArcMap 9.2 (Esri™) Geographic Information System was used to assess the spatial 















3.4   STUDY FINDINGS 
Over the study period 1,708 TB cases were notified, of which 1,386 (81%) were resident 
in the formal sector. Of the 1,386 TB cases 1, 213 were adult cases and 170 were 
childhood cases, with 3 cases excluded from analysis due to no recorded age.  
 
TB patients in the formal sector did not differ from those in the informal sector (Table 
3.1) in terms of age (p=0.23), gender (p=0.62), site of TB disease (ie pulmonary vs 
extra-pulmonary TB [EPTB] disease; p=0.84) and HIV status (p=0.96). Patients in the 
formal and informal sectors did not differ in terms of TB mortality (p=0.78), nor in TB 
treatment completion rates (p=0.86) or treatment failure rates (p=0.13). However, TB 
cases from the formal sector were more likely to be transferred out of the community 
than those from the informal areas (p=0.01) and less likely to interrupt TB treatment 
(p=0.02).  
 
Table 3.1: Comparison of demographics and TB disease characteristics between TB 
patients residing in the formal sector and those residing in the informal sector of Site M∞ 
 
 
TB cases in 
formal sector 
(n=1,386) 






Age : Median (IQR) 31 (24-39) 30 (24-37) 0.23 
Gender    
    Male 746 (54%) 168 (52%)  
    Female 640 (46%) 154 (48%) 0.62 
TB category    
    New TB case 1,062 (77%) 241 (75%) 0.50 
    Retreatment TB case 324 (23%) 81 (25%)  
Site of TB disease    
    Pulmonary TB 1,062 (74%) 239 (74%) 0.84 
    Extra-pulmonary TB 365 (26%) 83 (26%)  
TB outcomes ∞    
    Cured/Treatment completed 1,013 (73%) 237 (74%) 0.86 
    Treatment interrupted 116 (8%) 41 (13%) 0.02 
    Treatment failure  10 (1%) 0 (0%) 0.13 
    Died 93 (7%) 23 (7%) 0.78 
Transferred out of community 147 (11%) 19 (6%) 0.01 
Tested for HIV    
     HIV status known 973 (70%) 239 (74%) 0.15 
HIV status *    
     HIV-infected 645 (66%) 158 (66%)  
     HIV-uninfected 328 (34%) 81 (34%) 0.96 
∞ Some outcomes data were missing: analysis were run on available data 














3.4.1  Childhood TB Infection and Exposure to Adult TB Case on Residential Plot  
Of the 831 children analyzed in the TST survey, 651 (78%) lived in the formal sector and 
640 (77%) of those had not had childhood TB during the period from 1997 to 2007. The 
640 children included in this analysis did not differ significantly from the total TST study 
sample in terms of age (p=0.96), gender (p=0.25), BCG status (p=1.00) or positive TST 
reaction (p=0.69).   
 
Of the 640 children, 321 were TST positive, with a median age of 12 years (interquartile 
range [IQR]: 9-14). The remaining 409 were TST negative and had a median age of 10 
years (IQR: 8-13).  
 
Of the 640 TST survey participants, 359 (56%) had been exposed to an adult TB case 
on their plot. Of these 359 children, 316 (49%) were exposed to PTB, of which 265 
(41%) were exposed to smear-positive PTB. Table 3.2 shows the characteristics of the 
adult TB case by the child participants’ TST result.   
 
 
Table 3.2: TST results and exposure to adult TB cases on the same residential plot: 
 






















Total (n=640) 359 (65) 316 (49) 265 (41) 115 (18) 
TST positive (n=231) 149 (65) 137 (59) 123 (53) 39 (17) 
TST negative (n=409) 210 (51) 178 (44) 142 (35) 76 (19) 
p-value* 0.001 0.001 <0.001 0.61 
* Comparison of proportion exposed between TST positive and TST negative children. 
 
Figures 3.1 and 3.2 show the distribution in the community of adult TB cases together 












result, compared to a negative TST result, were 71% higher in those children exposed to 
any TB case on their plot (odds ratio [OR]: 1.71; 95% confidence interval [CI]: 1.20-
2.44), 88% higher in those exposed to PTB (OR: 1.88; 95% CI: 1.32-2.68), and 110% 
higher in those exposed to sputum smear-positive PTB disease (OR: 2.10, 95% CI: 
1.46-3.01) compared to no plot-based exposure to adult TB.  Exposure to sputum 
smear-negative PTB was not associated with a positive TST result (OR: 0.95; 95% CI: 
0.59-1.54), and this finding persisted after adjusting for HIV status of notified adult TB 




Figure 3.1: Distribution of children with TST positive results and of adult TB cases from 
1997 to 2007 in the community 
In this figure, the solid dark line denotes the border of the formal sector in Site M. Grey 
borders within the formal sector denote residential plots. Grey-shaded rectangles indicate 
one or more adult TB cases occurred on that plot over the study period. Green dots of 
increasing size indicate increasing numbers of children with TB infection occurring on the 
plot during the study period. 
 
Among the 359 children exposed to an adult TB case on their plot, the number of adult 












sputum smear-positive TB case exposures ranged from 1 to 6 cases per plot (mean: 1.6 
cases). 
 
The odds of a positive TST result increased by 31% for every additional case of TB that 
a child was exposed to (OR: 1.31; 95% CI: 1.05-1.24), by 43% for every additional case 
of PTB (OR: 1.43; 95% CI: 1.11-1.84), and by 60% for every additional case of smear-
positive PTB (OR: 1.60, 95% CI: 1.21-2.11). The increasing association between 
positive TST result and exposure to smear-positive PTB cases persisted after adjusting 
for HIV status of the adult TB cases (OR: 1.62; 95% CI: 1.19-2.20).  
 
 
Figure 3.2: Distribution of children with TST negative results and of adult TB cases from 
1997 to 2007 in the community 
In this figure, the solid, dark line denotes the border of the formal sector in Site M. Grey 
borders within the formal sector denote residential plots. Grey-shaded rectangles indicate 
one or more adult TB cases occurred on that plot over the study period. Blue dots of 
increasing size indicate increasing numbers of children without TB infection on the plot 
during the study period. 
 
HIV status of adult TB cases was not significantly associated with the child’s TST result: 












0.65-1.60) and the odds of a positive TST result if the adult case was HIV-infected was 
0.88 (95% CI: 0.59-1.31). The TST result was not associated with age (p=0.73) or 
gender (p=0.28) of the adult exposure TB cases. 
 
3.4.2  Childhood TB Disease and Exposure to Adult TB Case on Residential Plot  
The annual rates of childhood TB disease in the community ranged from 443 to 
1,062/100,000 over the study period (Chapter 5), with a mean annual rate of 
728/100,000 for all TB. Childhood TB cases in Site M are described in more detail in 
Chapter 5. The median age of the 170 childhood TB cases from the formal sector was 2 
years (IQR: 1-6 years) and 58% were female. Childhood TB cases occurred on 144 plots 
in the community, with a range of 1 to 3 cases per plot (mean of 1.19 cases per plot). 
 
Of the 170 childhood TB cases in Site M from 1997 to 2007, 113 (66%) had one or more 
exposures to a notified adult TB case on their residential plot. In total, 92 (53%) were 
exposed to adult PTB cases. Childhood TB cases were exposed to significantly more 
smear-positive TB disease than smear-negative TB disease: 75 of childhood cases were 
exposed to smear-positive PTB and 17 to smear-negative PTB (44% of all child TB 
cases vs 10%; p<0.001). Figure 3.3 shows the distribution of child TB cases and adult 
TB cases in the community.  
 
Among the 113 children exposed to an adult TB case on their plot, the number of adult 
exposures ranged from 1 to 11 per plot (mean number of exposures: 2.4). The number 
of smear-positive TB case exposures ranged from 1 to 6 cases per plot (mean: 1.9). 
 
The 113 childhood TB cases that were exposed to TB cases on their residential plot did 
not differ significantly from the 57 childhood TB cases not exposed to TB on their plot in 
terms of age (p=0.23), gender (p=0.51) or HIV status (p=0.76). However, childhood TB 
cases not exposed on their residential plot are more likely to be retreatment TB cases 
than those exposed to TB on their plot (12% vs 4%; p=0.03). 
 
Timing of Adult and Childhood TB Cases on Residential Plots 
Among the 113 children with TB disease and with adult exposures on their plot, 47 
(42%) of the adult cases were diagnosed in the same year as the childhood cases.  
Overall, 25 (22%) were diagnosed before the childhood case and 41 (36%) after the 












exposure cases and the child case ranged from 9 years prior to the child’s TB diagnosis 
to 10 years after the diagnosis of the child TB case (median=1 year after child case; 
IQR: +1 year to -4 years after) (Figure 3.4).   
 
 
Figure 3.3: Distribution of childhood TB cases and of notified adult TB cases from 1997 
to 2007 in the community 
In this figure, the solid, dark line denotes the border of the formal sector in Site M. Grey 
borders within the formal sector denote residential plots. Grey-shaded rectangles indicate 
one or more adult TB cases occurred on that plot over the study period. Red dots of 
increasing size indicate increasing numbers of children with TB disease occurring on the 
plot during the study period. 
 
When analysis was restricted to the adult TB case most closely linked temporally to each 
child case, the time interval between cases varied from 3 years prior to child TB case to 
8 years after the child TB case (Figure 3.5). The adult cases which occurred in the same 
year, before the child TB case and after the child case did not differ statistically from 
each other with respect to age (p=0.91), gender (p=0.55), HIV status (p=0.87), TB 
category (ie new or retreatment TB: p=0.20) or TB treatment outcomes (p=0.40). The 


















Figure 3.5: Distribution of time difference in years between temporally closest adult TB 













Table 3.3: Temporal Associations between childhood TB cases and exposure to 




















Child TB cases 
(n=171) 113 (66) 92 (53) 75 (44) 17 (10) 
 
Adult TB case 
notified before or in 
same year as child 
case  
72 (64) 60 (83) 48 (67) 10 (14) 
 
Adult TB case 
notified after child 
case 
41 (36) 32 (78) 27 (66) 5 (12) 
p-value*  <0.001 0.47 0.93 0.80 
* Comparison of exposure proportions between adult cases notified before or in same 
year as child, to those notified after child case. 
 
 
3.4.3 Childhood TB Disease, Infection and Exposure 
The mean number of adult exposures per plot was lower in children with negative TST 
results compared to those with positive TST results (1.8 vs 2.2 respectively; p=0.03), 
and also compared to those with childhood TB disease (1.8 vs 2.4 respectively; p=0.02). 
There was no statistical difference between the mean number of adult exposures per 
plot for children with TB infection (TST positive) and those with TB disease (p=0.34). 
 
The mean number of adult smear-positive exposures per child is higher in children with 
TB disease than those with TB infection (1.9 vs 1.6; p=0.06), as well as higher than 
those without infection (1.9 vs 1.0; p<0.001). Children infected with TB had a significantly 
















3.4.4 Average Annual Exposure Rate 
The average annual exposure rate on residential plots for children with disease was 33% 
per annum, for children with infection it was 5.4% per annum and for children without 
infection, 5.1% per annum. 
 
 
3.5   DISCUSSION 
Children in this community had an extremely high exposure to adult TB disease in their 
restricted social environment as defined by their residential plot, and child TB infection 
and disease rates were strongly associated with this exposure to adult TB. 
 
The residential plots used as the unit for this analysis differs from the traditional 
household unit applied in other studies. Consistent with other peri-urban communities in 
South Africa, the residential plots in Site M are an average of 180m2 in size and are 
often crowded, with from 1 to 22 dwellings built on a plot (mean of 4 houses per plot). 
Plots are frequently shared by extended families, and represent a broadened but 
intimate social environment with communal living, including shared child care 
responsibilities.  
  
3.5.1 Risk Factors for TB Disease and Infection  
Childhood TB infection and disease were associated with adult TB cases on their 
residential plot.  The association was strongest with adult smear-positive PTB, rather 
than smear-negative PTB or extra-pulmonary forms of TB disease. A few studies have 
suggested that in endemic areas TB transmission to children frequently occurs outside 
the household317;337. However, in keeping with the bulk of published 
literature57;310;313;319;323, our studies would suggest that, especially in younger children, the 
main transmission risk remains in the residential social environment.  
 
Of note was the finding that the HIV status of the adult TB case was not an independent 
risk factor for infection or disease in children. The finding that smear-positivity and not 
HIV status of an adult TB index case is the main risk factor for TB infection in children 
exposed at home supports the suggestion in Chapter 2 that the HIV-associated TB 
epidemic alone is unlikely to be the primary driver of the force of infection in this 












increasing the burden of adult smear-positive TB cases in their immediate social 
network39.  
 
Some studies have reported an association between female index cases and increased 
risk of transmission54;319.  However, we found no association between the gender of the 
adult case and the risk of infection or disease for children, and this is in keeping with 
other study findings in published literature276;320;322.  
 
3.5.2 Annual Exposure Rates to TB Disease  
Whilst TST surveys assess the rates and force of TB infection in children, this analysis 
allowed an assessment of annual rate of exposure to adult TB cases on children’s 
residential plots. The average annual exposure to adult TB cases on residential plots 
was high for all participants living on serviced plots in this community, with >5% of 
infected and uninfected children being exposed to an adult TB case per year. The 
annual exposure rate was more than six-fold higher for children with TB disease. This 
substantial average annual exposure of children to TB on their residential plot was the 
product of the large burden of adult TB disease in this community together with 
overcrowding on plots and has resulted in high rates of both child TB infection and 
disease in Site M.  
 
This analysis was restricted to exposure to TB on the child’s residential plot, and while 
we have shown a strong association between exposure on plot and childhood TB 
infection and disease, we have not accounted for all transmission to children. There are 
several potential explanations for TB transmission to children in whom no adult TB case 
was identified on the residential plot. These could include an unrecognized primary 
source that subsequently moved off the plot, died prior to diagnosis, or remained 
subclinical, including so-called “chronic excretors”. In addition, modeling has shown that, 
while the greatest risk of transmission to children was from infectious adults on 
residential plots, up to 25% of transmission to children may be due to interaction with 
non-resident adults338.   
 
3.5.3 TB Control Programme and Childhood Exposure to TB Disease  
The high rates of child TB infection and disease are an indication of failure to control 












The majority of childhood TB disease (64%) was diagnosed in the same year or soon 
after an index adult TB case was notified to the TB control programme. However, over a 
third of child TB cases in this study were notified prior to the temporally closest notified 
adult case on their plot.  It was noted that adult cases were diagnosed as much as 8 
years after the childhood case of TB. The more temporally distant cases most likely 
represent secondary or even tertiary cases due to ongoing adult-to-adult transmission.  
 
Recent studies have illustrated that patient-initiated delayed presentation of TB cases to 
the health care services as well as provider-initiated delays in the diagnosis and the 
initiation of TB treatment are a considerable problem in resource limited settings339-342. 
These delays contribute to the infectious period of a case and therefore to TB 
transmission. 
 
This study was only able to assess the role of diagnosed adult TB on transmission to 
children. However, TB case finding has been low in this community: a random, 
community-based survey in Site M found that 0.1% of the adult population had 
undiagnosed smear-positive TB, and an equal proportion had undiagnosed culture-
positive TB, with an overall TB case detection rate of 37% in the community179. 
Undiagnosed and undetected TB would also contribute to TB transmission to children, 
and therefore the impact of adult TB cases on a residential plot was most likely 
underestimated in this study.   
 
Since 1996, the national TB control programme has mandated screening (including 
tuberculin skin testing)310, and provision of chemotherapy or chemoprophylaxis as 
appropriate, in all children <5 years who are close contacts of an infectious adult TB 
case195. The high rate of TB infection among children with household contacts suggests 
that this policy is not well implemented, and the failure to effectively implement this 
active child-contact tracing policy has been reporting in another South African study336. 
While children in this study are older than 5 years of age and as such may not have 
been included by the TB control programme, 25% of 6 year olds are already infected 
with TB. An evaluation of the contact tracing and screening component of the TB control 
programme is required in order to inform interventions for improved screening and 













3.5.4 The Role of Active Case-Finding 
Given the substantial annual exposure rate and risk of re-infection among children in this 
setting, in addition to improved contact tracing, a reduction in the annual exposure rate is 
also required. In order to achieve this reduction in exposure, enhanced and active case-
finding (ACF) may be needed to supplement the directly observed therapy, short-course 
(DOTS)-based programme. The yield of ACF varies in different settings. The yield of 
house-to-house active case-finding surveys in developing country settings has ranged 
from 0.1% to 0.2%179;343;344. However ACF in household contacts of diagnosed TB cases, 
both adult and paediatric cases, have shown substantial yield in diagnosing previously 
undetected cases in both high and low incidence settings54;184;345-347, especially among 
symptomatic household contacts328;348. A recent meta-analysis of ACF among household 
contacts of TB cases showed high yields in low-income countries: 7% active TB disease 
identified, and 40% latent TB infection. The yield of active TB disease was highest in 
children <5 years of age: 8.5% active TB disease cases identified349. This analysis, 
which included studies from 13 sub-Saharan African countries, strongly supports the 
value of targeted active case-finding among TB contacts.  
 
Targeted ACF is, therefore, likely to have a higher yield than random cross-sectional 
surveys and may decrease the prevalence of infectious cases, resulting in a lower rate 
of transmission to children. This study would suggest that in communities such as Site 
M, targeted ACF should include a patient’s residential plot, rather than only household. 
In addition to the TB case detection yield, efficacy of such a targeted intervention over 
time could be assessed through repeated TST surveys in children, to ascertain the 
impact on childhood infection rates. 
 
3.5.5 Strengths and Weaknesses 
In Site M, residential plots contain a mean of 4 households which share communal water 
and sanitation services, and constitute a geographically defined unit for social interaction 
between adults and children outside of the immediate household. This study was 
restricted to the formally serviced sector of the community in which 78% of the 
community was resident. We were unable to include adults and children living in the 
informal sectors as shack identifiers in this sector were not constant over the study 
period. However, TB patients in the formal and informal sectors did not differ significantly 












the formal sector were more likely to leave the community and less likely to default from 
TB treatment. These factors may mitigate the risk to children residing on the same plot 
as the adult TB cases, in which case our study would have underestimated the impact of 
exposure to adult TB cases on transmission to children.  
 
For the purposes of this analysis we assumed that the children had all lived in the 
community since 1997 or from birth. Some children may have immigrated into the 
community subsequent to these dates; however this would also have decreased the 
strength of association between adult-child TB exposures and resulted in an 
underestimation, rather than overestimation, of contact rate between adult and children 
with TB infection and disease.  
 
Children with TB disease were excluded from the analysis of TB infection. This 
conservative approach may have also resulted in an underestimation of the TB 
transmission. 
 
Molecular epidemiological studies to confirm the links between adult index cases and 
childhood cases would greatly strengthen these findings. Unfortunately, due in part to 
the minimal use of sputum testing in the investigation of childhood TB and in part to the 
low proportion of smear-positive cases in children306, few RFLP data are available for 
paediatric cases. Such studies would be of value in furthering our understanding of 
these dynamics.  
 
3.5.6 Conclusion 
TB transmission within households and close geographic social networks is an important 
component of both childhood infection and disease in this community. Transmission to 
children was strongly associated with sputum smear-positive PTB cases, and was not 
independently associated with the HIV status of the adult index case. Childhood TB 
disease is a sentinel of infectious adult prevalence and therefore childhood infection and 
disease rates need to be monitored in these high prevalence settings in order to 
ascertain the true burden of infection and disease. Active contact tracing and screening 
of children exposed to adult disease needs to be improved in these settings. 
Furthermore, targeted ACF, aimed at close social networks of both child and adult TB 































Chapter 3 reported on the risk factors associated with transmission of tuberculosis (TB) 
to children in the study community. While childhood TB disease is predominantly due to 
recent infection, adult disease may be due either to reactivation of previously acquired 
latent infection or rapid progression from recent TB infection. This chapter will explore 
TB transmission and the risk factors associated with transmission between adults in Site 
M.  
 
While reactivation of latent infection is responsible for most of B disease in the 
developed world350-355, in sub-Saharan Africa studies have reported that recent infection 
is responsible for a greater proportion of TB disease356-360.  Reactivation of latent 
infection is a manifestation of historical transmission, while recent infection is due to 
current, ongoing transmission.  In settings in which progression from recent infection, 
rather than reactivation of latent infection, is responsible for the majority of TB disease, 
an effective intervention to decrease transmission may have the greatest impact on TB 
control129.  
 
An improved understanding of current TB transmission in high TB and HIV settings, as 
well as the impact of the HIV epidemic on this transmission, is required. Furthermore, 
understanding the impact on TB transmission of an intervention targeted at HIV, such as 
a highly active antiretroviral therapy (HAART) programme, could inform the development 
of effective adjunctive TB control strategies in high TB and HIV prevalent communities. 
 
This chapter will address the third objective of this thesis, namely to describe the 
molecular epidemiology of TB in the study community, and to utilize molecular 
epidemiology to investigate the extent of clustering, as a measure of recent 
transmission, of Mycobacterium tuberculosis (Mtb) disease, to assess the impact of the 












demographics and household location, associated with transmission. Data from this 
chapter have been published in the third paper361 listed in the preface on page xi. 
 
4.2   BACKGROUND 
4.2.1 Introduction to Molecular Epidemiology 
Molecular epidemiology has been defined as “using the analysis of nucleic acids and 
proteins in the study of health and disease determinants in human populations”362. More 
simply stated molecular epidemiology is a multi-disciplinary approach that merges 
molecular methodologies and tools, including the ability to genotype organisms such as 
Mtb, with conventional epidemiological, statistical and clinical techniques. The result is a 
greatly increased ability to investigate and understand infectious disease epidemics, 
including those of TB and HIV. 
 
The applications of molecular epidemiology in the research of infectious diseases are 
many and various363. Molecular epidemiology has been used to identify circulating Mtb 
strains in communities357;364-367 and has enabled identification of clinical characteristics 
associated with specific strains350;361;368-372. Examples include the association of certain 
strains with drug resistance373;374, and the differing host immune responses to different 
strains, with potential implications for path genicity and/or virulence and clinical 
outcomes86;370;375-379. One study has even reported differing impacts of Mtb strains on 
HIV-replication in infected cells380.  
 
Molecular epidemiology has also enabled the study of the spread of Mtb strains within 
and between communities102;350;351;353;359;381-383. Despite intensive contact investigation, 
conventional methodologies often identify few epidemiological links between TB 
cases351;358;372;381;382;384;385. Molecular epidemiology has greatly expanded our ability to 
identify Mtb outbreaks and clusters350-352;354-360;381;386, including nosocomial 
transmission374;387-389, and to distinguish between endogenous re-activation and recent 
exogenous infection in TB disease127;351-353;355;356;360;390. This information has provided 
important insights into the performance of TB control programmes391;392, as well as 
aiding spatio-temporal investigations of transmission dynamics351;361;384, and the 














The W-Beijing strain is one of the most extensively studied Mtb strains, and is an 
excellent example of insights gained by molecular epidemiology. The W-Beijing strain 
appears to have originated in Asia, but has subsequently spread around the world400;401, 
and is an extremely common, emerging strain in South Africa317;361;366;367;402;403. The 
ubiquitous nature of W-Beijing suggests that the strain has a selection advantage, but 
the possible mechanisms for this are not well understood. It has been proposed that 
certain sub-lineages of W-Beijing may have increased transmissibility404, as supported 
by high bacillary loads272;375;376 and TB outbreaks367;401 associated with this strain, or that 
infection with this strain may progress more rapidly to disease402;404;405. The marked 
virulence of W-Beijing Mtb strains, shown in mice and rabbit models of infection86;375;406, 
support this hypothesis.  
 
4.2.2 Genotyping Technology 
While the genome of Mtb complex is highly conserved407, the pathogen does have 
polymorphic genomic regions363;396, and it is these regions that are the focus of 
genotyping methods. There are a number of different genotyping techniques, each with 
their own strengths and weaknesses. 
 
Restriction Fragment Length Polymorphism (RFLP) analysis was considered to be the 
gold standard genotyping technique for Mtb molecular epidemiology for many 
years363;373;382;408;409. While it is a complex and laborious method, requiring viable 
mycobacterial cultures, the procedure for RFLP analysis has been standardized410, 
allowing for comparison across laboratories411. In addition, RFLP is reproducible411 and 
remains one of the most discriminatory of all the genotyping techniques available for 
Mtb363.  
 
Insertion sequences (IS) are small mobile genetic units, which occur commonly in 
bacteria412. IS6110 is unique to Mtb complex413, and is, for the most part, distributed 
randomly throughout the genome414. The variability of the number and chromosomal 
positions of IS6110 enables the differentiation between Mtb strains408. 
 
The methodology for RFLP has been well described410;415. Following Mtb culture and 
DNA extraction, restriction endonuclease enzyme PvuII (which cleaves IS6110 at a 












These fragments are separated on an agarose gel by electrophoresis, transferred to a 
DNA membrane (Southern-blot) and labeled with a DNA probe mixed in a hybridization 
buffer.  The resulting Southern Blot hybridization of the restricted fragments and IS6110 
probe is highlighted by a chemiluminescence reaction.  Computer-assisted analysis of 
images is performed, with the position and number of DNA bands used to identify the 
strain416. The nomenclature for classifying IS6110 RFLP patterns has been well 
documented and described401. 
 
Other techniques include single-nucleotide polymorphisms (SNP), which is particularly 
useful in the study of microevolution of strains363;396, but does require extensive 
sequencing of multiple chromosomal targets363. Spacer oligonucleotide typing (or 
spoligotyping) is based on analysis of 43 interspersed spacer sequences in the direct 
repeat (DR) region of the Mtb genome417.This polymerase chain reaction (PCR)-based 
analysis is the simplest technique for strain genotyping but is less discriminatory than 
RFLP analysis363;401;418.  Mycobacterial Interspersed Repetitive Unit-Variable Number 
Tandem Repeat (MIRU-VNTR) typing is based on the analysis of 12 or 15 loci 
comprising major polymorphic tandem repeats409;419. When more than 12 loci are used, 
this method is as discriminatory as RFLP analysis, and indeed more so in mycobacterial 
strains with few IS6110 bands420;421. However, this technique may not be appropriate for 
the study of endemic strains, due to the slow rate of mutations in the combined loci422. 
 
Given the number of molecular techniques available, it is critical to choose the 
appropriate tool for the research question of interest. The key considerations are usually 
the stability of the biomarker used, and the diversity of the strains in the community363. 
The stability of the biomarkers is sometimes referred to as the “molecular clock” of the 
biomarkers: the biomarker must be stable enough to reliably link epidemiologically 
related cases, but change at a rate sufficient to distinguish non-related or distantly 
related strains363;423.  
 
For this thesis, IS6110 Restriction Fragment Length Polymorphism was used to 
genotype Mtb.  The biomarker IS6110 has been shown to have both a high degree of 
stability (with a transposition half-life of 2-4 years)423-425 and sufficient 
variability358;356;359;365 to ensure an excellent tool for identifying transmission at a 












comparison between different laboratories’ findings408;420. It has been widely used in Mtb 
molecular epidemiology, and as such there is much published RFLP data, allowing for 
comparison across different settings.  
 
One limitation of the RFLP technique for transmission analysis is that it has lower 
discriminatory power in strains with 6 bands or less. In this situation a second typing 
technique, utilizing different biomarkers, such as SNP or spoligotyping, may be of value 
in identifying genetically distinct strains422;426;427. Conversely, strains with identical 
patterns of more than 6 bands are most likely to be clonal363.  
 
4.2.3 Molecular Epidemiology and Understanding TB Transmission 
Based on the principle that organisms with similar or identical genetic fingerprints are 
epidemiologically related, clustering of identical Mtb strains is often interpreted as 
evidence of recent transmission, while unmatched or unique strains are considered to 
represent reactivation of previously acquired infection128;350;372;416;428.  As mentioned 
above, studies have reported that recent infection is responsible for as much as 42-61% 
of TB disease in sub-Saharan Africa356-360.   
 
Population-based molecular epidemiological studies have provided insights into risk 
factors associated with TB transmission, including urban residence353, prior 
imprisonment357 and locations including bars382;351;357 and churches357 have been 
identified in different settings. However, there are also conflicting findings as to whether 
gender353;357;359;429;430 or age351;353;356;357;359;430  are associated with clusters.  
 
While many of the studies in the developed world have reported an association between 
HIV infection and clustering350;351;353;431;432, countries with generalized epidemics have 
conflicting findings on whether HIV infection is associated with clustering of Mtb 
strains356-358;391;430;433-435. Few studies from African countries with high TB incidence have 
reported on the association between HIV infection and transmission, and most of these 
studies have reported that HIV-infection is not associated with transmission357;358;391;430. 
One study found an association between TB disease due to recent infection and HIV-
infection among older HIV-infected patients356.  No studies have reported on the impact 













4.3   STUDY DESIGN 
 
4.3.1 Study Participants 
Sputum specimens of acid-fast bacilli (AFB) smear-positive TB or smear-negative and 
Mtb culture-positive TB were collected from 2001 through 2008 from patients resident in 
the community, for genotypic analysis. Demographic and clinical data including age, 
gender, details of clinical diagnosis, disease management and clinical outcome, HIV 
status and location of residence of each patient were extracted from the clinic TB 
register and patient clinic folders.  
 
4.3.2  Sputum Specimens 
Sputum specimens were obtained from TB suspects in accordance with the National TB 
Control Programme diagnostic protocol195, and were labeled as study specimens at the 
clinical site, for identification by laboratory personnel.  All sputum specimens were 
assessed for the presence of Mtb bacilli by fluorescent (auramine) microscopy. AFB 
positive samples were cultured on Lowenstein-Jensen (LJ) slants, as were smear-
negative specimens for which culture was clinically indicated (for example, retreatment 
patients). From 2001 to end 2005 isoniazid and rifampicin susceptibility testing was 
performed on retreatment patients or patients still AFB positive after two months 
treatment, in accordance with the National TB Control Programme195. From 2006 to end 
2008, isoniazid and rifampicin susceptibility testing was performed on all Mtb specimens, 
and second line sensitivities were performed on all multi-drug resistant (MDR)-TB 
(resistant to at least isoniazid and rifampicin) specimens. Mtb culture-positive isolates 
were inoculated in duplicate into 7H9 liquid medium supplemented with oleic acid, 
albumin, dextrose and catalase (OADC) and 15% Glycerol at the research laboratory at 
the Institute of Infectious Diseases and Molecular Medicine at the University of Cape 
Town, and stored at -70ºC.  
 
4.3.3 Molecular Analysis of M. tuberculosis Strains  
Frozen duplicate culture stock was shipped to the Public Health Research Institute 
(PHRI) Tuberculosis Center at the University of Medicine and Dentistry of New Jersey. 
Culture stocks were sub-cultured on LJ slants and DNA extracted from each isolate. 
IS6110-based RFLP analysis was performed on each isolate as described elsewhere436. 












Mtb isolates with DNA fingerprints with an identical hybridization banding pattern were 
considered to be the same strain and assigned a strain code following the previously 
described nomenclature system381. In addition, Mtb strains were assigned to one of nine 
(I – VIII and II.A) discrete synonymous single nucleotide polymorphism (sSNP)-based 
phylogenetic lineages, as determined by RFLP patterns and previous analysis of PHRI 
Mtb clinical isolates437. Strain patterns that were only represented once in the PHRI 
database (ie no matching strain found in the database of over 10,000 strains collected 
from eight USA sites, three South African sites and over 11 other countries381) and did 




A unique strain is an isolate with an RFLP pattern that occurs only once within the study 
dataset, ie a singleton strain. Strain family is a group of strains that exhibit similar, but 
not identical, IS6110 hybridization profiles, suggesting common recent ancestry (e.g. W-
Beijing family, CC family, BM family) as described elsewhere363;437. Strain clusters were 
defined as more than one occurrence of a specific strain in the study period. The first 
case diagnosed with a specific clustered strain was defined as the index case in each 
cluster (temporally-based definition), and subsequent patients in the clusters were 
referred to as secondary cases. A couplet was a cluster comprising of two patients with 
the same Mtb strain. In addition, we also identified temporally-related couplets: these 
were two patients with the same Mtb strain that occurred within 12 months of each other 
and did not have another case with the same strain within 6 months on either side of the 
pair. 
 
Patients with unique strains (ie non-clustered strains) and index patients were 
considered likely to have TB disease due to reactivation of latent infection. Secondary 
cases in clusters were interpreted as having TB disease due to recent infection. 
 
The pre-HAART era was defined as the years 2001 to end 2004, and the post-HAART 
era as years 2005 to end 2008. We a priori chose 2005 as the cut-off year of HAART 
availability, as this was the first year that an appreciable proportion of patients were 














4.3.5 Data Analysis 
Data were analyzed using STATA 10.0 (StataCorp, College Station, Texas). Bivariate 
analyses employed Student’s t-, Wilcoxon rank sum tests and chi2 tests, as appropriate. 
The adjusted number of strains per year (corrected for the differing sampling rates) was 
calculated as the product of the number of strains per patient (based on available data) 
and number of sputum-positive patients each year.  Family diversity was calculated as 
the number of families divided by the number of isolates, and strain diversity was 
calculated as the number of strains divided by the number of isolates.  
 
The proportion of patients and strains occurring in clusters was determined as the total 
percentage of patients and strains in clusters (“n” method), and the proportion of patients 
arising from recent transmission was calculated using the (“n-1”) method351. The 
probability that a unique strain is in fact a couplet was determined by the following 
equation:  
, where A is the number of isolates in the community that were 
analyzed, and B is the number of isolates in the community that were not analyzed. 
 
Changes in unique strains and clustering over time were assessed using Cox-Stuart test 
for trend267;268. Multivariate logistic regression models were developed to examine factors 
associated with specific Mtb strains, as well as with clustering of strains and with the 
index cases of clusters.  
 
Patients were divided into age groups as follows, children (<15 years of age), 15-24 
years, 25-34 years, 35 to 49 years and ≥50years of age. The proportion of reactivation 
and recent infection disease was compared across these age groups. The age 
difference between cases occurring in couplets was calculated as the age of index case 
(in years) - age of the secondary case (in years).  The random probability that two cases 
with the same strain would occur on the same plot was determined by the Poisson 
distribution. 
 
ArcMap 9.2 (Esri™) Geographic Information System (GIS) was used to illustrate the 













4.4   STUDY FINDINGS 
4.4.1 Study Population  
From 2001 to 2008, there were 1,681 TB cases (excluding 30 patients transferred into 
the community already on treatment), of which 1,240 were pulmonary TB (PTB). Of 
these PTB cases, 862 were smear-positive cases and 1,048 were smear-positive and/or 
culture-positive. 
 
Sputum specimens were collected from 633 (64%) of the smear-positive cases, and 716 
(68%) of the smear- and/or culture-positive cases. Of these specimens, 521 (73% of 
collected specimens) had RFLP patterns available. Reasons for missed specimens and 
unavailable RFLP data are shown in Figure 4.1. The sampling rate from each year is 
tabulated in Table 4.1. 
 
 













Table 4.1: Number of smear and culture positive PTB patients, number of specimens 
retrieved, and number of patients for whom genotyping data is available, per year 
 





2001 72 20 (28%) 18 (25%) 
2002 83 44 (53%) 32 (39%) 
2003 98 63 (64%) 41 (42%) 
2004 115 63 (55%) 34 (30%) 
2005 191 97 (51%) 34 (18%) 
2006 162 128 (79%) 109 (67%) 
2007 164 150 (92%) 116 (71%) 
2008 163 151 (93%) 137 (84%) 
TOTAL 1,048 716 (68%) 521 (50%) 
 
 
Patients for whom we obtained RFLP patterns did not differ from those for whom we did 
not obtained RFLP patterns, with regard to age (p=0.22), gender (p=0.92) and HIV 
status (p=0.73). There was no difference in new and retreatment cases between the two 
groups (p=0.27). We were less likely to obtain RFLP data for TB patients who died 
(p=0.004), and more likely to obtain RFLP data for patients who failed treatment 
(p=0.03). There were no differences in the other TB outcomes between patients for 
whom RFLP data was obtained and those for whom RFLP data was not available. We 
were more likely to obtain RFLP data on patients receiving HAART (Table 4.2).  
 
The 521 patients with RFLP results ranged in age from 1 to 68 years (median age: 32 
years, interquartile range [IQR]: 26-39) and 12 (2%) of the patients were children. 
Overall 299 (57%) of the patients with genotyping data were male. In total, 456 (88%) 
patients tested for HIV, and 61% of those 456 patients tested were HIV-infected. Of the 
521 patients, 20 (4%) had confirmed MDR-TB and no cases of extensively-drug resistant 
TB were identified. TB treatment was completed by 82% of the 521 patients and there 
were 18 (4%) deaths among these patients.  
 
While RFLP data are available for 521 patients, in total 530 RFLP patterns are available, 













Table 4.2: Comparison of patients for whom sputum specimens were and were not 
















Age : Median (IQR) 33 (27-42) 32 (26-40) 0.09 32 (26-39) 0.22 
Gender      
   Male 183 (55%) 420 (59%)  299 (57%)  
   Female 149 (45%) 296 (41%) 0.28 222 (43%) 0.92 
TB category ∞      
 New TB case 228 (69%) 516 (72%) 0.26 378 (72%) 0.27 
 Retreatment after 
 previous cure 48 (14%) 83 (12%) 0.19 60 (11%) 0.34 
 Retreatment after 
 previous completion 43 (13%) 73 (10%) 0.19 50 (10%) 0.13 
 Retreatment after  
 treatment interruption 10 (3%) 40 (6%) 0.07 29 (6%) 0.23 
 Retreatment after  
 treatment failure 3 (1%) 4 (1%) 0.52 4 (1%) 0.69 
MDR TB      
Confirmed MDR TB 3 (1%) 24 (3%) 0.02 20 (4%) 0.01 
TB outcomes ∞      
 Cured/Treatment   
 completed 249 (75%) 523 (74%) 0.75 379 (74%) 0.84 
 Treatment interrupted 24 (7%) 78 (11%) 0.05 59 (12%) 0.07 
 Treatment failure  2 (1%) 9 (1%) 0.32 9 (2%) 0.03 
 Transferred out of  
  community 27 (8%) 65 (9%) 0.57 45 (9%) 0.94 
 Died 29 (9%) 29 (4%) 0.002 18 (3%) 0.004 
Tested for HIV      
    HIV status known 288 (87%) 629 (88%) 0.62 456 (88%) 0.98 
HIV status       
   HIV-infected 181 (63%) 377 (60%)  280 (61%)  
   HIV-uninfected 107 (37%) 252 (40%) 0.40 176 (39%) 0.73 
Receiving HAART 21 (26%) 61 (74%) <0.001 46 (75%) <0.001 
* Specimens missed compared to specimens received 
**Specimens with RFLP result compared to all specimens (ie sum of missed specimens and 
received specimens without genotyping data) 
∞ Comparison of specified category or outcome compared to all other categories/ known 
outcomes. 













4.4.2 Strain Diversity 
From 2001 to 2008, 243 genotypes were identified including 7 orphan strains.  
 
SNP clusters 
Figure 4.2 shows the phylogenetic tree for 529 isolates present from 2001 to 2008 (one 
strain was not assigned to an SNP cluster). Overall, strains from all nine SNP clusters 
were identified in the community. SNP clusters II and VI were the largest clusters with 
152 and 231 isolates in each cluster, respectively.  
 
On average there were 26 strains per year from 2001 to 2005, and an average of 75 
strains per year from 2006 to 2008. Following adjustment for different sampling rates in 
each year, there were on average 96 strains per year, with no significant trend found in 
the number of strains by year (p=0.17).  
 
 












Families and Strains 
The 530 isolates were divided into 52 strain families and 243 strains. Overall strain 
family diversity was 10% and strain diversity was 46%. The dominant strain families are 
W-Beijing (28%), CC-related (25%), AH (8%) and BM (5%). These four families 
comprise 66% of the strains in the community.  The strain diversity within the W-Beijing 
family is 24% (36 strains among 150 isolates), and 49% in the CC-related family (64 
strains among 130 isolates).  
 
In a multivariate logistic regression model adjusting for age, gender and sputum smear-
positive status, the W-Beijing family was associated with HIV-infected patients in the pre-
HAART era (odds ratio [OR]: 6.2; 95% Confidence interval [CI]: 1.8 – 21.3; p=0.004). 
This association was no longer statistically significant in the post-HAART era (OR: 1.6; 
95% CI: 0.9 – 2.7; p=0.06). Overall, the W-Beijing strain was not associated with sputum 
smear-positive PTB (p=0.21) and, among HIV-infected patients, W-Beijing was not 
associated with receiving HAART (p=0.88). In a multivariate logistic regression model 
adjusting for age, gender and sputum smear-positive status, the CC-related, AH and BM 
families were not associated with HIV status in either the pre-ART (p=0.49, p=0.58 and 
p=0.14 respectively) or post-ART era (p=0.86, p=0.19 and p=0.10 respectively).   
 
The W-Beijing family was associated with MDR-TB (p=0.01), and this association 
persisted after adjusting for HIV status (p=0.02). Of the 20 patients with MDR-TB, 7 
(35%) had the same W-Beijing strain.  
 
In the 46 patients on HAART at the time of TB diagnosis, 15 families were represented 
(33% family diversity) and 37 strains (80% strain diversity). The strain with the greatest 
representation was W451, with four (9%) patients on HAART infected with this strain.  
 
4.4.3 Unique versus Clustered Cases 
Of the 243 strains, 179 (74%) were unclustered, ie unique, and 64 (26%) occurred in 
clusters of two or more patients. Given the incomplete sampling rate, the mathematical 
probability that a unique strain was in fact a couplet (ie, that we missed a second 













Of the 521 patients, 174 (33%) had strains that were unique. Of the 347 patients who 
had strains that occurred in clusters (two patients with dual infections had strains in both 
unique and clustered groups), 63 (12%) were index cases for the clusters (one patient 
with a dual infection was the index case for two clusters), and the remaining 284 (55%) 
were secondary cases in clusters (Figure 4.3). The proportions of unique cases and 
clustered patients did not change significantly over the study period (p=0.50 and p=0.81 
respectively) (Figure 4.4), nor did clustering proportions change between the pre- and 
post- HAART implementation periods (p=0.62). In addition, the proportion of clustered 
patients among HIV-infected and HIV-uninfected patients did not change over the study 
period (p=0.29 and p=0.91 respectively). 
 
 
Figure 4.3: Distribution of unique and clustered TB cases, and index and secondary TB 
cases overall and by HIV status 
* Percentages of HIV-uninfected and HIV-infected are based on individuals of known HIV 
status (456 of 521) 















Figure 4.4: Proportion of strains that were unique and clustered, by year from 2001 to 
2008  
The proportion of unique strains did not change over the study period (p for trend=0.50) 
and the proportion of clustered strains did not change over the study period (p=0.81). 
 
 
In multivariate logistic analysis, patients with unique strains did not differ from those with 
clustered strains in terms of age (OR: 0.99; 95% CI: 0.97-1.01; p=0.47), gender (OR: 
0.9; 95% CI: 0.6-1.4; p=0.85), TB category (OR: 1.2; 95% CI: 0.8-1.8; p=0.47) or HIV 
status (OR: 1.0; 95% CI: 0.7-1.5; p=0.99). Among HIV-infected patients, those patients 
with unique strains did not differ from patients with clustered strains in terms of HAART 
status, and this finding persisted after adjusting for age, gender and TB category (OR: 
1.3; 95% CI: 0.6-2.6; p=0.47). 
 
4.4.4 Unique and Index Cases versus Secondary Cases 
Overall, 53% of HIV-uninfected patients were unique or index cases compared to 47% 
which were secondary cases (p=0.11).  Among HIV-infected patients, significantly more 
disease was due to secondary cases (58% vs 42% unique and index cases; p<0.001), 
and this was also true for HIV-infected patients on HAART (67% vs 33% respectively; 
p<0.001). HIV-infected patients were 1.6 times more likely to be secondary cases, rather 
than unique or index cases (OR: 1.6; 95% CI: 1.1- 2.3; p=0.02). When comparing HIV-
infected patients on and off HAART, there was no difference in distribution of unique and 













In multivariate logistic analysis, index cases did not differ from secondary cases in 
clusters in terms of age (OR: 0.99; 95% CI: 0.96-1.02; p=0.36), gender (OR: 0.8; 95% 
CI: 0.4-1.6; p=0.56) or TB category (OR: 0.87; 95% CI: 0.4-1.6; p=0.48). Index cases 
were less likely to be HIV-infected compared to secondary cases (adjusted OR: 0.3; 
95% CI: 0.2-0.6; p=0.001). Among HIV-infected patients, index cases did not differ from 
secondary cases in terms of HAART status (OR: 0.2; 95% CI: 0.02-1.4; p=0.09). 
 
HIV-uninfected index cases were more likely to be sputum smear-positive compared to 
HIV-infected index cases (97% smear-positive versus 81%; p=0.01). This was also true 
for all PTB cases in the community over the study period, regardless of whether RFLP 
data was obtained (79% of HIV-uninfected PTB cases were smear-positive versus 64% 
of HIV-infected cases; p<0.001). The association between index cases and HIV-
uninfected patients persisted in multivariate analysis adjusting for age, gender, TB 




Cluster sizes ranged from 2 to 53 patients, with a mean cluster size of 5.5 patients.  
While clustering was not associated with HIV status, the average cluster size in HIV-
infected patients was significantly larger than the average cluster size for HIV-uninfected 
patients (10 vs 5 respectively, p=0.002). 
 
Figure 4.5 shows the distribution of clustered strains over time, by HIV status.  Overall, 
78% of clusters were comprised of both HIV-infected and HIV-uninfected patients. 
Smaller, temporally associated clusters were noted among HIV-infected patients within 
the larger clusters of the W451 (in 2003, 2007 and 2008) and W330 (in 2008).  
 
Couplets 
In total, there were 26 clusters comprising of two identical strains (ie couplets). The age 
difference between adult patients in couplets ranged from the index case being 15 years 
older to 27 years younger than the secondary case.  Overall 44% of the index cases 
were 10 years older or younger than the secondary case. In temporally defined clusters, 












secondary case, with 57% of index cases being 10 years older or younger than the 
secondary case. 
 
Age and clustering 
As reported above, age was not linearly associated with unique cases, index cases or 
secondary cases. Figure 4.6 illustrates the distribution of unique, index and secondary 
cases by age groups, overall (Figure 4.6a), and by HIV status (Figures 4.6b and 4.6c). 
Overall there was no statistical difference in the distribution of unique and index cases 
versus secondary cases across the age groups (p=0.75), and this persisted when 
adjusted for HIV status (p=0.70). However, there was a trend for older patients to have a 
greater proportion of unique and index cases among HIV-uninfected patients (56% due 
to reactivation) and to have a greater proportion of secondary cases among HIV-infected 
patients (60% disease due to recent infection). 
 
There was no statistical difference in the distribution of index cases versus secondary 
cases between the age groups by HIV status (p=0.97), and this persisted when adjusted 
for HAART status (p=0.42). 
 
Retreatment TB and clustering 
Of the 521 patients, 143 (27%) were retreatment cases, of which 98 (68%) were 
clustered (p=0.57). Retreatment cases were not associated with HIV status (64% HIV-
infected; p=0.52). For 12 patients we obtained RFLP specimens from both the first and 
second TB episodes. Five of these patients interrupted TB treatment in the first episode 
and had the same Mtb strain in their second TB episode. Three of the patients 
completed treatment in the first episode, but had no bacteriological confirmation of TB 
cure. These three patients all had the same Mtb strain in their second episode.  The 
remaining four patients all had bacteriologically confirmed cures in their first TB episode, 
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Figure 4.6: Figure A: Distribution of patients with unique strains, and patients who are 
index cases and secondary cases in clusters; Figure B: Distribution of HIV-infected 
patients with unique strains, and HIV-infected patients who are index cases and 
secondary cases in clusters; and Figure C: Distribution of HIV-uninfected patients with 
















Geographical distribution of clusters 
On average 10% of adults in all clusters shared a residential plot with another adult 
infected with the same strain. Among couplets, both adults occurred on the same plot for 
3 of the clusters (12%).  Similarly, among temporally defined couplets, 3 of the 28 
couplets occurred on the same plot (11%). Random distribution of couplets across all 
plots in the community would have resulted in 1.9% of couplets occurring on the same 
plot, significantly fewer than noted in the study (p<0.001). Figure 4.7 shows couplets 




Figure 4.7: Couplet strains in the community  
Thick red borders denote both patients with same strain on the same plot. 
 
 
4.5   DISCUSSION 
This study described the molecular epidemiology of the TB epidemic in a high TB and 
HIV prevalent community, and assessed the impact of the HIV epidemic and a HAART 
programme on TB transmission in this setting. The study community is geographically 
well-defined, has substantial TB and HIV burden and has a high degree of Mtb strain 
diversity. These factors have enabled us to assess clustering and transmission in the 













4.5.1 Strain Diversity 
The study has demonstrated a broad diversity of Mtb strains, consistent with findings in 
other studies in sub-Saharan Africa357;438.  This may be compatible with the community’s 
relatively recent establishment (circa 1992) with immigration from a number of different 
areas of Southern Africa. The high degree of genotypic diversity within the large CC-
related family may indicate that it is an endemic Mtb family in this population. The W-
Beijing family also shows a high degree of diversity, although to a lesser degree than the 
CC family, suggesting W-Beijing strains may be emerging and diversifying in the 
community. However, chromosomal location of IS6110 insertions may impact on the 
movement of the IS elements and therefore, genetic diversity as determined by IS6110 
RFLP may be independent of strain endemicity.  
 
There was a relatively constant number of strains in the community in each year 
(approximately 96), and the proportion of both unique and clustered strains also 
remained constant, suggesting a steady state of Mtb strain movement in and out of the 
community.  
 
4.5.2 TB Disease due to Recent Infection versus Reactivation  
In interpreting molecular epidemiological data, single strains and the index cases of 
clusters are often considered to result from reactivation of previously acquired infection, 
and secondary patients in clusters represent disease due to recent infection. While there 
are a number of limitations to this interpretation, the approach is widely used128;350;372;416. 
Under these assumptions, at least 55% of TB disease in this community resulted from 
recent transmission of Mtb. Up to 45% of the TB disease was due to reactivation of 
previous latent infection, of which at least 12% resulted in transmission.  
 
However, the proportion of reactivation is most likely over-represented in this analysis, 
resulting in an underestimation of the proportion of recent infection. Of note is that 50% 
of children <15 years of age had unique strains or were index cases for a cluster. As TB 
disease in young children is predominantly the result of rapid progression of infection 
acquired from recent adult transmission204, these data suggest that the source case for 
these children was missed in this study. Social interaction data from this community 












community [S. Robertson; unpublished data], and this may partially explain unidentified 
source cases.  
 
Due to incomplete sampling rates, as much as 37% of single strains may in fact belong 
to clusters. Moreover, unique strains may be strains that do not transmit effectively, or 
are less pathogenic and, as such, result in latent infection rather than rapid progression 
to disease. If the latter is true, we may expect to see such strains re-appear in the 
community at a later date. This may explain clustered strains that have a wide time 
difference between strain appearances.  
 
Censoring due to the data collection period may have resulted in some strains being 
mistakenly classified as unique, that is, patients with the same strains may have been 
missed prior to 2001 and post 2008. In addition, specimens were only collected from 
sputum-positive TB patients. Transmission of Mtb does not always lead to sputum-
positive TB, but may be responsible for sputum-negativ  PTB or extra-pulmonary TB. 
We were unable to assess transmission resulting in these forms of TB.  
 
Therefore, recent transmission is most likely responsible for a greater proportion of the 
TB disease than estimated in this study.  This argument is further supported by the 
evidence high rates of recent infection among key groups in this study population, 
including patients with MDR-TB and retreatment patients who had previously completed 
TB treatment and had bacteriological confirmation of cure.  The high rates of disease 
due to recent infection are also in keeping with the substantial force of infection reported 
in Chapter 2.  
 
4.5.3 TB Transmission and HIV 
HIV-infected patients had a greater proportion of disease due to recent infection 
compared to HIV-uninfected patients. The majority of clusters contained both HIV-
infected and HIV-uninfected patients, suggesting that the HIV-associated and HIV-
unassociated epidemics are not independent of one another. However, within clusters, 
index patients were more likely to be HIV-uninfected and secondary cases were more 
likely to be HIV-infected. This indicates that HIV-uninfected patients may be responsible 













The association of HIV-uninfected patients with index cases persisted after adjustment 
for sputum smear status, and this suggests that HIV-infected patients are less infectious. 
This finding is consistent with studies that report lower infectivity of HIV-infected patients, 
irrespective of smear or culture status124;176;177. 
 
An alternative explanation for the greater representation of HIV-uninfected patients 
among index cases could be that HIV-infected patients have slower progression to TB 
disease, and therefore present to health services later than HIV-uninfected patients. 
Contrary to this hypothesis, available data report that, following TB infection, HIV-
infected patients progress more rapidly to TB disease compared to HIV-uninfected 
counterparts14;102;111, although there is inconsistency in the published literature as to 
whether HIV infection is associated with rapid or delayed presentation and diagnosis of 
TB339. The more rapid progression of HIV-infected patients to TB disease may also 
account for the lower rate of transmission from these patients.  
 
Our study showed that TB disease among HIV-infected patients was more likely to be 
due to recent infection, and that this was also true in patients receiving HAART. This 
suggests that ongoing transmission is still an important cause of disease among patients 
receiving HAART. However, the sample size for patients on HAART was small, and 
therefore further observation of this group is required.  
 
4.5.4 TB Transmission and Demographics 
No statistical association was found between patient age and clustering, or age and 
evidence of recent transmission. These findings suggest that transmission between 
adults is not age assortative in this community, and this is supported by the wide age 
range between index cases and subsequent secondary cases in couplets. However 
there was a trend for TB disease among older HIV-uninfected patients to be the result of 
reactivation of latent infection, and this is in keeping with findings elsewhere351;353;356.  
 
Despite the increased risk of infection reported among adolescent males in the 
secondary school tuberculin skin test survey (Chapter 2), there was no association 














4.5.5 TB Transmission and Geographical Location 
The spatial analysis, utilizing GIS, enabled us to determine that clusters did not occur in 
the same residential plots within the community. This was also true for temporally 
defined couplets.  This finding suggests that adult transmission does not occur 
predominantly on residential plots, but that most adult to adult transmission is occurring 
outside of the households. This is consistent with the published literature337;392;394, as well 
as with social interaction data, which report that the majority of both close and casual 
contacts  among adults occur off the residential plot [S Robertson; unpublished data].  
 
Other studies have reported hospitalization to be a risk factor for TB transmission374;387. 
Given that HIV primary care, HAART treatment and TB treatment are all managed at the 
same clinic in this community, assessing the possibility of nosocomial spread at the 
clinic was important. The high degree of both family and strain diversity in patients on 
HAART, as well as the lack of association of clustering in HAART patients suggests that 
nosocomial transmission of TB is not a substantial problem in the local HAART clinic. 
However, temporally-related clusters among HIV-infected patients were also identified 
within larger clusters, such as the W451 and W330 strain clusters.  These sub-clusters 
may reflect nosocomial transmission at the general HIV community clinic. Similar 
smaller, temporal clusters were noted in the AH family, but due to poor differentiation of 
strains with few bands, such as AH, conclusions can not be drawn from this observation. 
Further analyses are required in order to determine possible high risk locations for 
transmission in this setting. 
 
4.5.6 W-Beijing Family 
An association was noted between W-Beijing and HIV-infection in the first period of the 
study. However, later in the study period this association weakened.  
 
The association between HIV and W-Beijing may suggest that the W-Beijing strains 
differ functionally from the other strains so as to make them more transmissible to HIV-
infected patients compared to HIV-uninfected patients, or it may suggest an increased 
susceptibility of HIV-infected patients to the strain. Alternatively, studies have reported 
that W-Beijing elicits a decreased86;375;376 and non-protective immune response376;379 in 












presence of HIV-infection380, and W-Beijing strains may therefore progress more rapidly 
to clinical TB disease in the presence of HIV co-infection.  
 
The combination of a pathogenic strain together with an already compromised immune 
response may explain the strong association noted between W-Beijing and HIV in the 
early part of the study. Further, the weakening of this association following the wide-
scale implementation of the HAART programme may be due to the improvement of 
immune function among the HIV-infected population as a result of HAART. However, no 
negative association was found between W-Beijing and HAART. This may be due to 
small numbers and the short follow-up period of the post-HAART era, and further 
observation in this community may help to clarify this relationship.  
 
An alternative explanation for this initial association of W-Beijing and HIV infection may 
lie in the differing incubation periods (infection to disease) among HIV-infected and –
uninfected patients. This study has shown evidence to suggest that W-Beijing is an 
emerging strain in this community. The faster progression to TB disease among HIV-
infected patients14;102;111 may result in a strain appearing to be associated with HIV in the 
shorter term. It is possible that the W-Beijing epidemic established itself more quickly 
among HIV-infected patients, with the HIV-infected population serving to amplify this 
emerging strain. The subsequent weakening of the association between HIV and W-
Beijing may be due to “catch-up” of W-Beijing-associated disease in the HIV-uninfected 
population.  
 
Ongoing observation, with larger numbers of patients, is required for further study of this 
possible association between HIV and W-Beijing. 
 
Despite low MDR rates in this community (3% of PTB cases), we were able to show an 
association between W-Beijing and MDR-TB, and this is in keeping with the published 
literature401;439-442. Given the possible association between W-Beijing and HIV infection, 
this finding has serious implications for the spread of MDR-TB in these patients.   
 
4.5.7  Strength and Weaknesses  
This study linked genotyping data with clinical information, including HIV and HAART 













There are a few potential sources of selection bias in this study. Sputum samples and 
RFLP data was not collected on all the TB patients in this community over the study 
period. Although the incomplete sampling was, for the most part, random in nature, there 
were some clinical differences between those PTB patients for whom we did and did not 
obtain genotyping data. Patients for whom we did not obtained genotyping data had a 
higher mortality rate, and patients for whom genotyping data were available were more 
likely to have MDR TB or to be receiving HAART compared to those patients with 
missed specimens. The increased mortality in those patients without RFLP data may 
reflect a lower sputum retrieval rate from the local hospital, where sicker patients were 
initially diagnosed.  The increased yield in genotyping data on MDR patients was likely 
due to the increased number of sputum-positive specimens obtained from these patients 
during clinical management. Due to the incomplete sample collection from the study 
population the number of circulating strains, number of clusters and size of clusters will 
have been underestimated428;443. However, using mathematical modeling we were able 
to provide a corrected estimate of the number of circulating strains, as well as the 
proportion of unique strains that were most likely part of clustered couplets. Furthermore, 
the possibility that HIV-infected patients may have an increased risk of TB-related 
mortality prior to TB diagnosis, may result in a length-bias between HIV-infected and 
uninfected individuals. 
 
We inferred recent transmission of TB from clustered strains. Despite the traditional 
interpretation of identical strains as epidemiologically linked, it is important to recognize 
that clustering is not automatically synonymous with recent transmission.  In areas of 
high incidence, the proportion of clustered cases is influenced by factors such as the 
background strains, annual risk of infection, the age of the population (with clustering 
tending to be underestimated in younger patients and overestimated in older patients)444, 
geographical distribution351;385, as well as study duration444;445, sampling strategies and 
percentages428;443 and the genotyping method utilized.  The interpretation of clustering as 
evidence of transmission is enhanced in our study by the long study duration of eight 
years402;444, the substantial force of TB infection and the high diversity of strains in the 
community.  In addition, IS6110 fingerprinting is one of the most discriminatory typing 













While the temporally-based definition of index cases (as the first case that was 
diagnosed with TB disease in a cluster) is a relatively simply approach, it is recognized 
that the identification of true index or source cases is extremely difficult351;363;372;384 and 
no standardized method is available. Nonetheless, it is important to note that our 
approach does not take into account secondary transmission, and mathematical 
modeling may provide further insights into the transmission dynamics in this community 
 
4.5.8 Conclusion 
This study showed that recent transmission is responsible for the majority of TB disease 
in a high HIV and TB prevalent setting. This finding was particularly marked among HIV-
infected patients, possibly due to this group’s increased risk of rapid progression to 
disease following infection. Of importance is the finding that the HIV-associated and HIV-
unassociated TB epidemics were not independent of one another, and that HIV-
uninfected patients may be responsible for most of the transmission in this community. 
Age and gender did not appear to be associated with transmission, and the household 
was not the key location for adult to adult transmission. This study provided reassurance 
that the HAART clinic was not a location for TB transmission to vulnerable patients in 
this community. 
 
These findings have important implications for TB control, highlighting the necessity of 
identifying the factors and locations associated with transmission and the need to 
interrupt transmission patterns in these settings.  Our attention and interventions need to 
expand beyond HIV-infected patients, and include reducing transmission from HIV-























Chapter 5    Chapter 5 
 
Impact of an Antiretroviral Treatment    
Programme on TB Disease Incidence and 
Outcomes  
 
5.1   RATIONALE 
Incidence is the number of new cases of active tuberculosis (TB) disease occurring in a 
specified period of time3, and serves as the primary measure of the success or failure of 
TB control progammes446. 
 
A key target of the Millennium  Development Goals (MDG) is the reduction of the current 
global incidence of active TB of >1,300 cases/million population/year to an incidence of 
<1 case/million population/year by 20507;11. However, the current World Health 
Organization (WHO)-recommended Directly Observed Therapy, Short-course (DOTS)-
based TB control strategy is failing to contain the TB epid mic in high HIV prevalence 
countries, and adjunctive strategies are required in order to meet the MDG TB goals7. 
Understanding the impact of alternative interventions on TB incidence in different 
settings is necessary for the development of evidence-based adjunctive TB control 
strategies.  However, incident TB encompasses recognised (notified) and unrecognised 
TB disease, as well as TB patients who die before diagnosis. Therefore, incidence is 
difficult to measure directly, and even the long term follow-up of large cohorts may not 
fully identify all incident cases. As a result, TB incidence is often estimated from other 
data, such as prevalence or mortality data7. Alternatively, TB notification rates can be 
used as a surrogate measure of TB incidence.  
 
This chapter will address the fourth objective of the thesis, namely to describe the 
changes in TB disease incidence (as determined by TB notification rates) and outcomes 
in both the overall community population and in the HIV-infected and HIV-uninfected 
subsets of the population. These changes will be assessed over time and following the 
scale-up of highly active antiretroviral therapy (HAART) access in the community. Data 

















5.2   BACKGROUND 
5.2.1 Historical Perspective on TB epidemics 
In industrialised countries, TB incidence and mortality rates had begun to decline by the 
late 1800’s, and this decline persisted throughout most of the 20th century49;448-453. The 
decrease in TB rates have been well recorded in the United Kingdom448-450, Western and 
Eastern Europe49;450;452 and the United States of America7;453.  Figure 5.1A shows the 
decline in TB notification rates in Western European countries since 1980452, and Figure 




Figure 5.1: Figure A: TB notification rates from 12 Western European countries from 
1980 to 2000 (Figure A obtained from Dye, 2000452). Figure B: TB cases in the United 
States of America in the second half of the 20th century. (Figure B obtained from 
“Epidemiological Basis of Tuberculosis Control”49) 
 
As shown in Figure 5.2, these declines in TB rates occurred prior to the availability of 
such intervention strategies as chemotherapy and vaccination. This has led some 
scientists to argue that the reduction in TB rates was primarily due to improved living and 
working conditions as well as improved nutrition448;449;454. This theory is supported by the 
temporary increase in TB rates noted in England, Europe and America during the two 
World Wars450;453;455;456. Other theories as to the cause of the decline include decreased 
infection due to segregation of TB patients457, and natural selection458.  More recently, a 
modelling paper has shown that a major factor in the decline in TB rates was a decrease 















      
Figure 5.2: Pulmonary tuberculosis mortality rates in England and Wales (Figure 
obtained from Selgelid, Public Health Ethics451;460) 
 
5.2.2 Impact of HIV Epidemic  
Whatever the reasons for the decline in the TB infection rates and the subsequent 
decline in TB rates, in 1950 it was believed that TB would soon be eradicated. However, 
the rapid spread of HIV has had a profound and deleterious impact on TB control. While 
the impact of the HIV epidemic has been moderate in high income countries, the effect 
has still been evident. Since the escalation of the HIV epidemic, a deceleration of TB 
decline occurred in Western Europe in the late 1990’s7 and a small increase in TB cases 
was noted in America in the 1980’s and 1990’s49. TB rates in America have 
subsequently decreased once again, and the downward trends have been sustained into 
the 21st century.  
 
The impact of the HIV epidemic has been far more dramatic in low and middle income 
countries, especially where HIV prevalence is high. HIV has resulted in a substantial and 
sustained escalation of TB epidemics in a number of the global regions, including 
Eastern Europe and Africa (Figure 5.3)9;452. TB rates started increasing in Africa in the 
1980’s452 followed by increases in Eastern Europe in the 1990’s452 and this escalation of 
TB rates continues to-date in both regions9. It is estimated that 9% of all new TB cases 
are directly attributable to HIV globally, and as many as 31% of TB cases in Africa9.  
 
It should be noted that improved reporting of notified TB cases7 may also have 












changes such as rapid urbanization with immigration to the cities and resulting crowded 
living conditions37.  
 
Figure 5.3: TB notification rates in three WHO regions from 1980 to 20077 
 
The impact of HIV on TB epidemics is due to the substantially increased risk of TB 
disease in HIV-infected patients compared to HIV-uninfected individuals14-16;55;69;70. HIV-
infected patients have an increased risk of both reactivation of latent TB infection14;112 
and rapid progression to disease following recent infection14;112102;111. 
 
As previously mentioned, the current WHO-recommended TB control strategy is failing 
to contain the TB epidemic in high HIV prevalence countries7. In South Africa the overall 
incidence rates of all forms of TB were estimated to have increased from 360/100,000 in 
1997, to 925 in 2005 and 948 in 20077.  
 
The STOP TB Partnership has proposed adjunctive strategies to address this problem in 
low and middle-income countries with generalised HIV epidemics461, including the 
intensified case-finding, isoniazid preventative therapy, infection control462 and 
antiretroviral therapy (ART). Of these strategies, only provision of HAART has been 
extensively implemented, with substantial progress in patients’ access to HAART over 












5.2.3 Impact of HAART on Population TB Notification Rates  
While it is well documented that the incidence of active TB disease in HIV-infected 
patients is reduced by 54-92% by HAART36;45;169, the impact of HAART on TB rates at a 
population level remains uncertain. HIV-infected patients on HAART have a substantial 
reduction in TB risk45;46, but they still have a 5-10 times higher risk of TB disease 3 years 
into HAART treatment compared to HIV-uninfected individuals35;165.  The combination of 
prolonged survival and residual increased risk of TB incidence in HIV-infected patients 
on HAART will result in an increased number of highly susceptible individuals in the 
population. Therefore even substantial population coverage with HAART may have a 
limited impact on TB incidence at a population-level. However, empirical data addressing 
this issue are sparse and most evidence comes from mathematical modelling190. 
 
Despite the well-described TB benefits of HAART use for HIV-infected individuals, there 
are no population level studies describing the impact of increased access to HAART on 
community TB rates in areas with generalised HIV epidemics. Therefore we assessed 
the impact of increasing antiretroviral provision on TB notification rates in a community 
with high HIV prevalence. 
 
5.3  STUDY DESIGN 
5.3.1 Study Population  
As described in Chapter 1, Site M is served by a single primary care clinic that follows 
the national TB control programme guidelines463, based on WHO-recommended DOTS 
programme. The clinic manages all TB patients resident in the community and the 
protocol for diagnosis and management of TB patients did not change significantly from 
1997 to 2008.  The main change to the national TB protocol has been the addition, since 
2004, of active TB screening for patients initiating HAART. This screening was based on 
an initial symptom screen, followed by sputum investigation, and did not include testing 
for latent TB infection. Isoniazid preventative therapy has not been implemented in this 
community. Despite an apparently well-functioning TB programme, with treatment 
completion rates of approximately 80%464, we have previously reported escalating TB 
notification rates in this community prior to rapid, high coverage HAART availability39. 
HAART provision began in 2003 with patients in the community accessing antiretroviral 
treatment at the local clinic or local hospital, but the HAART programme was only 












5.3.2 Data Analysis 
TB and HAART data 
TB notification data were obtained from the study community TB clinic from 1997 to 
2008.  HIV status, HAART status and CD4 count data were obtained from TB register, 
clinical folders as well as clinic and hospital HAART databases. Children were defined 
as patients ≤14 years of age, and adults were defined as patients ≥15 years of age. All 
TB analyses were restricted to TB patients resident in the study community. 
 
Population Model 
Denominators for rate calculations were derived from the community population and HIV 
model, described in Appendix A. The population model, used to calculate overall and 
age-specific TB rates, was derived from the 1996 South African national census, and 
community household censuses performed in 2002, 2004, 2006 and 2008. The 
community HIV prevalence model, used to calculate TB rates among HIV-infected and -
uninfected population, was estimated using the Actuarial Society of South Africa (ASSA) 
2003 AIDS and Demographic model for the African population198;465. This model was 
adjusted based on the 2005179 and 2008197 community-based, random cross-sectional 
HIV prevalence surveys among adults ≥15 years of age in the study community. This 
model is described in more detail in Appendix A.   
 
Numbers of patients on HAART in each year, used as denominators for TB notification 
rates on HAART, were derived from the antiretroviral programme registers at the 
community clinic and local hospital. HAART coverage was calculated as the proportion 
of the adult HIV-infected population in the community receiving HAART in each year.  
 
HIV and TB rates calculations 
All TB rates were reported as cases/100,000. Age-specific TB rates were calculated in 5-
year intervals for patients ≤19 years of age, and in 10-year intervals from 20 to >50 
years of age.  Direct standardisation method was used to calculate the age-standardised 
annual TB rates for the population using the 1997 population as the reference 
population466. 
 
HIV testing was routinely offered to TB patients from 2002, and therefore HIV-associated 












patients and the analyses in HIV-infected and HIV-uninfected strata were restricted to 
patients with known HIV status. To account for missing HIV test results, a sensitivity 
analysis was performed in which extreme case scenarios for HIV-associated and non 
HIV-associated TB rates were calculated assuming 100% of patients with unknown HIV 
status were HIV-infected and HIV-uninfected, respectively.  
 
We a priori chose 2005 as the first year of HAART availability, as this was the first year 
that an appreciable proportion of patients were receiving HAART (>5% of HIV-infected 
patients). Mean changes in TB rates and significance of trends prior to large-scale 
HAART implementation (pre-2005) and following large scale HAART implementation 
(post-2004) were assessed using linear regression models. An autoregressive model 
with a one year lag was used to account for the autocorrelation of the data, and the 
impact of HAART was examined through an interaction term.  The median baseline CD4 
counts of patients initiating HAART in each year were calculated from the most recent 
CD4 count in the 3 month period prior to HAART initiation. 
 
Direct standardisation method466, using HIV-infected population as the reference 
population, was used to calculate age-standardised rate ratios (RR) of TB in HIV-
infected adults versus HIV uninfected adults, as well as HIV-infected adults off HAART 
versus adult patients on HAART.   
 
Notification rates were assessed over time for different categories of TB disease: 
namely, pulmonary TB (PTB), sputum smear-positive PTB, extra-pulmonary TB (EPTB) 
and retreatment TB. Patients with concurrent PTB and EPTB diagnoses were counted 
twice: once in each category. Retreatment TB was defined as a new TB diagnosis in a 
patient who had previously completed TB treatment.  
 
TB outcomes (including treatment completion, treatment interruptions and all cause 
mortality) were reported as a proportion of TB patients initiated on TB treatment in each 
year, excluding those who were transferred out of the community during the treatment 
course.  TB completion was defined as TB treatment completion or cure.  
 
Trend analysis for proportion of smear-positive PTB and TB outcome rates over time 













Data were analysed using Stata Version 10.0 (StataCorp, College Station, Texas). All 
statistical tests were 2-sided at alpha=0.05.  
 
5.4 STUDY FINDINGS 
5.4.1 TB cohort 
Over the 12 year study period, 1,973 TB cases were notified in the study community.  
Of these, 232 of these cases were children, with a median age of 2 years (interquartile 
range [IQR]: 1 – 5 years) and 56% were female. In total, 1,736 were adult cases, the 
median age of which was 32 years (IQR: 26 – 40 years), and 45% were female. Age 
data were not available for five patients, and they were therefore excluded from age-
based analyses.  
 
Overall TB notification rates in this community increased from 630/100,000 in 1997 to a 
peak of 2,132/100,000 in 2005 and decreased to 1,816/100,000 in 2008 (Table 5.1). TB 
notifications rates increased by an annual average of 134/100,000 cases from 1997 to 
end 2004 (95% confidence interval [CI]: 111 to 157; p<0.001), followed by a reduction of 
92 cases per year from 2005 to 2008 (-295 to 111; p=0.37). 
 
Overall, HIV testing was performed in 78% of adult cases, of which 67% were HIV-
infected. From 2002, 89% of adult TB cases tested for HIV, of which 68% were HIV-
infected. In 2003, 1% of the total HIV-infected population were receiving HAART. By the 
end of 2005 this proportion had increased to 13%, and by the end of the study period, 
22% of the total estimated HIV-infected population were receiving HAART (Figure 5.4). 
Overall 21% of the estimated adult HIV-infected population was receiving HAART by the 














Figure 5.4: Overall HIV prevalence and HAART coverage in Site M 
 
5.4.2 TB  Notification by Age 
Table 5.1 shows TB notifications and rates overall, and in children and adults from 1997 
to 2008.   
 
Figure 5.5 shows TB notifications by age strata over the study period. TB notification 
rates remained relatively stable in children over the study period. These trends are 
discussed in more detail under “Childhood TB Notification". In most adult age categories, 
TB notification rates steadily increased from 1997-1998 to 2003-2004, and appeared to 
stabilise from 2005 to 2008, while rates decreased in the 20-29 year olds, in the same 
period. The annual age-standardised rates confirmed these trends, with an increase in 
annual rate from 1998 to 2005, followed by a decreasing trend to 2008 (Table 5.1). 
 
5.4.3 Childhood TB Notification 
Total childhood TB notification rates have remained relatively stable from 1997 to 2008 
(p=0.38; Table 5.1).  Overall childhood TB rates did not show a significant trend either 
prior to 2005 (average annual decrease of 32 cases/100,000; 95% CI: -70 to 6; p=0.10) 















Figure 5.5: TB rates by age stratification and year in the study community, from 1997 to 
2008  
The population numbers in each age category were used as the denominators for the 
age-specific rates calculations. 
 
In summary, overall there were no significant trends in notification rates in the 5-year 
age groups, with the exception of initially increasing TB notification rates in young 
adolescents (10-14 years). This was followed by a subsequent stabilising of TB rates in 
this age group (Figure 5.6). 
 
TB notification rates (per 100,000) in the ≤4 year old age group ranged from 
1,164/100,000 in 1997 to 1,579 in 2008, with the lowest rate recorded in 2003 
(565/100,000) and a peak of 2,095 in 2007. There were no significant trends in 
notification rates in this age group: from 1997 to 2004 there was an average annual 
decrease of 84 cases/100,000 (95% CI: -177 to 6; p=0.07) and from 2005 to 2008 there 
was an average annual increase of 152 cases (95% CI: -428 to 732; p=0.61).  Similarly, 
the 5 to 9 year old age group showed no significant trends in notification rates, with an 
average decrease of 13 cases/100,000 per year (95% CI: -37 to 10; p=0.26) followed by 












Table 5.1: Total, childhood and adult TB notification numbers and notification rates in the study community, from 1997 to 2008  
 
Number of TB cases   Population   TB Rates/100,000  
Year 
Total TB Childhood TB* Adult TB*  
 
Total  Children  Adult  
 





1997 40 10 29 
 
6,353 1,658 4,695 
 
630 603 618 
Reference  
population 
1998 66 20 46  7,188 1,883 5,305  918 1,062 867 882 
1999 71 10 61  8,023 2,107 5,916  885 475 1,031 1,060 
2000 85 13 71  8,858 2,331 6,527  960 558 1,088 1,117 
2001 138 26 111  9,693 2,555 7,138  1,424 1,018 1,555 1,582 
2002 144 13 130  10,502 2,780 7,722  1,371 468 1,684 1,762 
2003 173 13 160  11,651 2,937 8,714  1,485 443 1,836 1,876 
2004 198 22 176  12,801 3,095 9,706  1,555 711 1,813 1,914 
2005 277 25 252  12,990 3,055 9,935  2,132 818 2,536 2,784 
2006 255 24 231  13,180 3,015 10,165  1,935 796 2,273 2,386 
2007 261 30 231  13,886 2,824 11,062  1,880 1,062 2,088 2,171 
2008 265 26 238  14,592 2,634 11,958  1,816 987 1,990 2,183 














TB notification rates in young adolescents (10-14 years) initially increased from 1997 to 
end 2004, with an average annual increase of 49 cases/100,000 (95% CI: 5 to 92; 
p=0.03). From 2005 to 2008, adolescent TB notification rates declined non- significantly 
by an average of 28 cases/100,000 per year (95% CI: -116 to 59; p=0.53). 
 
Sputum smear-positive TB rates in all children ranged from 53/100,000 in 1998 to 
152/100,000 in 2008. While there was no statistically significant trend noted in childhood 
smear-positive TB rates from 1997 to end 2004 (p=0.78) or from 2005 to end 2008 
(p=0.71), across the entire study period there was an increasing trend in smear-positive 
rates among children (p=0.05). 
 
 
Figure 5.6: Childhood TB notifications rates in the study community, by 5 year age-
strata, from 1997 to 2008 
 
Analysis by HIV and HAART status is not possible in these age groups, as uptake of 
HIV-testing is very low, with HIV status unknown for 53% of all childhood TB patients, 
and 66% of TB patients in the 10-14 year age group. Furthermore, only 3 of the 
childhood TB patients were receiving HAART at time of TB diagnosis, all of them under 
9 years of age.   
 
HAART coverage was higher in children, compared to adults. By 2008, an estimated 
35% of HIV-infected children in Site M were receiving HAART, significantly more than 












estimated that over 50% of the HIV-infected young adolescents (10-14 years of age) 
were receiving HAART. 
 
5.4.4 Adult TB Notification 
As shown in Figure 5.7, from 1997 to end 2004 adult TB notification rates (per 100,000) 
increased by an average of 95 cases a year (95% CI: 31 to 159; p=0.004). From 2005, 
the rate of adult cases decreased by an average of 182 cases per year (95% CI: -295 to 
-70; p=0.02).   
 
   
Figure 5.7: Adult TB notifications rates and antiretroviral coverage in study community, 
from 1997 to 2008  
  This figure shows the rapid scale-up of HAART coverage and the increasing TB 
notification rates from1997 to 2004 (p=0.004), followed by a decrease in TB notification 
rates from 2005 to 2008 (p=0.02). 
 
5.4.4.1 HIV-Infected and HIV-Uninfected TB Notification  
Table 5.2 shows TB notification data for HIV-uninfected patients, as well as HIV-infected 
patients not on HAART and those patients on HAART at time of TB diagnosis from 2002 
to 2008. Adult TB rates in HIV-infected and HIV-uninfected TB patients are shown in 
Figure 5.8A, including extreme case scenarios for HIV-associated and non HIV-
associated TB rates assuming 100% of patients with unknown HIV status were HIV-













In summary, TB rates among HIV-uninfected patients remained relatively stable, 
showing only a modest decline after 2004. In contrast, TB rates in HIV-infected patients 
increased significantly from 2002 to 2004, followed by a significant decline.  
 
TB rates (per 100,000) in patients known to be HIV-uninfected did not change 
substantially from 2002 to 2004 (with an average annual increase of 58 cases/100,000; 
p=0.59), but declined by 82 cases per year from 2005 (95% CI: -139 to -25; p=0.01).  
From 2002 to the end of 2004, overall TB rates in known HIV-infected adults increased 
by an average of 432 cases per year (95% CI: 109 to 755; p=0.01), after which rates 
decreased significantly by 578 cases per year (95% CI:      -697 to -459; p<0.001).   
 
5.4.4.2 TB Notification and HAART  
The number of HIV-infected patients initiating HAART in each year is shown in Table 
5.2. Figure 5.8B shows TB rates (per 100,000) in HIV-infected patients stratified by 
HAART status.  In summary, TB rates among HIV-infected patients not on HAART 
increased from 2002 to 2004, followed by a significant decline from 2005, while TB rates 
in patients on HAART showed a dramatic decline from 2004. 
 
TB rates in HIV-infected patients not on HAART increased by an average of 367 cases 
per year from 2002 to end 2004 (95% CI: -392 to 1126; p=0.34). From 2005, there was a 
significant average annual decrease of 409 TB cases in HIV-infected patients not on 
HAART (95% CI: -518 to -300; p<0.001). TB rates in HIV-infected patients on HAART 
decreased significantly from 2004 by an average of 1,155 cases per year (95% CI: -1246 
to -1064; p<0.001). 
 
Table 5.3 shows the age-standardised rate ratios of TB in adult HIV-infected patients off 
HAART compared to those on HAART. After standardizing for age differences across 
annual populations, HIV-infected patients not on HAART had a lower rate of TB 
compared to HIV-infected patients on HAART early in the HAART programme (RR=0.41 
in 2004). However, as the period of the HAART programme increased, the RR of TB in 
patients off HAART increased to nearly twice that of the patients receiving HAART 














Table 5.2: TB notification rates among adult HIV-uninfected and HIV-infected patients in the study community, from 1997 to 2008 
 




























2002 38 70 0 1,737 0 635 4,030 0 
2003 50 85 0 1,993 0 744 4,265 0 
2004 52 100 8 2,233 104 696 4,697 7,692 
2005 81 130 20 2,303 290 1,061 6,458 6,897 
2006 56 120 28 2,591 491 739 5,714 5,703 
2007 59 126 25 2,877 547 721 5,408 4,570 
2008 68 129 21 3,164 680 773 5,193 3,088 
 
   
  Table 5.3: Age Standardised Rate Ratios (RR) for TB disease in HIV-infected patients on and off HAART in the study community, from 











   *HIV-infected population used as reference population for age standardised rates 
HIV-infected off HAART  HIV-infected on HAART 
Year 
Crude Rate Age Standardised Rate* 
 Crude Rate Age Standardised Rate* 




2004 4,697 4,750  7,692 11,616 0.61 0.41 
2005 6,458 6,772  6,897 6,712 0.94 1.01 
2006 5,762 6,014  5,499 5,883 1.05 1.02 
2007 5,408 5,760  4,570 4,497 1.18 1.28 













Table 5.4: Adult TB site of infection and retreatment rates (per 100,000), overall and by HIV-status, in the study community from 1997 to 2008  
 
Pulmonary TB  Extra-pulmonary TB  Retreatment TB 
























1997 554    64    256   
1998 735    151    151   
1999 862    220   304   
2000 965    123    276   
2001 1,247    308    350   
2002 1,178 2,533 551  531 1,554 100  376 979 167 
2003 1,469 3,211 655  390 1,154 89  505 1,204 238 
2004 1,381 3,403 629  474 1,523 94  556 1,478 227 
2005 2,164 5,384 943  523 1,650 144  664 1,867 249 
2006 1,849 4,554 673  502 1,428 106  580 1,775 119 
2007 1,718 4,101 660  452 1,390 86  497 1,425 98 
2008 1,581 3,603 648  443 1,233 136  585 1,233 273 
Note: 1) Patients of unknown HIV status are excluded in the HIV-stratified analyses 












Table 5.5: Adult TB treatment outcomes, overall and by HIV-status, in the study community from 1997 to 2008  
 
TB Treatment Completion  TB Treatment Interruption  TB Mortality 





















1997 17 (63%)    5 (19%)    2 (7%)   
1998 32 (80%)    7 (18%)    1 (3%)   
1999 53 (98%)    0 (0%)    1 (2%)   
2000 46 (77%)    4 (7%)    7(12%)   
2001 75 (81%)    8 (9%)    11 (9%)   
2002 93 (79%) 49 78%) 29(81%)  13 (11%) 6 (10%) 4 (11%)  10 (8%) 8 (13%) 1 (3%) 
2003 122 (79%) 61 (74%) 42 (86%)  16 (10%) 8 (10%) 5 (10%)  17 (11%) 13 (16%) 2 (4%) 
2004 125 (82%) 75 (80%) 41 (87%)  11 (7%) 7 (7%) 2 (4%)  18 (11%) 12 (13%) 3 (6%) 
2005 176 (79%) 106 (78%) 60 (86%)  26 (12%) 12 (9%) 8 (11%)  20 (9%) 17 (13%) 1 (1%) 
2006 170 (78%) 103 (75%) 45 (83%)  29 (13%) 19 (14%) 7 (13%)  16 (7%) 12 (9%) 2 (4%) 
2007 181 (85%) 116 (85%) 52 (91%)  17 (8%) 9 (7%) 4 (7%)  13 (6%) 10 (7%) 1 (2%) 
2008 171 (78%) 110 (78%) 50 (79%)  25 (11%) 16 (11%) 8 (13%)  12 (5%) 6 (4%) 3 (5%) 
















   
Figure 5.8: Figure A: TB rates in adult HIV-infected and HIV-uninfected patients in the 
study community, from 2002 to 2008. Figure B: TB rates in adult HIV-infected patients 
receiving HAART and adult HIV-infected patients not receiving HAART, over the same 
time period 
  Figure A shows the increase in TB notification rates among HIV-infected patients from 
2002 to 2004 (p=0.01), followed by a decrease in notification rates from 2005 to 2008 
(p<0.001). This figure also shows the stable TB notification rates among HIV-uninfected 
patients from 2002 to 2004 (p=0.59), followed by a moderate decline from 2005 (p=0.01). 
Extreme case scenario sensitivity analyses are also shown.  
Figure B shows the increase in TB notification rates from 2002 to 2004 among HIV-
infected patients not receiving HAART (p=0.34), followed by a decrease in notification 
rates from 2005 to 2008 (p<0.001). This figure also shows the decreasing TB notification 












5.4.4.3 Baseline CD4 Count  
The number of HIV-infected patients initiating HAART in each year is shown in Table 
5.2.The median baseline CD4 counts in patients commencing HAART increased from 15 
cells/µl in 2003, to 86 cells/µl in 2004, 129 cells/µl in 2005, peaking at 153 cells/µl in 
2006, and then stabilising at 122 cells/µl in 2007 and 141cells/µl in 2008.  
 
5.4.4.4 TB Categories  
Pulmonary and Extra-Pulmonary TB 
Pulmonary and extra-pulmonary TB rates (per 100,000), overall and by HIV-status, are 
reported in Table 5.4.   
 
In summary, both overall PTB and smear-positive PTB rates increased significantly from 
1997 to 2004, and then declined from 2005. Among HIV-uninfected patients, PTB and 
smear-positive PTB rates were stable from 2002 to 2004, decreasing moderately from 
2005. Among HIV-infected patients PTB and smear-positive PTB rates increased from 
2002, followed by a significant decline from 2005. In both PTB and smear-positive PTB, 
the decline in rates was greater in HIV-infected patients receiving HAART. PTB and 
smear-positive PTB rates by HIV and HAART status are illustrated in Figures 5.9A and 
5.9B respectively. 
 
Total PTB rates increased by an annual average of 131 cases/100,000 from 1997 to 
2004 (95% CI: 117 to145; p<0.001), followed by a significant decline from 2005 (average 
annual decrease of 171 cases; 95% CI: -240 to 102; p<0.001). In HIV-uninfected 
patients, PTB rates were stable from 2002 to end 2004 (p=0.34), and declined 
moderately from 2005, with an average decrease of 83 cases per year (95% CI: -124 to -
41; p<0.001).  In HIV-infected patients, PTB rates increased from 2002 by an average of 
452 cases per year (95% CI: 256 to 648; p<0.001), followed by a significant decline from 
2005, with an average decrease of 561 cases per year (95% CI: -694 to -428; p<0.001). 
The decline in PTB rates was significant in both HIV-infected patients not on HAART 
(average decrease of 441 cases per year; 95% CI:   -579 to -302; p<0.001) and in 
patients receiving HAART (average decrease of 762 cases per year; 95% CI: -1191 to -













Overall sputum smear-positive PTB rates (per 100,000) increased significantly from 
1997 to end 2004, by an annual average of 81 cases/100,000 (95% CI: 52 to 109; 
p<0.001). Sputum smear-positive rates then declined after 2005, by an annual average 
of 109 cases (95% CI: -333 to 114; p=0.34). No significant increase was detected in 
either HIV-uninfected or HIV-infected patients from 2002 to end 2004 (p=0.93 and 
p=0.67 respectively).  From 2005 smear-positive PTB declined in both HIV-uninfected 
patients (average annual decrease of 48 cases; 95% CI: -94 to -1; p=0.04) and in HIV-
infected patients (overall p=0.004). The decline in HIV-infected patients was noted in 
both patients not on HAART (average annual decrease of 192 cases; 95% CI: -368 to -
16; p=0.03) and in HIV-infected patients receiving HAART (average annual decrease of 
430 cases; 95% CI: -765 to -94; p=0.01) (Figure 5.9B).  
 
There was no change over time in the proportion of PTB cases that were sputum smear-
positive, either in HIV-uninfected patients (p-value for trend=0.27) or HIV-infected 
patients (p=0.31), including HIV-infected patients not receiving HAART (p=0.23).  HIV-
infected patients had significantly lower odds of smear-positive PTB compared to HIV-
uninfected patients, and this finding persisted when adjusted for age and gender (odds 
ratio [OR]: 0.46; 95% CI: 0.34 – 0.61; p<0.001). However, HIV-infected patients did 
account for 52% of the overall burden of smear-positive disease. There was no 
difference in sputum smear-status among HIV-infected patients on or off HAART 
(p=0.40). 
 
In summary, total EPTB rates and HIV-uninfected EPTB increased significantly to 2004, 
after which the EPTB rates stabilised. Among HIV-infected patients, the increase in 
EPTB from 2002 to 2004 was modest, followed by a decrease that was most marked in 
those patients receiving HAART. EPTB rates by HIV and HAART status are illustrated in 
Figures 5.9C. 
 
Overall EPTB rates (per 100,000) increased significantly from 1997 to 2004, by an 
average annual rate of 62 cases per year (95% CI: 17 to 107; p=0.01), and then 
stabilised from 2005 (95% CI: -617 to 561; p=0.93). In HIV-uninfected patients, EPTB 
rates (per 100,000) increased modestly from 2002 to end 2004 (average annual 
increase of 2 cases per year; p<0.001), but were stable from 2005 to end 2008 (p=0.49).  












2004 by an average of 36 cases/100,000 per year (95% CI: -156 to 223; p=0.73), 
followed by a significant decline from 2005, with an average decrease of 138 cases per 
year (95% CI: -243 to -34; p=0.01). The decline in EPTB rates was not significant in HIV-
infected patients off HAART (p=0.97) but was significant in patients receiving HAART 
(average decrease of 477 cases per year; 95% CI: -785 to -169; p=0.002).  
 
Based on the TB register data, EPTB cases were comprised of 51% TB of “other 
respiratory organs” (eg pleural effusions) 38% “other organs” (including pericardial TB, 
hepatic TB etc), 5% military TB, 2% TB lymphadenitis, 1% peritoneal or intestinal TB, 
1% TB meningitis, 1% TB of the bones or joints and 1% TB of the genito-urinary tract 
 
Retreatment TB 
In summary, retreatment TB rates overall, and among HIV-uninfected and HIV-infected 
patients, increased over the first part of the study period. From 2005, retreatment rates 
overall and in HIV-uninfected patients stabilised. Retreatment rates in HIV-infected 
patients declined from 2005, with the greatest decline occurring in those patients 
receiving HAART. Retreatment TB rates by HIV and HAART status are illustrated in 
Figures 5.10. 
 
Overall retreatment TB rates (per 100,000) increased significantly from 1997 to 2004, at 
an annual average increase of 53 cases/100,000 (95% CI: 31 to 75; p<0.001), after 
which retreatment rates stabilised (annual average decrease of 44 cases; 95% CI: -91 to 
2; p=0.06). Retreatment TB rates increased in HIV-uninfected patients from 2002 to end 
2004, with a modest average annual increase of 48 cases (95% CI: 47 to 48; p<0.001), 
and were subsequently stable from 2005 to end 2008 (p=0.95). In HIV-infected patients 
not receiving HAART, retreatment TB rates increased by an average of 138 cases per 
year (95% CI: 138 to 139; p<0.001) from 2002 to 2004, and then decreased by an 
annual average of 188 cases (95% CI: -238 to -137; p<0.001). Annual retreatment TB 
rates in HIV-infected patients on HAART decreased significantly from 2004 by an 















Figure 5.9: Figure A: Adult PTB rates by HIV and HAART status; Figure B: Adult sputum 
smear-positive PTB rates by HIV and HAART status; and Figure C: Adult EPTB rates by 












  Figure A shows the stable PTB notification rates among HIV-uninfected patients from 
2002 to 2004 (p=0.34), followed by a moderate decline from 2005 (p<0.001). This figure 
also shows the increase in PTB notification rates among HIV-infected patients not 
receiving HAART from 2002 to 2004 (p<0.001), followed by a decrease in notification 
rates from 2005 to 2008 (p<0.001). The decreasing PTB notification rates among HIV-
infected patients receiving HAART is also illustrated (p<0.001). 
Figure B shows the stable smear-positive PTB notification rates among HIV-uninfected 
patients from 2002 to 2004 (p=0.93), followed by a moderate decline from 2005 (p=0.04). 
This figure also shows the smear-positive PTB notification rates among HIV-infected 
patients not receiving HAART from 2002 to 2004 (p=0.67), followed by a decrease in 
rates from 2005 (p=0.03).  The decreasing PTB notification rates among HIV-infected 
patients receiving HAART is also illustrated (p=0.01).  
Figure C shows the increasing EPTB notification rates among HIV-uninfected patients 
from 2002 to 2004 (p<0.001), followed by a stabilizing of rates from 2005 (p=0.49). This 
figure also shows the relatively stable rates of EPTB notification rates among HIV-
infected patients not receiving HAART from 2002 to 2004 (p=0.73), and from 2005 
(p=0.97).  The decreasing EPTB notification rates among HIV-infected patients receiving 




Figure 5.10: Adult retreatment TB rates by HIV and HAART status, in the study 
community from 2002 to 2008 
  This figure shows the retreatment TB notification rates among HIV-uninfected patients, 
increasing modestly from 2002 to 2004 (p<0.001), and stabilising from 2005 (p=0.95). 
This figure also shows the increase in retreatment TB notification rates among HIV-
infected patients not receiving HAART from 2002 to 2004 (p<0.001), followed by a 
decrease in rates from 2005 to 2008 (p<0.001). The decreasing retreatment TB rates 














5.4.4.5 TB Outcomes  
TB outcomes, specifically treatment completion, mortality and treatment interruptions, 
both overall and by HIV status, are tabulated in Table 5.5.  There were 14 patients over 
the 12 year period for which outcomes were not recorded (11 were multi-drug resistant 
(MDR)-TB patients who were transferred to an MDR treatment facility). These 14 
patients have been excluded from the outcome analysis. 
 
In summary, there were no significant changes in TB treatment completion or 
interruption rates among HIV-uninfected and HIV-infected patients. TB mortality 
decreased significantly from 2002, and this decrease was predominantly in HIV-infected 
patients. 
 
TB treatment completion rates averaged 80% over the study period, with no significant 
change over that time (p-value for trend=0.94). TB treatment completion rates did not 
change significantly for HIV-uninfected or HIV-infected patients from 2002 to 2008 
(average completion rate in HIV-uninfected: 85%, p=0.93; and average completion rate 
in HIV-infected: 78%, p=0.39). HIV-uninfected patients were more likely to complete 
treatment compared to HIV-infected patients (p=0.002), although this difference did not 
persist when adjusted for mortality (p=0.32). 
 
Overall treatment interruption rates averaged 10% from 1997 to 2008, with no significant 
change over that time (p-value for trend=0.69). TB treatment interruption rates did not 
change significantly for HIV-uninfected or HIV-infected patients from 2002 to 2008 
(average completion rate in HIV-uninfected: 10%; p=0.69 and average completion rate in 
HIV-infected: 10%; p=0.61). There was no difference in the interruption rates between 
HIV-uninfected and HIV-infected patients (p=1.00). 
 
Overall mortality during TB treatment decreased over the study period from 8% in 2002 
to 5% in 2008 (p-value for trend=0.02; Figure 5.11). While TB mortality rates remained 
relatively constant in HIV-uninfected individuals (p=0.93), TB mortality dropped 
significantly in HIV-infected patients from 13% in 2002 to 4% in 2008 (p=0.001).  












   
Figure 5.11: Adult TB mortality rate overall and by HIV-status, in the study community 
from 2002 to 2008 
This figure shows the decline in all cause TB mortality rates overall (p=0.02) and among 
HIV-infected patients (p=0.001). TB mortality rates remained stable in HIV-uninfected 
patients (p=0.93).  
 
The proportion of patients that were transferred out of the community to another health 
facility remained constant, both from 1997 to end 2004 (p-value for trend=0.35) and from 
2005 to 2008 (p=0.31). Similarly, the transfer-out rates remained constant for HIV-
uninfected patients (p=0.96) and HIV-infected patients (0.83). There was no statistical 




This study demonstrated an association between the implementation of a high coverage 
HAART programme and TB notification rates in a community with high burdens of both 
TB and HIV. In this community, adult TB notification and mortality rates decreased with 
the rapid and high coverage implementation of a HAART programme. Overall TB rates 
in children remained relative constant over the study period. 
 
In Chapter 2 we noted the exceptionally high risk of TB infection and re-infection in this 
community. We hypothesized that the high adult HIV prevalence in Site M179;197, coupled 












individuals, from both reactivation of latent infection and recent infection14;102, could 
explain the substantial incidence of TB disease in this setting.  This analysis has shown 
that HIV-uninfected TB rates have remained relatively stable in this community over the 
time period, and HIV-infected adult TB notification rates are at least six-fold higher than 
those in HIV-uninfected patients. This emphasises that HIV-associated TB rates have 
been responsible for the burden of TB disease in this community. 
 
5.5.1 Childhood TB Notifications and Outcomes 
In keeping with historical data on the natural history of TB69;304, children under 5 years 
had the highest rates of paediatric TB disease, followed by substantially lower rates in 
children between 5 and 9 years and a slow increase once again in children greater than 
10 years of age.  
 
According to the WHO childhood smear-positive TB rates in South Africa are an 
estimated 29/100,0007. However, in the last two years of this study, the smear-positive 
TB rates in children in this community have been 2.5 to 5 fold higher than that estimated 
rate.  As discussed in Chapter 3, sputum-positive TB rates for children grossly 
underestimate the total paediatric TB burden, and this is highlighted in this study, with 
only an average of 8% of the overall paediatric disease reflected in the smear-positive 
rates.  
 
Of note is that children under 4 years of age had TB rates comparable with the adults in 
the community, reflecting a substantial burden of morbidity in this age group. However, 
the TB rates in children under 10 years of age were stable over the study period, with no 
statistical evidence of a direct benefit of the HAART programme. Children in this 
community are subjected to a substantial force of TB infection and re-infection and have 
a high annual exposure rate (Chapter 2 & 3). In addition, young children are at an 
increased risk of progression to disease following infection69;304, even among HIV-
uninfected children. The high burden of childhood disease may be more attributable to 
this considerable, combined risk of infection and progression to disease than to 
paediatric HIV infection.  
 
Childhood TB is a reflection of the adult TB epidemic. While the adult TB rates have 












impact of this decrease on childhood TB rates, and the four years of follow-up post-
HAART implementation may be insufficient time to detect evidence of possible reduction 
in TB transmission and disease in this vulnerable group. Furthermore, while there are 
conflicting findings with regards to this hypothesis, HIV-uninfected adults may be more 
responsible for transmission to children. HIV-uninfected TB rates have not declined as 
dramatically as the rates among HIV-infected patients and this may also contribute to the 
relatively stable rates in children under 10 years of age.   
 
Prior to HAART programme TB rates in young adolescents of 10 to 14 years of age were 
increasing over time. However, subsequent to the availability of HAART TB rates appear 
to have stabilised in this group. HAART coverage is high among HIV-infected 
adolescents and therefore the stabilising of TB rates in young adolescents may reflect 
the benefits of the HAART programme.  
 
5.5.2 Adult TB Notifications and Outcomes 
The decrease in adult TB notification rates in the study community occurred against a 
background of increasing national TB notification rates, as shown in Chapter 17. TB rates 
in HIV-uninfected adults have remained relatively stable from 1997 to 2004, with HIV-
associated TB driving the escalating epidemic in the study population.  While HIV-
uninfected rates showed a decline from 2005, the reduction in community TB notification 
rates in this study was predominantly due to a decrease in TB rates in HIV-infected 
patients, and more specifically, in patients receiving HAART. This finding was consistent 
for overall adult TB notification rates, as well as for PTB, EPTB and retreatment TB 
rates. 
 
Although the HIV prevalence in this community was reasonably stable from 2002 to 
2008, the adult TB notification rates in HIV-infected patients continued to escalate until 
2005. Following the rapid scale-up of HAART availability from 2005, the TB rates in HIV-
infected patients not on HAART stabilised and then decline moderately. However, there 
was a dramatic, almost 3-fold declined in TB rates in those HIV-infected patients on 
HAART. Of note is the increasing reduction in risk of TB for patients on HAART 
compared to patients off HAART, as illustrated by the age-standardised RR increasing 
from 0.41 in 2004 to nearly 2 in 2008. Similarly, there were high initial EPTB and 












HAART, followed by a substantial reduction in EPTB and retreatment TB in HIV-infected 
patients on HAART.  These findings are most likely due to the immune system recovery 
associated with antiretroviral treatment and the consequent reduction in TB risk in HIV-
infected patients on treatment45;46;152;170. 
 
The levelling-off and subsequent decline of TB notification rates (overall TB rates as well 
as EPTB and retreatment rates) in HIV-infected patients not on HAART may be due to 
the removal of those with the highest TB risk (lowest CD4 counts)46 from this group into 
the group on HAART. This stabilising of notification rates suggests that the rate at which 
people are removed from the susceptible pool approximates the rate at which HIV-
infected patients not on HAART are progressing into a high-risk state of immune 
compromise. This finding suggests that the rate at which a HAART programme is 
implemented in a community might be an important variable determining the impact of 
this intervention on overall HIV-associated TB rates. The importance of the rate of 
HAART implementation is emphasised by the fact that TB control may rely on reducing 
TB incidence rapidly in order to reduce transmission effectively452. 
 
Although TB does occur at all CD4 strata, the highest risk of TB in HIV-infected patients 
occurs at low CD4 counts (<200cells/µl)34;75 . The South African National Antiretroviral 
programme recommended initiating patients on HAART at CD4 count <200cells/µl, or 
WHO clinical stage IV 199, although new guidelines will allow for the earlier initiation of 
HAART treatment for TB patients and pregnant women (at CD4 count <350cells/µl). 
Patients initiating HAART have a high risk of TB in the first months of treatment 
compared to later in treatment, due to the risks associated with low baseline CD4 counts 
and with possible unmasking of sub-clinical TB76;152;166. The overall increase in median 
baseline CD4 count in our study reflects the initiation of patients with more advanced 
disease onto treatment in the early stages of the HAART programme. With increasing 
duration of the HAART programme, the pool of severely immune-compromised patients 
off treatment decreased, patients were started on HAART at higher baseline CD4 
counts. However, despite the overall increase in median baseline CD4 count, by 2008 
the median CD4 count at initiation of HAART was still well below 200cells/µl and TB risk 
prior to HAART initiation remained high, as evidenced by the nearly 2-fold higher 
standardised RR in HIV-infected patients off HAART compared to those patients on 













HIV-infected patients off HAART accounted for 64% of TB disease in 2008, and thus 
contribute a large portion of the TB burden. By 2008 the HAART coverage in this 
community was high, at 90% of the estimated community need as defined by the 
national HAART guidelines199;468. If similar coverage rates and impacts were achieved 
nationally, a greater than 20% reduction in TB rates might be attained, as seen in this 
community. But this impact could be more substantial if treatment was initiated earlier in 
the HIV-disease process, before the higher TB risk associated with advanced immune 
suppression, thus also reducing TB burden prior to HAART initiation and during the early 
months on HAART.   
 
Alternative explanations of changes in notification rates 
While there was a strong temporal association between the decline in TB notification 
rates and the implementation of a high coverage HAART programme, and there is 
substantive biological plausibility to support this association, it is worth considering 
alternative explanations for the decrease noted in TB notification rates. 
 
Prevalence of TB is a function of TB incidence and period of infectivity in the community.  
Period of infectivity can be decreased by earlier diagnosis and treatment of cases. The 
key change to case-finding activities was the introduction of active case-finding for TB in 
patients initiating HAART.  This practise may have resulted in a decrease in TB 
prevalence, thus indirectly contributing to the decrease in notifications over time. In 
addition, in 2005 a community-based cross-sectional survey was performed in 10% of 
the study community, investigating participants for active TB disease179. A sensitivity 
analysis, excluding those participants diagnosed in that survey from the notification data, 
showed no change in the study results, including the peak noted in 2005 (Appendix B). 
Therefore this survey did not appear to have had a direct effect on the notification rates 
in this community. The increased TB screening of HAART-eligible patients (through 
symptom screen and sputum investigation) that was associated with the scale-up of the 
HAART programme in 2005 may, in part, explain the 2005 peak in notification rates. This 
theory is strengthened by the observation that the peak is considerably more marked in 
PTB, specifically smear-positive PTB disease.  This increased screening together with 












indirectly to the moderate increase in TB notifications also noted in HIV-uninfected 
patients.  
 
Other possible explanations for the study findings included improved TB treatment 
completion rates, which may have resulted in decreased TB transmission, in turn 
reducing TB incidence. However TB completion rates remained stable over the study 
period, and this was consistent for both HIV-infected and HIV-uninfected patients. Period 
of infectivity, and thus prevalence could be decreased by increased TB-associated 
mortality; however, TB mortality has decreased over the period of observation. There 
were no changes in the infection control policies within the clinic over this period, and 
therefore decreased nosocomial TB transmission is unlikely to explain the study findings.  
 
This community showed substantial population growth over the study period, and a 
changing age distribution in the population may have impacted the TB notification rates. 
However, age-standardised rates were calculated using the population age distribution 
in 1997 as the reference population, and these results confirmed the trends in TB 
notification rates. Although changing social conditions may also impact TB transmission 
in communities, this community has remained one of extremely poor socio-economic 
status since its establishment in 1994. The unchanging social impact on TB rates is 
reflected by the stable TB notification rates among young children.  
 
Sputum Smear-Positive PTB 
HIV-infected patients have a reduced likelihood of sputum smear-positive TB disease, 
due to impaired immune responses, and as a result are thought to contribute less to TB 
transmission9. Therefore it is reasonable to hypothesise that patients on HAART, with 
improved immune functioning, may have an increased smear-positivity rate, and 
consequently contribute more to transmission than their HIV-infected counterparts not on 
HAART. However, in this study we reported that smear-positive rates declined in 
patients receiving HAART, although that decline was less than noted in all PTB, or in 
EPTB and retreatment TB. This is in keeping with the findings of another recent study 
that reported no increase in smear-positivity rates in HIV-infected patients receiving 
HAART469. In addition, smear-positive PTB rates in HIV-infected patients off HAART also 














TB is a major cause of mortality in HIV-infected patients in sub-Saharan Africa7;17. A key 
finding in this study is the significant reduction in TB mortality rates in HIV-infected 
patients. The use of HAART has been associated with a reduction in TB-associated 
mortality among individuals and in treatment cohorts470;471. In our study the 
implementation of a community HAART programme was also associated with a 
decrease in overall TB mortality, predominantly due to the decrease in HIV-infected 
patients. In 2002, the mortality rate in HIV-infected TB patients was four times greater 
than that of HIV-uninfected patients, but had decreased to the same rate as HIV-
uninfected patients by 2008. This suggests that HAART programmes may greatly assist 
in achieving the Stop TB Partnership goal to halve TB mortality rates by 2015. As 
mortality measures may more quickly reflect the impact of an intervention compared to 
incidence measures452;472, this result supports the finding of decreasing notification rates. 
While overall reduction in TB notification rates has a potential public health benefit, the 
finding of decreased mortality risk reflects substantial ben fit for the individual patient. 
 
No change was noted in TB treatment completion or interruption rates among HIV-
infected and -uninfected patients over the study period. In particular, this study did not 
demonstrate improved adherence to TB treatment among HIV-infected patients after the 
implementation of the HAART programme. Numbers of patients interrupting treatment 
were too small to provide a statistical comparison between HIV-infected patients on and 
off HAART. 
 
5.5.3 Strengths and Weaknesses 
While the adult TB notification rate analyses are robust (Appendix B), it should be noted 
that the absolute numbers of paediatric TB cases were relatively small and this may 
have impacted the statistical analyses of this group. Furthermore, rates of HIV testing 
were extremely low among paediatric patients, hampering a HIV-stratified analysis.  
 
HIV testing uptake was also not complete among adult TB patients, although with 78% 
of adults tested, testing rates were substantially higher than among children. In order to 
explore the potential biasing influence of those patients with unknown status we 
performed an extreme case scenario analysis among adult patients. The result of this 












(Figure 5.8A). The population denominators were derived from community census data 
with the assumption of linear growth between censuses and HIV–infected denominators 
were obtained from a mathematical model fitted to local HIV data. Sensitivity analyses 
were run for models assuming different trends of population growth and different 
assumptions for HIV prevalence. These analyses also did not show substantive changes 
in study inferences (Appendix B). This community is typical of many recently urbanised 
populations in South Africa, but there is a need for further investigation to confirm the 
generalisability of our findings in other high prevalence settings. In addition, a longer 
period of observation is required to confirm persistence of these changes.  
 
This study was performed in a well-demarcated community, with population data derived 
from frequent community censuses. All residents receive their TB treatment at a single 
clinic, and therefore TB notification data is likely to be a complete representation of TB 
notifications in the community. Similarly, residents obtained HAART from the clinic or the 
local referral hospital and access to both these databases ensured an accurate 
description of the HAART programme in this community.  These analyses are dependent 
on the fidelity of the relevant data records, and therefore the databases underwent a 
10% quality control assessment. 
 
While TB notification rates are frequently used as a surrogate measure for TB incidence, 
there are limitations to this method particularly in settings in which the TB control 
programme relies on passive case-finding (ie self presentation by patients when 
ill)179;473;474. The accuracy with which notification data reflect TB disease burden is 
dependent on the case detection rate of the TB programme179;344;475;476. The case 
detection rate, in turn, is affected by the patients’ knowledge and beliefs regarding TB 
disease, recognition of TB symptoms, subsequent health seeking behaviour and access 
to medical facilities341;342;474;477-479. The timely and accurate diagnosis of the patient at the 
health care facility will also influence the precision of notification data as a measure of 
disease burden341;342;478 as will the quality and accuracy of data reporting. Case detection 
rates in this community were unknown for the earlier years of the study, but ranged from 
48% in 2005 to 60% in 2008 (Chapter 6)179;197. Therefore the notification data reported in 
this study underestimated the true incidence of TB in this community, and represents a 
conservative estimate of this measure of disease burden. The increasing case detection 












and should have resulted in increasing notification rates. Therefore this observation 
supports the robust nature of the study finding of decreasing trends. 
 
5.5.4 Conclusion 
In conclusion, against a background of increasing TB notifications nationally, we have 
shown that a rapidly implemented, high coverage HAART programme can reduce the TB 
notification rates and TB mortality within a community heavily affected by both HIV and 
TB epidemics. This reduction in TB was due predominantly to the decrease in adult TB 
rates in HIV-infected patients receiving HAART, and may be the result of both active TB 
screening and improved immune function in these patients. The overall reduction in TB 
notification rates has a potential public health benefit, while decreased mortality rates 

























Impact of an Antiretroviral Treatment   
Programme on TB Disease Prevalence 
 
 
6.1  RATIONALE 
While tuberculosis (TB) notification rates are often used as a measure of disease 
burden, there are limitations to this methodology, particularly in settings in which the TB 
control programme relies on passive case-finding (ie self presentation by patients when 
ill)179;473;474. The accuracy with which notification data reflect TB disease burden is 
dependent on the case detection rate of the TB programme179;344;475;476, as discussed in 
Chapter 5.   
 
Once receiving TB chemotherapy, TB patients are considered to be less infectious60, 
and it is this group of patients that is reflected in notification data. Untreated or 
inadequately treated TB disease, in contrast, is often unrecognised and is an important 
driver of transmission in a population49;60;65;114. TB prevalence is the proportion of a 
population with active TB disease, both treated (diagnosed) and untreated 
(undiagnosed), at a given point in time. Measuring the prevalence of TB in a population, 
therefore, provides information on the case detection rates of a TB programme as well 
as a useful measure of the reservoir of transmittable TB. In addition, the impact of 
interventions on disease burden is usually reflected in disease prevalence before it is 
noted in incidence measures452.  
 
This chapter aims to address the final objective of the thesis, namely to determine the 
prevalence of microbiologically-confirmed pulmonary TB disease in both the HIV-
infected and HIV-uninfected subsets of the population and describe changes in the 
prevalence of PTB disease since the scale-up of antiretroviral therapy (ART) access in 
the community. Data from this chapter have been published in the fifth paper197 listed in 
the preface on page xi. 
 
6.2   BACKGROUND 
As noted in Chapter 1, a key target of the World Health Organization (WHO) and the 














TB prevalence estimates for the African region, we are failing to achieve this target and 
the WHO has called for national surveys in high burden countries, such as South Africa, 
in order to more accurately monitor prevalence trends7. However, evaluating population 
TB prevalence is logistically challenging: cross-sectional surveys are costly due to the 
large sample sizes required, particularly in low prevalence settings480, and require well-
trained staff and reliable laboratory services480;481. As a result, few population surveys 
have been preformed in resource poor countries344;473;476;482;483, with surveys more often 
limited to high risk groups such as TB contacts308;326-328;484;485, prisoners486-490, 
miners178;491;492 or HIV-infected patients35;157;492-500. Thus, due to the paucity of population 
data, TB prevalence described by the WHO for most countries is not measured directly, 
but is an indirect estimate based on related parameters11. 
 
In the particular example of South Africa, prevalence data has been calculated from TB 
incidence and trends in TB mortality7.  Based on these calculations the WHO estimated 
the TB prevalence in South Africa was 707/100,000 in 2005, and 692/100,000 in 2008, 
with 50% of the TB prevalence occurring in HIV-infected individuals7.  
 
6.2.1 Community-Based Cross-Sectional Surveys  
Few community-based surveys have been implemented in resource poor settings343;501-
503, including sub-Saharan Africa280;344;473;475;476;482;483;504;505.  
 
Sub-Saharan Africa 
Community-based studies performed in sub-Saharan Africa in the last decade have 
reported TB prevalences among symptomatic participants ranging from 0.2% to 
6%344;473;476, while overall community TB prevalences have been reported in the range of 
0.4% to 4.5%280;475;505;506. These surveys have also consistently reported case detection 
rates well below the WHO target of 85%344;474;476;505. Despite the significant impact of HIV 
on TB epidemics in Africa, only three studies have reported HIV status linked to TB 
results280;475;506, and all reported a higher TB prevalence among HIV-infected patients. 
No studies have reported the highly active antiretroviral therapy (HAART) status of HIV-
infected participants or assessed the impact of HAART programmes on TB prevalence.   
 
Comparison of the findings of these surveys is complicated by differing inclusion criteria 












different participant age ranges), varied study procedures (such as sputum specimens 
and/or chest X-rays), and different definitions as to what constitutes a prevalent TB case. 
Despite these difficulties, a recent review and meta-analysis of population-based active 
case-finding (ACF) surveys reported an overall median prevalence of previously 
undiagnosed TB of 0.7% in sub-Saharan Africa communities507.  
 
South Africa 
A small number of community-based prevalence surveys have been performed in South 
Africa. Studies performed in the 1970’s and early 80’s, prior to the escalation of the HIV 
epidemic, reported prevalences of sputum-positive TB from 1.5-2.1%256;329;508 in South 
African communities. 
 
Since the escalation of the HIV epidemic, few community TB surveys have been 
reported in South Africa179;482;483. In 2007, the prevalence of pulmonary TB (PTB) in a 
rural sub-district was reported to be 0.16%474. While in 2009, in an urban community with 
relatively low HIV prevalence (<12% among women accessing antenatal care359;509), 
sputum positive TB prevalence of 1% was reported among adults older than 14 years of 
age, compared to adult sputum positive TB prevalence of up to 3% in a high HIV 
prevalent community (HIV prevalence of 23%)179. Only one South African study has 
reported HIV data linked to the TB results179, and consequently there is little information 
on the impact of the HIV co-epidemic on the TB burden in these communities.  
 
6.2.2 TB prevalence in Site M 
In 2005, prior to the extensive implementation of the HAART programme, we performed 
a community-based, TB prevalence cross-sectional survey in Site M. The survey 
reported a 3% overall TB prevalence in this community, of which just over half was 
previously undiagnosed TB.  In particular a high rate of untreated, laboratory-confirmed 
PTB was reported among HIV-infected individuals179, with a 44% case finding proportion 
among these participants compared to 57% among HIV-uninfected participants. 
 
In order to assess the impact of the subsequent high coverage HAART programme on 
TB prevalence in this community, we repeated the cross-sectional survey in 2008, 














6.3   STUDY DESIGN 
This study was performed from June to December 2008, and the same methodology as 
the 2005 survey was used179. A house-to-house enumeration of the community provided 
a database of 14,592 residents, of whom 1,500 residents ≥15 years of age were 
randomly selected for study participation (10% of the community).  
 
All participants completed a structured questionnaire, investigating participant 
demographic characteristics, TB history, TB symptoms (cough, night sweats, loss of 
appetite and loss of weight), risk factors for TB (including housing, alcohol use, smoking 
and recreational drug use, prior imprisonment, and employment history) and risk factors 
for HIV infection. Questionnaires were interviewer-administered in the participants’ home 
language.   
 
Two sputum specimens were collected from each participant: an early morning sputum 
produced at home, and a second, induced-sputum collected at the site using saline 
nebulisation. Both sputum specimens were tested at the same laboratory for acid-fast 
bacilli (AFB) by microscopy and for Mycobacterium tuberculosis (Mtb) growth by culture. 
An oral transudate specimen was collected for anonymous HIV testing, with HIV results 
linked to TB results.  
 
6.3.1 Laboratory Procedures 
Sputum specimen smears w re examined for AFBs using an auramine-O stain. Sputum 
sediments were cultured in the Mycobacterial Growth Indicator Tubes (MGIT) automated 
system and incubated for 6-8 weeks before being reported as negative. Positive cultures 
were examined for the presence of AFB by Ziehl Neelsen staining and were identified as 
Mtb complex using a polymerase chain reaction assay. The oral mucosal transudate 
specimen for HIV testing was collected using the Orasure® oral fluid collection device 
(Orasure Technologies, Bethlehem, PA). The Vironostika Uni-Form II HIV-1 and HIV-2 
plus 0 ELISA test (bioMérieux SA, Marcy l'Etoile, France) was used to test for HIV-1 and 













6.3.2 Case Definitions  
Following on the 2005 methodology, participants who reported on the questionnaire that 
they were currently receiving TB treatment were classified as “treated TB cases”. 
“Untreated TB cases” were defined as participants without a prior known TB diagnosis, 
but with laboratory confirmed infection, as identified by two positive AFB smear results or 
two positive Mtb culture results, or a positive AFB smear result confirmed by a positive 
Mtb culture on separate specimens. All untreated TB cases that were identified were 
referred to the local TB clinic for chemotherapy. 
 
6.3.3 Data Analysis  
Data were analyzed using STATA 10.0 (StataCorp, College Station, Texas). 
Bivariate analyses employed Student’s t-, Wilcoxon sum rank and chi2 tests, as 
appropriate. A comparison of age and gender of randomly selected residents and 
enrolled participants to the population demographics for 2005 and 2008 were performed 
to confirm the representativeness of the randomly selected and enrolled groups.  
 
TB prevalence was calculated as the proportion of TB cases identified in the total study 
sample, and as the proportion of TB cases identified in the HIV-infected and uninfected 
subsets. Multiple logistic regression models were developed to examine changes in 
overall TB prevalence, as well as treated and untreated TB prevalence between the two 
surveys, after adjusting for variation in individual participant characteristics. These 
models were weighted for the proportion of the population sampled in each survey. 
Median CD4 counts were calculated for the total HAART cohorts in 2005 and 2008, 
based on each HAART patients’ averaged CD4 count recorded in the survey year. 
Annual median CD4 counts were compared across the two years with Wilcoxon’s sum 
rank test. Case-finding proportion was calculated as the proportion of prevalent cases, 
overall and by HIV status, that were reported as treated TB cases.  
 
Univariate logistic regression analyses were performed to determine the key risk factors 
for prevalent TB (overall, treated and untreated) in each year. Subsequently, a 
multivariate logistic regression model for TB was developed, adjusting for significant risk 













95% Confidence intervals (CI) were based on the Poisson distribution and all statistical 
tests were 2-sided at alpha=0.05. 
 
6.4   STUDY FINDINGS 
6.4.1 Demographic Characteristics 
Of the 1,500 residents selected for participation in the 2008 survey, home visits 
confirmed that 1,383 of these individuals (92%) were still resident in the community, and 
eligible for the study. Of these 1,250 (90%) consented to enrol in the study, 121 (9%) 
refused participation and 12 (1%) were not contacted after 5 home visits.  In the initial 
survey in 2005, 762 (78%) of 971 randomly selected, eligible residents were enrolled in 
the study, with a refusal rate of 15%179. Demographic characteristics of the two samples 
are shown in Table 6.1.  
 
In 2005, residents selected for study participation did not differ significantly from the 
general population by age (median age 27 vs 28 years respectively; p=0.54) or by 
gender (48% vs 51% male in both groups; p=0.11). Similarly, participants enrolled in that 
study were representative of the general population in terms of age (median age 27 vs 
28; p=0.31), and gender (51% males vs 48% respectively; p=0.11).  In 2008, residents 
selected for study participation did not differ from the general population by age (median 
age 28 years for both groups; p=0.43) or by gender (54% males in both groups; p=0.81) 
and nor did participants who enrolled in the study (median age 28 years in both groups; 
p=0.41 and 54% males in both groups; p=0.84). 
 
6.4.2 TB and HIV Testing 
All participants were nebulised for sputum specimens, however, a small proportion of 
participants were unable to produce sputum. In 2005 sputum samples were obtained 
from 761 of the participants (99%), and in 2008, sputum specimens were obtained form 
1,225 (98%) of the sample. The culture contamination rate of specimens was consistent 
across the two surveys (7% in 2005 vs 8% in 2008; p=0.41). 
 
In 2005, 4 participants (1%) declined HIV testing; among those that were tested the HIV 
prevalence was 23% (95% CI: 20-26%)179. Of the 174 HIV-infected participants, 5% 
(95% CI: 2-10%) were receiving HAART.  In 2008, 43 participants (3%) declined HIV 












these 20% (95% CI: 14-23%) were receiving HAART. There was no significant 
difference in HIV prevalence between the two surveys (p=0.23), although significantly 
more HIV-infected participants were receiving HAART in 2008 compared to 2005.                               
 
Table 6.1: Demographic, TB risk factors and clinical characteristics of two survey 
samples 
 
 2005 Survey 2008 Survey p-value 
Community size ±10,500 ±15,000  
Study sample 762  (15% refusal) 
1,250 
(9% refusal)  
Demographics    
     Median age, yr (IQR) 27 (22-35) 27 (22-33) 0.23 
     Gender: male (%) 340 (45) 648 (52) 0.002 
     Median school grade completed  
     (IQR) 10 (8-11) 10 (8-11) 0.001 
     Presently employed (%) 398 (52) 662 (53) 0.75 
     Median residence, yr (IQR) 5 (3-7) 5 (2-10) 0.52 
     Median residents in household 
      (IQR) 3 (2-5) 3 (2-4) 0.01 
     Median persons sleeping in same 
     Room  (IQR) 2 (2-3) 2 (1-3) 0.09 
Risk factors    n(%)     
     Ever had TB in past 58 (8) 101 (8) 0.71 
     Alcohol intake in past 6 mo 324 (43) 408 (33) <0.001 
     Visited shebeen (bar) in past 6 mo 180 (24) 261 (21) 0.15 
     Smoked in past 6 mo 205 (27) 289 (23) 0.06 
     Recreational drugs in past 6 mo 29 (4) 54 (4) 0.57 
     Employment History    
          Past mining 43 (6) 44 (4) 0.02 
          Health Care Worker 21 (3) 21 (2) 0.10 







On HAART (% of HIV-infected) 
[95% CI] 




IQR = Interquartile range; CI = Confidence Interval 
All values are n(%) unless otherwise specified. 














6.4.3 Comparison of TB Prevalence in 2005 and 2008 
Total Study Population TB prevalence 
In 2008, 12 participants (1%) reported receiving TB treatment at the time of study 
participation, and a further 8 (0.6%) untreated cases were identified. The prevalence 
results of the 2005 and 2008 surveys, overall and by HIV status are reported in Tables 
6.2A and 6.2B. The overall TB prevalence (treated and untreated cases) declined 
significantly from 3% in 2005179 to 1.6% in 2008 (p=0.04). When adjusted for age, 
gender, HIV status, as well as demographic and risk profile characteristics that differed 
between the two surveys, this reduction in prevalence bordered on significant (p=0.05), 
as shown in Table 6.3. The reduction in prevalent treated TB (from 1.5 to 1.0%) was not 
significant (adjusted p=0.34); however the reduction in prevalent untreated TB from 1.6% 
to 0.6% was significant, and remained significant following adjustment as above (crude 
and adjusted p=0.05) (Table 6.3 and Figure 6.1).  
 
 
Figure 6.1: Prevalence of treated and untreated TB in the total study sample  
*adjusted for age, gender, HIV status, education level, mean residents in household, 
reported alcohol use, smoking and history of working in a mine 
 
In 2005, 50% (n=6) of the untreated TB cases had smear-positive PTB179, while in 2008, 
13% (n=1) of the untreated cases had smear-positive PTB (p=0.09).  
 
In 2008, untreated TB was not associated with reported symptoms, including cough 
(p=0.20), night sweats (p=0.35), loss of appetite (p=0.32) or loss of weight (p=0.22). This 













The total TB prevalence in HIV-uninfected participants remained unchanged between 
surveys (adjusted p=0.90), as did the prevalence of both treated TB and untreated TB in 
this group (adjusted p=0.90 and p=0.69 respectively) (Figure 6.2). 
 
 
Figure 6.2: Prevalence of treated and untreated TB among HIV-uninfected participants  
*adjusted for age, gender, education level, mean residents in household, reported alcohol 
use, smoking and history of working in a mine 
 
HIV-infected participants 
The total TB prevalence dropped significantly in HIV-infected participants from 9.2% to 
3.6% (adjusted p=0.01). While the decrease in treated TB prevalence was not significant 
in this group (4.0% in 2005 vs 2.3% in 2008; p=0.22 after adjustment for age, gender, 
HAART status, and demographic and risk profile characteristics as above), the 
prevalence of untreated TB cases declined significantly from 5.2% in 2005 to 1.3% in 
2008 (adjusted p=0.02) (Figure 6.3). The multivariate logistic models for total TB 
prevalence and untreated TB prevalence in HIV-infected participants are reported in 
Table 6.4.  
 
HAART 
The distribution of treated and untreated TB cases by HAART status in HIV–infected 
patients is shown in Table 6.2A (2005) and Table 6.2B (2008). The proportion of both 
overall and untreated TB cases on HAART decreased significantly from 2005 to 2008 












in this community was 269 (interquartile range [IQR]: 177-350) in 2005, and 350 (IQR: 
240-504) in 2008 (p<0.001).  
 
 
Figure 6.3: Prevalence of treated and untreated TB among HIV-infected participants  
* adjusted for age, gender, education level, mean residents in household, reported alcohol 
use, smoking and history of working in a mine 
 
Case Finding Proportions 
As shown in Table 6.2A and 6.2B the case finding proportion by the TB clinic in this 
community increased from 48% in 2005 to 60% in 2008. Case-finding proportions did not 
change significantly in HIV-uninfected participants (57% vs 56%). However, in the HIV-
infected population case-finding increased substantially from 44% to 64%.  Case-finding 
increased for patients on HAART, from 50% in 2005, to 100% in 2008. 
 
Table 6.2A: 2005 TB prevalence survey results, overall and by HIV and HAART status 
 
2005 Tuberculosis Survey 













Total TB cases 762 3.0 (23) 1.5 (11) 1.6 (12) 48% 
HIV-uninfected cases 584 1.2 (7) 0.7 (4) 0.5 (3) 57% 
HIV-infected cases 174 9.2 (16) 4.0 (7) 5.2 (9) 44% 
HIV-infected not on 
HAART 165 7.3 (12) 3.0 (5) 4.2 (7) 42% 













Table 6.2B: 2008 TB prevalence survey results, overall and by HIV and HAART status 
 















Total TB cases 1250 1.6 (20) 1.0 (12) 0.6 (8) 60% 
HIV-uninfected cases 901 1.0 (9) 0.6 (5) 0.4 (4) 56% 
HIV-infected cases 306 3.6 (11) 2.3 (7) 1.3 (4) 64% 
HIV-infected not on 
HAART 246 2.8 (7) 1.2 (3) 1.6 (4) 43% 




6.4.4 Comparison of TB Risk Factors in 2005 and 2008 
Risk factors of overall prevalent TB in 2005 and 2008 are reported in Appendix C. In 
summary, in 2005, in both univariate and multivariate analysis, the significant risk factors 
associated with prevalent TB were being in prison in the last 6 months (odds ratio [OR]: 
21.5; 95% CI: 4.4-105.4; p<0.001), being HIV-infected (OR: 8.8; 95% CI: 3.1-24.8; 
p<0.001) and receiving HAART (OR: 111.2; 95% CI: 20.8-594.5; p<0.001). 
In 2008, following adjustment for gender, age and relevant risk factors, only HIV-infected 
status (OR: 2.8; 95% CI: 0.9-7.7; p=0.05) and receiving HAART (OR: 7.9; 95% CI:2.3-
27.8; p=0.001) remained significant risk factors for any TB, although a history of 
employment in the mines bordered on significant risk (OR: 4.4; 95% CI: 0.9-21.3; 
p=0.07). A history of imprisonment in the past 6 months was not significantly associated 
with risk of TB prevalence. 
 
In 2005, the significant risk factors for treated prevalent TB in univariate analysis were 
previous history of imprisonment in the past 6 months (OR: 20.3; 95% CI: 3.8-109.3; 
p<0.001), HIV-infected status (OR: 3.2 compared to HIV-uninfected; 95% CI: 0.9-10.5; 
p=0.06) and HIV-infected persons receiving HAART (OR: 32.4 compared to HIV-
uninfected; 95% CI: 5.5-189.8; p<0.001). These risk factors persisted in a multivariate 













Table 6.3:  Multivariate logistic model for TB prevalence (overall, treated and untreated) in the total study population 
 
- p-values compare total TB, treated TB and untreated TB to participants with no TB, adjusted for the variables presented in the table 
- OR = odds ratio 
Total TB prevalence  Treated TB prevalence  Untreated TB prevalence  
OR (95% CI) p-value  OR (95% CI) p-value  OR (95% CI) p-value  
Survey year   
    2005 1  1  1  
    2008 0.53 (0.28 – 0.97) 0.05 0.66 (0.28 – 1.56) 0.34 0.39 (0.15 – 0.96) 0.05 
Age  (in years) 1.01 (0.97 – 1.05) 0.61 1.03 (0.97 – 1.07) 0.19 0.98 (0.91 – 1.04) 0.48 
Gender   
    Male 1  1  1  
    Female 0.88 (0.40 – 1.96) 0.75 0.71 (0.25 – 2.09) 0.52 1.08 (0.31 – 3.84) 0.90 
Education  (years in school) 0.99 (0.89 – 1.11) 0.92 0.90 (0.79 – 1.02) 0.11 1.26 (0.99 – 1.60) 0.06 
Number of residents in household 1.08 (0.94 – 1.25) 0.29 1.17 (0.98 – 1.40) 0.09 1.00 (0.78 – 1.27) 0.98 
Alcohol intake in past 6 months 0.96 (0.46 – 1.97) 0.90 0.84 (0.31 – 2.31) 0.74 1.12 (0.40 – 3.12) 0.83 
Smoked in past 6 months 2.14 (0.94 – 4.90) 0.07 2.27 (0.74 – 6.90) 0.15 1.77 (0.49 – 6.40) 0.38 
Past employment in mines 1.97 (0.62 – 6.30) 0.25 0.34 (0.04 – 3.03) 0.34 12.19 (2.48 – 59.92) 0.002 
HIV status   
    HIV-uninfected 1  1  1  



































  - p-values compare total TB and untreated TB to HIV-infected participants with no TB, adjusted for the variables presented  
    in the table 
- OR = odds ratio 
Total TB prevalence  Untreated TB prevalence  
OR (95% CI) p-value  OR (95% CI) p-value  
Survey year  
    2005 1  1  
    2008 0.35 (0.15 – 0.80) 0.01 0.20 (0.07 – 0.74) 0.02 
Age  (in years) 1.03 (0.98 – 1.09) 0.22 1.04 (0.96 – 1.14) 0.29 
Gender  
    Male 1  1  
    Female 0.93 (0.31 – 2.83) 0.90 1.40 (0.23 – 8.45) 0.72 
Education  (years in school) 1.00 (0.87 – 1.16) 0.95 1.24 (0.92 – 1.67) 0.15 
Number of residents in household 0.98(0.79 – 1.23) 0.86 0.80 (0.55 – 1.17) 0.25 
Alcohol intake in past 6 months 1.01 (0.41 – 2.50) 0.99 1.80 (0.50 – 6.43) 0.37 
Smoked in past 6 months 1.26 (0.40 – 3.98) 0.70 1.57 (0.28 – 8.97) 0.61 












Participants with untreated prevalent TB in 2005 had similar risk factors as treated TB 
cases with a previous history of imprisonment in the past 6 months (OR: 13.5; 95% CI: 
1.3-143.9; p=0.03), HIV-infected status (OR: 10.8 compared to HIV-uninfected; 95% CI: 
2.4-47.8; p=0.002) and HIV-infected persons receiving HAART (OR: 133.6 compared to 
HIV-uninfected; 95% CI: 12.4-1438.9; p<0.001) persisting as significant risk factors for 
untreated TB after adjustment for age and gender (Table 6.6).  
 
In 2008, the only significant risk factor for treated prevalent TB in univariate analysis was 
a history of receiving HAART (OR: 10.5 compared to HIV-uninfected participants; 95% 
CI: 3.1-35.9; p<0.001), and this persisted after adjusting for age and gender (Table 6.7).  
 
In univariate analysis untreated prevalent TB in 2008 was associated with a history of 
employment in the mines (OR: 17.4; 95% CI: 4.0-75.2; p<0.001), and imprisonment in 
the past 6 months (OR: 12.4; 95% CI: 1.4-107.7; p=0.02) which carried twice the risk of 
those who had ever been in prison (excluding the last 6 months) (OR: 6.5; 95% CI: 1.5-
27.6; p=0.01). HIV-infected participants off HAART bordered on statistical significance 
as a risk factor for untreated TB. In multivariate analysis, only a history of mining 
employment remained a significant risk factor (OR: 28.2; 95% CI: 2.6-308.2; p=0.01), 
although ever having been imprisoned bordered on significance (OR: 5.4; 95% CI: 0.9-
33.8; p=0.07). HIV-infected status was not significantly associated with risk of untreated 
TB, and receiving HAART remained perfectly predictive of not having untreated TB 
(Table 6.8). 
 
In these models, no prevalent TB was considered “failure”, and therefore variables that 













Table 6.5: Risk factors for treated tuberculosis in 2005 
 
Univariate analysis  Multivariate analysis 
Risk factor 
OR (95%CI) p-value OR (95%CI) p-value 
Age 1.03 (0.99-1.07) 0.17 1.04 (0.98-1.10) 0.19 
Gender: Male                  1                  1 
              Female 0.67 (0.20-2021) 0.51 0.50 (0.13-2.00) 0.33 
Median residents in household 1.05 (0.81-1.37) 0.71   
Median persons sleeping in same room 0.97 (0.57-1.66) 0.92   
Ever had TB in the past Perfectly predicts failure   
Alcohol intake in past 6 months 1.63 (0.49-5.40) 0.42   
Visited shebeen (bar) in past 6 months 1.40 (0.30-6.52) 0.67   
Smoked in past 6 months 2.31 (0.70-7.65) 0.17   
Recreational drugs in past 6 months 0.39 (0.05-3.18) 0.38   
Employment History   
    Past mining 1.70 (0.21-13.62) 0.62   
    Health Care Worker 0.28 (0.03-2.28) 0.23   
    Prison in past 6 months 20.31 (3.77-109.29) <0.001 27.14 (4.15-177.54) 0.001 
HIV-uninfected                  1                 1 
HIV-infected 3.17 (0.95-10.53) 0.06 7.04 (1.65-30.05) 0.01 
HIV-infected on HAART  32.44 (5.54-189.84) <0.001 93.53  (11.18-782.30) <0.001 
- p-values compare treated TB to participants with no TB in 2005 














Table 6.6: Risk factors for untreated tuberculosis in 2005 
 
 
Univariate analysis  Multivariate analysis 
Risk factor 
OR (95%CI) p-value OR (95%CI) p-value 
Age 0.98 (0.92-1.04) 0.52 0.96 (0.88-1.05) 0.41 
Gender: Male                  1                  1 
              Female 1.12 (0.35-3.57) 0.84 0.59 (0.16-2.27) 0.45 
Median residents in household 0.70 (0.48-1.03) 0.07 0.77 (0.52-1.15) 0.20 
Median persons sleeping in same room 0.89 (0.51-1.54) 0.68   
Ever had TB in the past Perfectly predicts failure   
Alcohol intake in past 6 months 0.97 (0.31-3.09) 0.96   
Visited shebeen (bar) in past 6 months 0.93 (0.25-3.48) 0.92   
Smoked in past 6 months 1.39 (0.41-4.65) 0.60   
Recreational drugs in past 6 months Perfectly predicts failure   
Employment History   
    Past mining 1.55 (0.20-12.28) 0.68   
    Health Care Worker Perfectly predicts failure   
    Prison in past 6 months 8.31 (0.96-72.20) 0.06 13.49 (1.26-143.99) 0.03 
HIV-uninfected                  1                  1 
HIV-infected 5.33 (1.67-17.01) 0.01 10.76 (2.42-47.84) 0.002 
HIV-infected on HAART  29.2 (5.05-168.80) <0.001 133.60  (12.40-1438.98) <0.001 
- p-values compare untreated TB to participants with no TB in 2005 












 Table 6.7: Risk factors for treated tuberculosis in 2008 
- p-values compare treated TB to participants with no TB in 2008 
- OR = odds ratio 
 
Univariate analysis  Multivariate analysis 
Risk factor 
OR (95%CI) p-value OR (95%CI) p-value 
Age 1.04 (0.99-0.108) 0.11 1.03 (0.98 – 1.09) 0.24 
Gender: Male                  1                  1 
              Female 0.76 (0.24-2.42) 0.65 0.60 (0.18-1.97) 0.40 
Median residents in household 1.15 (0.91-1.45) 0.26   
Median persons sleeping in same 
room 0.76 (0.42-1.37) 0.36   
Ever had TB in the past Perfectly predicts failure   
Alcohol intake in past 6 months 1.04 (0.31-3.47) 0.95   
Visited shebeen (bar) in past 6 months 2.89 (0.37-22.52) 0.31   
Smoked in past 6 months 2.41 (0.76-7.66) 0.14   
Recreational drugs in past 6 months Perfectly predicts failure   
Employment History   
    Past mining Perfectly predicts failure   
    Health Care Worker Perfectly predicts failure   
    Prison in past 6 months Perfectly predicts failure   
    Ever spent time in prison  
    (excl last 6 months) 0.98 (0.13-7.70) 0.99   
HIV-uninfected                  1                  1 
HIV-infected not on HAART 1.30 (0.35-4.84) 0.69 2.3 (0.55-10.15) 0.25 












Table 6.8: Risk factors for untreated tuberculosis in 2008 
- p-values compare untreated TB to participants with no TB in 2008 
- OR = odds ratio 
 
 
6.5   DISCUSSION 
The key finding of this study was that the prevalence of microbiologically-confirmed adult 
PTB declined significantly between 2005 and 2008, and this decline was due to a nearly 
three-fold decrease in TB prevalence in the HIV-infected population (from 9.2% to 3.6%). 
Among HIV-infected participants, the decrease in TB prevalence was predominantly due 
to a four-fold decline in untreated TB. This decrease was temporally associated with the 
scale-up of a HAART programme and the greatest reduction in prevalence was noted 
among HIV-infected patients on HAART. In this group TB prevalence dropped from 44% 
to 6.7%, and the largest decline was seen in untreated TB cases.  
Univariate analysis  Multivariate analysis 
Risk factor 
OR (95%CI) p-value OR (95%CI) p-value 
Age 1.02 (0.96-1.09)  0.50 0.96 (0.87-1.06) 0.41 
Gender: Male                  1                  1 
              Female 0.64 (0.15-2.70)  0.55 3.30 (0.42-26.13) 0.26 
Median residents in household 1.16 (0.88-1.55)  0.29   
Median persons sleeping in same room 0.82 (0.41-1.65) 0.59   
Ever had TB in the past Perfectly predicts failure    
Alcohol intake in past 6 months 2.01 (0.52-8.34) 0.30   
Visited shebeen (bar) in past 6 months 0.26 (0.07-1.06) 0.06 0.37 (0.07-2.06) 0.25 
Smoked in past 6 months 2.03 (0.48-8.53) 0.34   
Recreational drugs in past 6 months Predicts failure perfectly   
Employment History   
    Past mining 17.39 (4.02-75.22) <0.001 28.24 (2.59-308.21) 0.01 
    Health Care Worker Predicts failure perfectly   
    Prison in past 6 months 12.41 (1.43-107.65) 0.02 10.12 (0.57-179.61) 0.12 
    Ever spent time in prison  
    (excl last 6 months) 6.50 (1.53-27.56) 0.01 5.40 (0.86-33.75) 0.07 
HIV-uninfected                  1                  1 
HIV-infected not on HAART 3.90 (0.97-15.73) 0.06 2.48 (0.54-11.43) 0.24 













In keeping with the notification data for Site M, the prevalence of treated TB among HIV-
infected patients decreased by nearly 50%, and this decrease was greatest among HIV-
infected patients on HAART (although these reductions did not reach statistical 
significance).  Similarly, this survey also reported a relatively steady state of TB among 
HIV-uninfected patients.  
 
6.5.1 Understanding the Change in TB Prevalence 
To explain these findings, we postulate that a wide-spread HAART programme can 
decrease prevalent TB in a community through two mechanisms: increased TB active 
case-finding, and immune recovery associated with HAART. 
 
Increased Case-Finding in the HAART Program 
When patients entered the HAART programme, they underwent active screening for TB, 
based on national and WHO policies199;510. Screening for TB was based on symptom 
review and, in patients with symptoms suggestive of TB sputum, staining for AFB and/or 
culture for Mtb growth was performed. The effective implementation of this policy is 
demonstrated by the increased proportion of case finding in the HIV-infected population, 
most notably among those on HAART, while the case finding proportion in HIV-
uninfected remained unchanged. This has resulted in a significant decrease in the 
previously large burden of undiagnosed, untreated TB in HIV-infected patients reported 
in the first survey.  
 
ACF may be removing patients from the infectious pool more quickly than would have 
occurred through the passive case-finding policy of the national TB control 
programme195. Furthermore, the substantial decrease in untreated smear-positive TB 
cases may suggest that active case-finding is removing the more infectious cases55;56 
from the community.  As a result, it is possible that part of the decrease in TB prevalence 
may be due to a reduction in TB transmission. This hypothesis would also explain in part 
the decrease in notification rates observed in the community (Chapter 5). The effect of 
reduced transmission may be more evident among the HIV-infected patients due to the 
more rapid rate of progression to TB disease following recent infection in this group 
compared to HIV-uninfected individuals102. Subsequently, any benefit to the HIV-












short interval between these surveys.  Indeed, the proportion of clustering of Mtb strains 
in this community has not changed over the past 4 years, suggesting persistent 
transmission. However, given the short post-HAART observation period, the decreasing 
notification rates and prevalence of TB overall and the variable incubation period for TB, 
there may be a time lag in observing the impact of decreased transmission. Increased 
follow-up time is needed to confirm or refute this hypothesis. 
 
None-the-less, the reduction of TB prevalence noted in this study is in keeping with the 
results of mathematical models which have assessed the impact of intervention 
strategies such as active case-finding on population TB rates189;511.  
 
Risk of Disease: Immune Recovery on HAART 
ACF would transfer untreated TB cases into the treated, notified group. However, rates 
of treated TB did not increase in this population; in contrast, treated TB in HIV-infected 
participants had declined between the two surveys. This finding may reflect changes in 
the immune status of the HIV-infected population related to high HAART coverage. It is 
well documented that HAART, and the subsequent CD4 count recovery, is associated 
with a substantial reduction in TB risk in HIV-infected patients45;46;152;170. The rapid scale-
up of the HAART programme in this community (with 20% of HIV-infected population 
receiving HAART in 2008) resulted in a large treatment cohort, with an increasing mean 
CD4 count (as found in treatment cohorts in similar settings35) and, therefore, a 
decrease in risk of TB disease in HIV-infected patients. This is also reflected in the 
decreasing TB notification rates among HIV-infected patients, particularly those on 
HAART (Chapter 5). While the HAART cohort had a higher mean CD4 count in 2008 
compared to 2005, the median CD4 count in 2008 is still relatively low. Therefore it is 
possible that the impact on reduction of TB prevalence may continue to increase with 
ongoing HAART initiation and accumulative immune recovery. 
 
The revised HIV treatment guidelines in South Africa now allow for HAART initiation in 
TB patients with CD4 counts <350cell/µl512.  As initiating HAART at higher CD4 counts 
has been shown to be associated with improved immune recovery149;150, this policy may 














6.5.2 Alternative Explanations for Study Findings 
Over the study period there have been no significant changes in the TB control 
programme, other than the ACF in HAART patients over the study. Therefore, the 
decrease in TB prevalence in this community is unlikely to be due to changes in TB 
control policies. This is supported by the stable rates of treated and untreated TB in HIV-
uninfected participants in this study. Similarly, TB-associated mortality rates have 
declined in this community (Chapter 5), particularly among HIV-infected patients, and as 
such an increase in mortality is not likely to be responsible for the decrease in TB 
prevalence. Emigration could result in a decreased prevalence of disease, but biennial 
censuses performed from 2002 to 2008, show that net immigration is greater than 
emigration in this growing community, with a 12% increase in population size between 
the two surveys (Appendix A). Furthermore, the same TB control programme laboratory 
services, with consistent specimen processing protocols, were used for the microscopy, 
culture and differentiation of sputum specimens in both surveys, and the same culture 
contamination rate was reported across both surveys. 
 
6.5.3 Active Case-Finding in Different Populations 
The recently published DETECTB study reported on the impact of population-based 
ACF strategies on TB prevalence280. As with our study, the DETECTB study was 
performed in a southern African community with high TB and HIV burdens and assessed 
the impact of ACF interventions by performing two community-based surveys on 
randomly selected samples of the adult residents, pre and post the implementation of 
the interventions. Similar to our study, participants, regardless of symptoms, provided 
sputum specimens for TB testing, including Mycobacterium tuberculosis culture, and 
also underwent HIV testing.  
 
However, DETECTB assessed the impact of a different intervention strategy: employing 
regularly repeated ACF interventions in the general population. In addition, the 
researchers of the DETECTB study reported that there was little change in the coverage 
of the HAART programme in their study site over the study period, compared to the rapid 
scale-up of HAART coverage in Site M.   
 
As with our study, the DETECTB study reported a substantial reduction in the population 












findings, the reduction in prevalence was predominantly due to a decrease in TB 
prevalence among HIV-uninfected participants, with a non-significant reduction among 
HIV-infected participants.   
 
The difference in the study findings are most likely due to the targeting of different 
populations. The ACF interventions in DETECTB relied on symptom-based screening to 
identify TB suspects, and on sputum microscopy for TB diagnosis.  Screening 
participants by the presence of a cough, as done in DETECTB, has a very low sensitivity 
for detecting TB among HIV-infected patients513 and more recently a systematic review 
and meta-analysis of ACF studies has shown that testing HIV-infected patients for TB 
regardless of reported symptoms provides a significantly higher TB yield507. Similarly, 
sputum microscopy has been shown to have a low yield in HIV-infected patients513, who 
have an increased prevalence of smear-negative culture-positive TB disease18;118. As a 
result, the DETECTB interventions predominantly targeted the detection of TB disease 
among the HIV-uninfected population, and consequently this is where the benefit was 
most noted. In contrast, our intervention was targeted at the HIV-infected population.  
 
The TB epidemic in high TB and HIV settings comprises both HIV-associated TB and 
HIV-unassociated TB. These two studies show that community-based ACF strategies 
that utilize symptom-based screening will have a substantial impact on TB prevalence 
among the HIV-uninfected population, while the scale-up of HAART programmes, with 
associated ACF, have a marked impact on HIV-associated TB.  These studies suggest 
that combining these two interventions, each targeting a different subset of the 
community population, may have an additive benefit for TB epidemics in high TB and 
HIV burdened settings.  
 
6.5.4 Risk Factors Associated with Prevalent TB 
In 2008, treated prevalent TB was associated with HIV-infected status, and in particular 
it was strongly associated with HIV-infected participants receiving HAART. In contrast 
HIV-infected patients on HAART did not have an increased risk of untreated TB.  These 
findings most likely reflect the ACF among HIV-infected patients starting HAART.  
 
In direct contrast to the findings in 2005, in 2008 HIV-infected patients not on HAART 












community awareness of TB in this population, due to increased screening among HIV-
infected patients initiating HAART, as well as the community surveys. With the 
implementation of a high coverage HAART programme, the greatest risk for untreated 
TB was associated with more “traditional” risk factors such as past employment in the 
mines, or time spent in overcrowded prison conditions. 
 
6.5.5 Strengths and Weaknesses 
This is the first repeated cross-sectional TB prevalence survey following the large-scale 
availability of HAART in a sub-Saharan Africa community. The study was performed 
among randomly selected individuals in a well-defined community, with HIV and HAART 
data linked to TB results. 
 
The sample of residents randomly selected to participate in both studies, as well as 
those residents that enrolled in the studies, did not differ demographically from the total 
study populations in each survey year. The 2008 survey participants did have a lower TB 
risk profile compared to the participants in the 2005 survey, including less crowding in 
the household, as well as lower rates of previous mining employment and alcohol use. 
However, following adjustment for these variables, the decrease in both overall TB 
prevalence as well as untreated TB prevalence in HIV-infected participants between the 
two surveys remained statistically significant.  
 
HIV testing was accepted by 98% of the participants (averaged across both surveys) 
and HIV status was available for all TB cases, both treated and untreated.  
 
This relatively small community is typical of many recently urbanised populations in 
South Africa, but there is a need for further investigation to confirm our findings in other 
high HIV and TB prevalence settings. A third survey to confirm the downward trend in TB 
prevalence would also strengthen these findings. 
 
6.5.6 Conclusion 
Undiagnosed TB prevalence is an important driver of TB transmission49;60;65;114. This 
study showed a significant decline in adult TB prevalence, in particular undiagnosed TB 
prevalence in HIV-infected patients, associated with the introduction of a rapid and high 












decrease in TB notifications reported in Chapter 5, and may be due to the increased 
case-finding in the HAART programme, and as well as the impact of HAART-associated 
immune recovery on TB risk.  These findings suggest that high coverage HAART 
programmes may contribute to TB control in high TB and HIV prevalence settings. It is 
possible that HAART programmes combined with symptom-based ACF interventions 
among the general population may have an even greater impact on TB prevalence in 





















This thesis has described the epidemiology of tuberculosis (TB) in a high HIV and TB 
prevalent community, with a focus on the effect of HIV and a highly active antiretroviral 
therapy (HAART) programme on the TB epidemic in this setting.  
 
Because of the extremely variable incubation period for TB (i.e. the period from infection 
to disease),  it is helpful to consider TB pathogenesis, and associated risk factors, in two 
phases: the acquisition of infection (i.e. transmission) and the development of disease71. 
Below I discuss the impact of an HIV epidemic and a HAART programme on firstly, the 
transmission of TB and secondly, the burden of TB disease in the study community. 
 
7.2  TB TRANSMISSION 
This work has reported a substantial rate of ongoing TB transmission in this community, 
as shown by the high risk of acquiring TB infection in children, ranging from 4-7% per 
year. These high rates of transmission resulted in substantial prevalence of TB infection 
among children and adolescents. This prevalence increased with age, reaching over 
50% among adolescents, and consequently, the majority of adults in this community 
have been infected with TB.  
 
7.2.1 Impact of HIV on TB transmission 
Tests for assessing TB infection are based on measuring, directly or indirectly, an 
immune response to TB antigens, and it is therefore difficult to assess the impact of HIV 
on the risk of TB infection, and transmission. However, this thesis provided some 
important insights into this complex relationship.   
 
Not withstanding the caveats of immune-based testing, data from the secondary school 
tuberculin skin test survey showed that HIV-infected patients were not at an increased 
risk of acquiring TB infection. However, the role of HIV infection in the transmission of 
TB is more complicated.  Analysis of molecular epidemiologically linked clusters has 













this community, with most clusters comprising of both HIV-infected and HIV-uninfected 
patients. 
 
The contribution of HIV to TB transmission is postulated to depend on the prevalence of 
HIV-infected sputum smear-positive disease. Data presented here showed that while 
HIV-infected patients had lower odds of smear-positive pulmonary TB (PTB) disease 
compared to HIV-uninfected patients, the rates of smear-positive disease in this group 
were still higher than those in HIV-uninfected patients, and HIV-infected patients were 
responsible for at least 50% of the total burden of smear-positive PTB disease.  
 
While HIV-infected and -uninfected adults contribute equally to the smear-positive PTB, 
molecular epidemiological data reported that HIV-infected patients were significantly less 
likely to be an index case for clusters in this community (while HIV-infected patients 
accounted for 61% of all sputum positive PTB cases, only 40% of index cases were HIV-
infected), and the association between HIV status and ind x cases persisted even after 
adjusting for sputum smear-positive status. Therefore, it appears that HIV-infected 
sputum-positive cases may be less infectious than their HIV-uninfected counterparts, 
and this is in keeping with other reports124;176;177. A shorter infectious period in the 
community, due to rapid progression of TB disease and increased mortality124;178 among 
HIV-infected patients may also explain the decreased contribution of HIV-infected 
patients to ongoing transmission.  
 
Other evidence to support the argument that HIV-infected adults contribute 
proportionally less to transmission include the observation that TB notification rates 
among HIV-uninfected adults have remained stable over the time of escalating HIV 
prevalence and HIV-associated TB epidemics, and only declined modestly following the 
implementation of the HAART programme. This finding also suggests that while the HIV-
associated and HIV-unassociated TB epidemics are inter-related, the HIV-associated 
epidemic has not had a substantial impact on transmission to the HIV-uninfected 
population. Even considering the longer incubation period of TB in HIV-uninfected 














The risk of transmission to children may be different to that of adults. While children 
were at increased risk of acquiring TB infection and disease from adult TB source cases 
on their residential plot, the HIV status of the adult source case was not a risk factor for 
this transmission. It is probable that the extended contact period between the sputum-
positive adult case and the susceptible child may have overcome the less infectious 
nature of HIV-infected adult cases.  
 
In conclusion, the HIV-associated TB epidemic has undoubtedly contributed to the 
transmission in this community by increasing the burden of sputum smear-positive TB 
cases. However, it appears that the HIV-associated epidemic contributed proportionally 
less to transmission, compared to HIV-uninfected patients.  
 
7.2.2 Impact of a HAART Programme on TB transmission 
Given the conclusion above, it is possible that a HAART programme would not have a 
dramatic impact on TB transmission in this setting. Indeed, the stable rates of TB 
disease in children despite the scale-up of the HAART programme would support this 
hypothesis, as does the consistent proportions of clustered TB cases noted in the 
molecular epidemiological data.  
 
Of note was that the scale-up of the HAART programme was associated with a 
significant decline in adult PTB prevalence, including sputum smear-positive PTB, as 
well as an increase in TB case-finding proportions in the community. One would have 
anticipated that these findings would be associated with a decrease in TB transmission. 
The apparent lack of impact on transmission may be due to the fact that both the 
reduction in TB prevalence and the increase in case-finding were predominantly noted in 
the HIV-infected population and there was no difference in either measure among the 
HIV-uninfected population. The relatively less infectious nature of HIV-infected PTB may 
explain the modest impact noted.  
 
However, there was some suggestion of a mild impact of the HAART programme on 
transmission, as seen in the modest decline noted in HIV-uninfected TB notification rates 
despite constant case-finding proportions.  The effect of reduced transmission may be 
noted first among the HIV-infected patients due to the more rapid rate of progression to 












notifications among HIV-infected patients not receiving HAART was observed. The 
incubation period of TB is longer in HIV-uninfected patients, and as such, there may be a 
time lag to observing the impact of this intervention on transmission more generally. 
Therefore, the full effect of the reduced incident and prevalent disease among HIV-
infected patients on transmission may not yet be evident and the four years of follow-up 
post-HAART implementation may be insufficient time to detect the overall impact on the 
reduction in TB transmission. The modest decline in sputum smear-positive PTB 
notification rates noted among both HIV-infected and HIV-uninfected patients suggest 
that longer term review of the potential impact of the intervention may be important.  
 
7.2.3 Reducing TB Transmission 
While HAART was associated with improved immune function in the HIV-infected cohort 
and the HAART programme was associated with increased TB case-finding, we have 
not reported a substantial impact on TB transmission.  
 
Molecular epidemiological data reported that recent transmission was responsible for at 
least 55% of the TB disease burden in this community, and there was further evidence to 
suggest that this may be a conservative estimate. Therefore, specific steps to decrease 
TB transmission may be critical to control TB in this setting. Reducing TB transmission 
may be comprised of two components: firstly reducing the prevalence and infectious 
period of TB cases, and secondly, inplementing social and environmental changes that 
would decrease the effective contact number of infectious cases. Both these approaches 
require an understanding of the transmission dynamics in the community. 
 
This thesis has reported that children have an extremely high annual exposure to adult 
TB disease within households and close geographic social networks, and child TB 
infection and disease rates were strongly correlated with this residential exposure to 
adult TB. Therefore, strategies for reducing the prevalence and infectious period of TB 
cases could include targeted active case-finding (ACF). Current ACF activities are 
restricted to patients initiating HAART and the screening of children in close contact with 
adult PTB cases334. However, the screening and management of child contacts is poorly 
implemented319;335;336.  The data presented here suggest that improving the 
implementation of and expanding current contact tracing policies could assist in the 












TB contacts to contacts of all ages, regardless of HIV status, and extending case-finding 
beyond the household to the close social network of the TB case. In this community, that 
would entail extending ACF to the patient’s residential plot.  
 
In contrast, the molecular epidemiological data indicated that adult to adult transmission 
did not occur primarily on residential plots. Of importance, it was noted that transmission 
did not appear to be occurring at the local HAART clinic. If high transmission locations 
for adults were identified, targeted ACF could be implemented in these locations. 
Further, environmental interventions, including improved ventilation and possible 
installment of ultra-violet lights, might impact transmission in these locations.  
 
7.3   BURDEN OF TB DISEASE 
The extra-ordinarily high transmission rates in this community are reflected in the 
substantial rates of TB disease in the community. TB notification rates reached over 
2,000/100,000 in Site M, and TB prevalence was as high as 3% among adult residents 
in 2005. 
 
While the HIV epidemic may not be primarily responsible for transmission, it was 
certainly contributing significantly to the burden of TB disease in this community. 
Consequently, it was in TB disease burden that the greatest benefit of a HAART 
programme was noted.  
 
7.3.1 Impact of HIV on Burden of Disease 
HIV-infected patients have a considerably increased risk of progression to TB disease, 
both from reactivation of latent infection and following recent infection14;102. Therefore, 
the substantial HIV prevalence among adults in Site M179;197 together with the high 
prevalence and force of TB infection, account for the overwhelming burden of TB 
disease in this setting.   
  
The HIV epidemic is driving the TB burden of disease, and this was reflected in the 
observation that the 25% of the community population infected with HIV were 
responsible for approximately 70% of the TB disease burden. As a result, overall 
community TB notification rates escalated from 1997, even while notification rates 












7.3.2 Impact of a HAART Programme on Burden of Disease  
In terms of benefit at an individual level, the HAART programme was associated with a 
substantial reduction in TB mortality among HIV-infected patients.  At the community 
level, the scale-up of the HAART programme was associated with a substantial 
decrease in TB disease burden. The trend of increasing TB notification rates was 
reversed, with a 20% reduction in adult TB incidence, as well as a 50% reduction in adult 
TB prevalence, from 2005 to 2008. In both incidence and prevalence, the decrease in 
TB rates was due predominantly to a decline among HIV-infected patients, particularly 
among patients receiving HAART.  
 
While the greatest reduction in TB notification rates was noted among patients on 
HAART, a decrease in notification rates was also noted in HIV-infected patients not 
receiving HAART, as well as modest decline noted in HIV-uninfected patients. Similarly, 
while the greatest reduction in the prevalence of TB disease was noted among HIV-
infected patients receiving HAART, a decline was also not d among HIV-infected 
patients not receiving HAART (although the latter was not statistically significant).  
However, prevalence among HIV-uninfected residents remained unchanged. 
 
The reduction in TB notification rates and TB prevalence (especially previously 
unrecognized TB prevalence) among patients on HAART was most likely due to the 
combination of screening for TB disease among patients initiating HAART and the 
immune system recovery associated with antiretroviral therapy45;46;152;170.  The risk of TB 
disease increases as the CD4 cell count decreases45;75;113 and the reduction in TB rates 
in patients not receiving HAART was probably due to the removal of those with the 
highest TB risk (lowest CD4 counts) from this group into the group on HAART. There 
was an increasing overall average CD4 count in the HAART cohort, and it is possible 
that the ongoing identification and treatment of those patients with lowest CD4 counts 
may have resulted in an improvement in the average CD4 count in the overall HIV-
infected population in this community, thus impacting TB rates among HIV-infected 
patients generally.  
 
While there was a strong temporal association between the decline in both TB 
notification and prevalence rates and the implementation of a high coverage HAART 












have also discussed alternative explanations for the study findings. Changes in the TB 
control programme, in TB treatment outcomes as well as changes in the population 
structure were excluded as possible causes of the declining TB rates.  
 
In summary, although the greatest benefit to TB burden was noted among HIV-infected 
patients receiving HAART, the net result was a decreased overall burden of TB disease, 
both incidence and prevalence, in the community. These studies, therefore, showed that 
a high coverage HAART programme did have an impact on TB burden at a community 
level.   
 
7.4   Overall Impact of HAART Programme on TB Control 
This thesis has shown that HAART can have a positive impact on a community TB 
epidemic. However, the extent and sustainability of that impact will depend on: 
 
1) The impact of HAART on TB transmission in the community. The impact of 
HAART on TB transmission is dependent on the degree to which the HIV-associated 
epidemic is contributing to transmission in the community. In this study community, the 
contribution of HIV-infected TB patients to transmission was proportionally less than that 
of the HIV-uninfected patients. Consequently, the impact of HAART on transmission 
appeared to be relatively minor. However, longer term follow-up and analysis of TB rates 
in this community are required to assess this relationship more fully.  
 
2) The point in the HIV disease process at which HAART is initiated. A substantial 
proportion of patients initiating HAART in South Africa have already had at least one 
episode of TB35;174, and patients initiating HAART at low baseline CD4 counts have a 
high risk of TB in the first months of treatment76;152;166.   A nearly 2-fold higher TB rate 
ratio in HIV-infected patients off HAART compared to those patients on HAART was 
reported by the end of this study period, and patients off HAART accounted for 64% of 
the total burden of TB disease in 2008. Starting patients on HAART earlier in the HIV 
disease process may prevent much of this pre- and early HAART disease. This strategy 
may also result in improved immune recovery150, which may have long term benefits with 













3) The rate of HAART programme implementation and the coverage obtained among 
the HIV-infected population. In this study community, 22% of the HIV-infected population 
was receiving HAART and this high coverage was achieved over a short time period. 
Given that HIV-infected patients are responsible for 70% of TB disease and that patients 
receiving HAART have a 2-fold lower rate of disease, it is probably that the greater the 
proportion of HIV-infected patients receiving HAART, the greater the overall reduction in 
TB rates. The decline of notification rates among HIV-infected patients not receiving 
HAART indicates that the rate at which a HAART programme is implemented in a 
community might be an important variable determining the impact of this intervention on 
overall HIV-associated TB rates. However, it should be noted that as the coverage of a 
HAART programme increases, treatment adherence and the monitoring and 
management of patients with drug interactions and side effects become more 
challenging514 and this may in turn adversely impact the sustainability of the benefits of a 
HAART programme.   
 
7.5   FUTURE RESEARCH 
A number of future research questions have been highlighted in this work. Firstly, it is 
clear that the issue of transmission has been neglected recently in TB research. While 
this thesis has provided important insights into transmission dynamics in high HV and TB 
prevalent settings, there are still unanswered questions that are critical for informing the 
development of effective intervention strategies. One such question involves the 
identification of key locations for adult TB transmission, and further molecular 
epidemiological studies could provide these data. In addition, a tuberculin skin test 
survey among young children (<5 years of age), would provide insights into possible 
changes in transmission rates over the period of HAART availability.  
 
Secondly, these data have suggested that targeted ACF may assist in the earlier 
identification and treatment of TB cases. Studies are needed to assess the effectiveness 
of targeted ACF among TB contacts as an adjunctive intervention. Based on our 
findings, we would recommend using an expanded definition of contacts to include 
people of all ages and HIV status, as well as extending contact tracing beyond the 













Thirdly, the variability of the TB incubation period may mean that any indirect benefit of a 
HAART programme among HIV-uninfected patients may not have been observed over 
the time period of this study. In addition, due to the fact that patients on HAART remain 
at a higher risk for TB disease compared to HIV-uninfected patients35;156;165;169, the 
benefits shown to TB burden may be off-set in the long term, to a greater or lesser 
extent, by the increased life expectancy of patients on HAART. Therefore, ongoing 
monitoring and analysis of trends in communities such as Site M are needed to assess 






























In 2008, there were over 9 million new cases of tuberculosis (TB) disease globally and 
TB remains a significant cause of morbidity and mortality in countries with high HIV 
prevalence, such as South Africa7. An improved understanding of the interaction 
between these epidemics, and the impact of interventions, in high TB and HIV settings is 
required in order to inform TB control strategies. The body of work outlined in this 
doctoral thesis has provided a detailed description of the epidemiology of TB in a well-
defined community with a high burden of HIV and TB, and has focused on the effect of 
the HIV epidemic and a highly active antiretroviral therapy (HAART) programme on the 
TB epidemic in this setting.  
 
A high rate of TB transmission was reported among both children and adults over the 
study period. This has resulted in a large pool of latently infected individuals in the study 
community and, given the increased risk of TB disease following recent infection49,71-73, 
has also contributed to the community’s burden of disease.  
 
The risk factors identified for transmission to children and adults were different. Children 
were at increased risk of acquiring TB infection, and therefore disease, from adult TB 
source cases on their residential plot, and the HIV status of adult source cases was not 
a risk factor for this transmission. In contrast, the majority of adult to adult TB 
transmission occurred away from the individuals’ residential plots. Of note is that there 
was no evidence of significant nosocomial transmission at the HAART clinic.  
 
While the adult HIV-infected and HIV-uninfected TB epidemics were inter-related, HIV-
infected TB patients contributed proportionally less to the transmission of TB than HIV-
uninfected peers. Furthermore, HIV infection was not associated with an increased risk 














The substantial HIV prevalence in the study site, combined with the high prevalence and 
incidence of TB infection, resulted in the HIV epidemic contributing significantly to the 
burden of TB disease in this community. The HAART programme was associated with 
active TB screening at HAART initiation, and improved immune function in patients 
receiving treatment.  Consequently, the high coverage HAART programme resulted in a 
significant reduction in TB notification, TB-associated mortality and TB prevalence rates. 
Although the greatest benefit to TB burden was observed among HIV-infected patients, 
a net decrease in the overall burden of TB disease, both incidence and prevalence, was 
noted in the community.  
 
This work has highlighted the urgent need for interventions that reduce TB transmission 
as an adjunct to improved case management. Despite the reduction in TB incidence and 
prevalence, the impact of HAART on TB transmission appeared to be relatively small. 
However, due to the prolonged incubation period for TB disease, longer term 
observation is required to confirm this finding.The findings reported here suggest that 
interventions aimed at reducing transmission will need to target the HIV-uninfected 
population.  
 
In conclusion, in a high TB and HIV disease setting, the HIV epidemic contributed 
significantly to the burden of TB disease, but was responsible for proportionally less TB 
transmission compared to HIV-uninfected patients. A high coverage HAART programme 
was associated with a reduction in the overall burden of community TB disease, as well 
as a marked reduction in TB-associated mortality, reflecting a significant public health 
and individual benefit of this intervention. However, the impact of HAART on TB 
transmission was relatively minor, albeit over a short period of observation. Further 
studies on TB transmission are warranted, and interventions aimed at reducing 

















Population and HIV Model for Study Community 
 
A.1 SITE M POPULATION 
Population data for the population model were obtained from the 1996 South African 
national census, and from house-to-house census’ performed by the Desmond Tutu HIV 
Centre (DTHC) in the study community in 2002, 2004, 2006, and 2008.  
 
The 1996 South African national census provided age and gender composition of the 
community population for that year.  The 2002 DTHC survey provided age composition 
of the community in 10-year age groups. The 2004, 2006 and 2008 DTHC census’ 
collected the age (in years) and gender of each individual in the community.  
 
For the population model 1996, 2004, 2006 and 2008 data were divided into 5-year age 
strata for the total population. The population was also divided into male and female 
categories, with 5-year age strata in each gender. The 10-year strata in 2002 were 
divided into 5-year age groups, by extrapolating the proportions of the 5-year age strata 
from 2004 and 2006. Similarly, the gender distribution for 2002 was extrapolated from 
the gender proportions in each age strata in 2004 and 2006.  
 
Linear growth in each age stratum was extrapolated for the years between surveys, both 
for the total population and for gender categories.  
 
The total population model is tabulated in Table A1. 
 
A.2 HIV PREVALENCE 
HIV prevalence for 1996 to 2004, by 5-year age strata and gender, were derived from 
the Actuarial Society of South Africa (ASSA) 2003 AIDS and Demographic model for the 
African population198;465.  
 
In 2005 and 2008, the DTHC performed community-based, random cross-sectional HIV 












status was available by age (years) and gender. These survey results were compared to 
the ASSA model predictions for the community. 
 
The HIV prevalence results of the 2005 survey were not statistically different to that of 
the ASSA model predictions for the community (overall adult prevalence 23.2 vs 23.5% 
respectively; p=0.71). 95% confidence intervals were calculated for survey HIV 
prevalence in each age strata, assuming a poisson distribution. The ASSA model 
predictions for 5-year age strata fell within these confidence intervals (Figure A1).  
 
 
Figure A1: Comparison of HIV prevalence by 5-year age strata as reported by the 2005 
DTHC HIV survey (with 95% confidence intervals) versus ASSA model predictions 
 
The HIV prevalence reported in the 2008 survey was higher than that predicted by the 
ASSA model (overall adult prevalence 26.5% vs 24.1% respectively; p=0.001). 95% 
confidence intervals were calculated for HIV prevalence in each age strata, assuming a 
poisson distribution. On comparison of the survey data vs ASSA model predictions, the 
survey showed a shift towards older HIV-infected population (Figure A2). A comparison 
of HIV prevalence and gender between the survey and ASSA model, also showed shift 
towards higher HIV prevalence among older women in the survey (Figure A3(i) and 














Figure A2: Comparison of HIV prevalence by 5-year age strata as reported by the 2008 
DTHC HIV survey (with 95% confidence intervals) versus ASSA model predictions 
 
The ASSA model did not adjust for the impact of an antiretroviral programme in the 
community. The differences noted in 2008 are in keeping with the expected impact of a 
highly active antiretroviral therapy (HAART) programme: with decreased mortality in the 
HIV-infected population on HAART22-24, both a moderate increase in HIV prevalence as 
well as a shift in age distribution, towards an older HIV-infected population, is expected. 
Similarly, as the HAART programme enrolled a greater proportion of women, this 
change is expected to be most marked in this gender468.  
 
Based on these findings, the DTHC HIV survey data were used for the community HIV 
prevalence model for 2005 and 2008.  HIV prevalence by 5-year age strata and gender 
were extrapolated between 2005 and 2008, assuming a linear trend.   
As the DTHC surveys did not include 0-14 year olds, the HIV prevalence for these age 


























































































































Figure A3: Changes in HIV prevalence in 5-year age strata in females as reported by the 

































































































































Figure A4: Changes in HIV prevalence in 5-year age strata in males as reported by the 
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Table A1: Study Community Population: 1996 - 2008 
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Table A2: Study Commmunity HIV-infected Population: 1997 - 2008 
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Sensitivity Analyses for TB Notification Rates 
 
 
TB notification rates were calculated based on population and HIV models that were 
generated based on assumptions of the trends of population growth and best fit HIV 
prevalence rates. Therefore, to determine the robustness of the notification analyses, 
sensitivity studies were performed with models assuming different trends of population 
growth and different assumptions for HIV prevalence from the final study population 
model.  Analysis of the adult notification rates, overall and by HIV status were performed 
for these sensitivity analyses. Analyses for HIV-infected patients on ART were not 
included in the sensitivity studies, as the denominators for these rates were not 
modeled, but obtained from ART databases. 
 
B.1 SITE M POPULATION MODEL 
As described in Appendix A, the community population model that supplied 
denominators for rates calculations was based on repeated community censuses and 
assumed linear growth of the population between census years. Although other 
population growth trends were assessed, the linear trend was the best fit, based on the 
R2 Goodness of Fit test (r2=0.98 for total population, and r2=0.99 for adult population). 
 
However, TB notification rates were re-calculated based on population models assuming 
different population tends. 
The different population growth trends assessed were: 
- exponential growth between census years  
(r2=0.95 for total population, and r2=0.97 for adult population) 
- logarithmic growth between census years 
(r2=0.96 for total population, and r2=0.91 for adult population) 
- power growth between census years 
(r2=0.99 for total population, and r2=0.97 for adult population) 
 
The proportion of population HIV-infected was obtained from the HIV model used 
throughout the main analysis, and was therefore constant across the 4 population 













As shown in Figures B1, B2 and B3, the different models yielded no substantive 
changes in adult TB notification trends, overall or by HIV status.  In overall adult TB rates 
all models showed a significant increase from 1997 to 2004, and a significant decline 
from 2005.  
 
With regards to adult HIV-uninfected TB notification trends, all models showed a stable 
trend in TB rates from 2002 to 2004, and all models reporting a decrease in rates from 
2005, although only the linear and exponential models reported the decrease to be 
statistically significant. 
With regards to adult HIV-infected TB notification trends, all models showed an increase 
in TB rates from 2002 to 2004 (with only the power trend population model not reporting 
a statistically significant increase), and all models reporting a significant decrease in 
rates from 2005. 
 
Figure B1: Total adult TB notification rates as calculated using the linear, exponential, 
logarithmic and power trend based population models  
TB notification rates escalated from 1997 to 2004 in the linear population model (ie the model 
used in the main analysis; p=0.004), as well as in the exponential population model 
(p<0.001), the logarithmic population model (p<0.001) and the power population model 
(p<0.001). TB notification rates decreased from 2005 to 2008 in the linear population model 
(p=0.02), as well as in the exponential population model (p<0.001), the logarithmic population 













Figure B2: HIV-uninfected adult TB notification rates as calculated using the linear, 
exponential, logarithmic and power trend based population models 
Among HIV-uninfected patients TB notification rates remained stable from 2002 to 2004 
in the linear population model (ie the model used in the main analysis; p=0.59), as well as 
in the exponential population model (p=0.46), the logarithmic population model (p=0.45) 
and the power population model (p=0.46). TB notification rates decreased among HIV-
uninfected patients from 2005 to 2008 in the linear population model (p=0.01), as well as 
in the exponential population model (p=0.002), the logarithmic population model (p=0.11) 




Figure B3: HIV-infected adult TB notification rates as calculated using the linear, 
exponential, logarithmic and power trend based population models 
Among HIV-infected patients TB notification rates escalated from 2002 to 2004 in the 
linear population model (ie the model used in the main analysis; p=0.01), as well as in the 
exponential population model (p<0.001), the logarithmic population model (p=0.05) and 
the power population model (p=0.09). TB notification rates decreased among HIV-
infected patients from 2005 to 2008 in the linear population model (p<0.001), as well as 
in the exponential population model (p<0.001), the logarithmic population model (p=0.01) 












In summary, for overall TB notification rates, as well as rates in HIV-uninfected and HIV-
infected adults, the exponential trend model showed a marginally higher rate of TB 
notification increase from 1997 to 2004, and a slightly sharper decline following 2005. 
The logarithmic trend model conversely showed a marginally slower escalation of all TB 
notification rates, followed by a less marked decline. The linear model therefore presents 
a “middle road” denominator for the data analysis.  
 
B.2 HIV PREVALENCE MODEL 
As described in Appendix A, the community HIV prevalence model used to determine 
denominators for TB rates calculations was obtained from the Actuarial Society of South 
Africa (ASSA) 2003 AIDS and Demographic model465 for the African population, and 
adjusted from 2005 onwards based on the results of the 2005 and 2008  cross-sectional 
HIV prevalence surveys179;197 performed in the study community. 
 
The analysis for adult TB rates in HIV-uninfected and HIV-infected patients, as well as 
HIV-infected patients not receiving ART status, were repeated using the ASSA 2003 
model for the African population for the full duration of the study (ie, unadjusted for 
community prevalence survey results), the ASSA 2003 model for the Western Cape 
(province in which study community is based) and the Eastern Cape. The Eastern Cape 
was chosen as the study population is predominantly Xhosa speaking individuals who 
have immigrated from that province. The study population size was obtained from the 
population model used throughout the main analysis, and was therefore constant across 
the 3 models.  
 
Figures B4 and B5 illustrate the estimated HIV prevalence for Site M population, as well 
as the HAART coverage, based on each model. 
 
Due to the fact that the ASSA 2003 AIDS and Demographic model did not account for 
the impact of ART programmes, the final population model has a slightly high HIV 
prevalence estimate compared to the different provincial models generated by the ASSA 
model. Consequently, the HAART coverage for the Site M HIV-infected population is 





























ASSA model: South Africa: African population
ASSA model: Western Cape: African population
ASSA model: Eastern Cape: African population
 





























ASSA model: South Africa: African population
ASSA model: Western Cape: African population
ASSA model: Eastern Cape: African population
 
Figure B5:  The HAART coverage among HIV-infected population as estimated by each 
model 
The HAART coverage by end 2008 was 21% according to the final study model, 24% 
based on the ASSA national model for Africans and the ASSA Eastern Cape model for 












Below are the TB rates among the HIV-uninfected, HIV-infected and HIV-infected not 
receiving HAART populations, as determined by each model (Figures B6-8).  
 
Among HIV-uninfected patients (Figure B6), all four models showed stable TB rates from 
2002 to end 2004, and all the models reported a modest but significant decline in HV-
uninfected TB rates from 2005. 
 
Figure B6:  The TB rates among HIV-uninfected population as estimated by each model 
Among HIV-uninfected patients TB notification rates remained stable from 2002 to 2004 
in the final Site M model (p=0.59), as well as in the ASSA models for African populations 
in South Africa (p=0.61), the Western Cape (p=0.60) and the Eastern Cape (p=0.59).  
TB notification rates decreased among HIV-uninfected patients from 2005 to 2008 in the 
final Site M model (p=0.01), as well as in the ASSA models for African populations in 
South Africa (p=0.002), the Western Cape (p=0.002) and the Eastern Cape (p=0.003). 
 
 
Among HIV-infected patients (Figure B7), all four models showed a significant increase 
in TB rates from 2002 to end 2004, and all the models reported a significant decline in 







































Site M model ASSA model: South Africa: African population
ASSA model: Western Cape: African population ASSA model: Eastern Cape: African population  
Figure B7:  The TB rates among HIV-infected population, as estimated by each model 
Among HIV-infected patients TB notification rates increased significantly from 2002 to 
2004 in the final Site M model (p=0.01), as well as in the ASSA models for African 
populations in South Africa (p<0.001), the Western Cape (p<0.001) and the Eastern 
Cape (p<0.001). TB notification rates decreased significantly among HIV-infected 
patients from 2005 to 2008 in the final Site M model (p<0.001), as well as in the ASSA 
models for African populations in South Africa (p<0.001), the Western Cape (p<0.001) 
and the Eastern Cape (p<0.001). 
 
 
Among HIV-infected patients not receiving HAART (Figure B8), all four models showed 
an increase in TB rates from 2002 to end 2004, although the increases were only 
significant in the ASSA South African and Western Cape models. All the models 
reported a significant decline in TB rates in this group from 2005. 
 
The final population model provided conservative estimates of HIV-infected TB rates, 
compared to the other models. However, as these figures illustrate, using the different 
models to determine community HIV prevalence does not result in any substantive 







































Site M model ASSA model: South Africa: African population
ASSA model: Western Cape: African population ASSA model: Eastern Cape: African population  
Figure B8:  The TB rates among HIV-infected patients not receiving HAART, as 
estimated by each model 
Among HIV-infected patients not receiving HAART TB notification rates increased, but 
not significantly from 2002 to 2004 in the final Site M model (p=0.34), as well as in the 
ASSA models for the Eastern Cape (p=0.21). The increases noted in the ASSA South 
African (p<0.001) and the Western Cape (p<0.001) models were significant. TB 
notification rates decreased significantly among HIV-infected patients not on HAART from 
2005 to 2008 in the final Site M model (p<0.001), as well as in the ASSA models for 
African populations in South Africa (p<0.001), the Western Cape (p<0.001) and the 
Eastern Cape (p=0.2). 
 
 
B.3 FURTHER SENSITIVITY ANALYSES  
Pre and post HAART cut-off 
The use of 2005 as the pre and post HAART cut-off was an a priori decision, based on 
the scale-up of the ART programme in this year: HAART coverage increased from 5% in 
2004 to 13% in 2005.  
 
However a sensitivity analysis was performed using 2004 as the HAART cut-off. In this 
revised analysis the post HAART trends remained in the same direction as the main 
analysis (ie showing a decrease), although these tends no longer reached statistical 
significance.  Overall TB rates declined by an annual average of 23 cases/100,000 
following 2003 (p=0.66), HIV-uninfected TB rates declined by an average of 52 cases 
per year (p=0.47) and TB rates in HIV-infected patients declined by an annual average 













Definition of TB patients “on HAART”  
In the main analysis all patients who were receiving HAART at the time of TB diagnosis 
were classified as “on HAART”, regardless of duration of HAART treatment. Given the 
possibility that TB disease diagnosed in the first 3 months of HAART treatment 
represents TB disease that was present, although unrecognised, at the time of HAART 
initiation76;152;166, these patients could also conceivably be considered to belong in the TB 
patients “off HAART” group. However, in the study clinic all HIV-infected patients were 
actively screened for TB disease prior to starting HAART. Given that no evidence of 
clinical disease was evident at the time of HAART initiation, it was decided to classify all 
TB patients receiving HAART as “on HAART”, regardless of HAART treatment duration. 
However, a sensitivity analysis was performed, re-classifying all TB patients who had 
received HAART for less than 85 days (ie 3 months) in the “off HAART” group.  
 
Overall 31(30% of the original “receiving HAART” group) TB patients were re-classified 
from the “HIV-infected patients receiving HAART” group to the “HIV-infected patients not 
receiving HAART” group. The sensitivity anlaysis findings are presented in Figure B9.  
The TB notification rates of patients on HAART were lower than those presented in the 
main analysis, and the decreasing tend in these rates was not significant (p=0.84). 
However, if year 2004 was excluded from the analysis (only two TB patients were 
receiving HAART in that year), the decreasing trend in this group reached statistical 
significance (p=0.002). Overall, this sensitivity analysis confirmed the trends reported in 
Chapter 5.  
 
Figure B9: Adult TB notification rates by HAART status, with TB patients in the first 3 












This figure shows the increase in TB notification rates from 2002 to 2004 among HIV-
infected patients not receiving HAART (p=0.16), followed by a decrease in notification 
rates from 2005 to 2008 (p<0.001). This figure also shows the decreasing TB notification 
rates from 2004 to 2008 among HIV-infected patients receiving HAART (p=0.84).  
 
Impact of TB Prevalence Survey 
In 2005 a cross-sectional community TB survey was performed in Site M (Chapter 6).  
This survey was performed on a randomly selected 10% of the adult population. Based 
on the findings of the survey, 12 additional patients were started on TB treatment in 
2005 and 2006, 6 of whom were HIV-infected.  
 
To determine if the survey had a direct impact on TB notifications, analyses were re-run 
excluding the patients identified by the survey. The analyses are shown in Figures B10 
and B11. These analyses showed no significant difference in the main findings of the 
study.  
 
Overall TB rates still showed a significant increase from 1997 to 2004, followed by a 
significant decline from 2005. Similarly, HIV-uninfected TB rates were stable from 2002 
to end 2004, followed by a moderate decline (as noted in the main analysis), and HIV-
infected TB rates increased significantly from 2002 to 2004, after which they decreased 
significantly (as in the main analysis). 
Of note is that the peak in TB notifications observed in 2005 was unaffected in this 
analysis. This supports our theory that the increase in 2005 is predominantly due to the 














Figure B10: Overall adult TB notification rates in Site M, excluding patients identified in 
the 2005 survey  
TB notification rates increased significantly from1997 to 2004 (p<0.001), followed by a 
significant decrease in TB notification rates from 2005 to 2008 (p=0.01). 
 
 
Figure B11: Adult TB notification rates by HIV status, excluding patients identified in the 
2005 survey 
This figure shows the stable TB notification rates among HIV-uninfected patients from 
2002 to 2004 (p=0.61), followed by a moderate decline from 2005 (p<0.001). This figure 
also shows increasing TB notification rates among HIV-infected patients from 2002 to 














B.4 ATERNATIVE ANALYSIS 
Logistic Regression Models 
Logistic regression provides an alternative method for modeling the population TB rates. 
This approach is based on the absolute count data (TB cases and population size), 
rather than converting to TB cases/100,000. Therefore a logistic regression analysis was 
performed as a sensitivity analysis. Figure B12 illustrates the odds ratios of overall adult 
TB disease in the population, using 1997 as the reference year. Figure B13 reports the 
odds ratios of adult TB overall and in HIV-infected and uninfected populations using 

















Figure B12: The odds ratios of overall adult TB disease in the population, using 1997 as 
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Figure B13: The odds ratios of adult TB overall and in HIV-infected and uninfected 














In conclusion, exhaustive sensitivity analyses were performed for this study, including 
differing population and HIV prevalence models and considering an alternative HAART 
cut-off date, the possible impact of other studies in the community on TB notifications, as 
well as alternative analyses techniques. All analyses supported the main findings of the 





























Risk Factor Models for TB Prevalence in 2005 and 2008 
 
 
Table C1: Total Prevalent Tuberculosis in 2005 
 
 
Univariate analysis  Multivariate analysis 
Risk factor 
OR (95%CI) p-value OR (95%CI) p-value 
Age 1.01 (0.97-1.04) 0.61 1.01 (0.96-1.06) 0.78 
Gender: Male 1 1 
              Female 0.88 (0.38-2.01) 0.75 0.54 (0.20-1.44) 0.22 
Median residents in household 0.89 (0.71-1.11) 0.30   
Median persons sleeping in same 
room 0.93 (0.63-1.37) 0.72   
Ever had TB in the past Perfectly predicts failure   
Alcohol intake in past 6 months 0.25 (0.54-2.86) 0.60   
Visited shebeen (bar) in past 6 
months 1.12 (0.41-3.05) 0.83   
Smoked in past 6 months 1.78 (0.76-4.18) 0.19   
Recreational drugs in past 6 months 0.87 (0.11-6.66) 0.89   
Employment History   
    Past mining 1.62 (0.67-7.15) 0.52   
    Health Care Worker 0.61 (0.08-4.77) 0.64   
Prison in past 6 months 13.71 (3.38-55.54) <0.001 21.47 (4.37-105.43) <0.001 
HIV-uninfected 1 1 
HIV-infected 4.15 (1.80-9.59) 0.001 8.79 (3.12-24.76) <0.001 



















Univariate analysis  Multivariate analysis 
Risk factor 
OR (95%CI) p-value OR (95%CI) p-value 
Age 1.03 (0.99-1.07) 0.10 1.01 (0.96-1.06) 0.83 
Gender: Male 1 1 
              Female 0.71 (0.29-1.76) 0.46 1.06 (0.33-3.42) 0.92 
Median residents in household 1.15 (-.96-1.39) 0.13   
Median persons sleeping in same 
room 0.78 (0.50-1.23) 0.29   
Ever had TB in the past Perfectly predicts failure   
Alcohol intake in past 6 months 1.38 (0.56-3.41) 0.48   
Visited shebeen (bar) in past 6 
months 0.79 (0.28-2.19) 0.65   
Smoked in past 6 months 2.25 (0.91-5.56) 0.08 2.10 (0.71-6.25) 0.18 
Recreational drugs in past 6 months Perfectly predicts failure   
Employment History   
    Past mining 5.11 (1.44-8.14) 0.01 4.39 (0.91-21.30) 0.07 
    Health Care Worker Perfectly predicts failure   
Prison in past 6 months 4.57 (0.57-36.55) 0.15   
Ever spent time in prison  
    (excl last 6 months) 2.71 (0.89-8.25) 0.08 1.57 (0.48-5.83) 0.47 
HIV-uninfected 1 1 
HIV-infected 2.10 (0.83-5.33) 0.12 2.77 (0.99-7.73) 0.05 
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